simendan has been researched along with Heart Failure in 459 studies
*Heart Failure: A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION. [MeSH]
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 7 (1.53) | 18.2507 |
2000's | 208 (45.32) | 29.6817 |
2010's | 186 (40.52) | 24.3611 |
2020's | 58 (12.64) | 2.80 |
Authors | Studies |
---|---|
Jun, M; Lan, L; Libiya, Z; Shubin, J; Xiangli, S | 1 |
Bartuś, S; Gąsior, M; Gierlotka, M; Grześk, G; Główczyńska, R; Jaguszewski, M; Kasprzak, JD; Kubica, J; Legutko, J; Leszek, P; Nessler, J; Pacileo, G; Ponikowski, P; Sobkowicz, B; Stępińska, J; Straburzyńska-Migaj, E; Tycińska, A; Wojakowski, W; Zawiślak, B; Zymliński, R | 1 |
Errigo, V; Martucci, ML; Masarone, D; Melillo, E; Pacileo, G; Pacileo, R; Petraio, A; Pollesello, P | 1 |
Aldea Perona, A; de Mora Martin, M; García-González, MJ; Jiménez Sosa, A; Lara Padron, A; López Díaz, J; López Fernandez, S; Martínez-Sellés, M; Morales Rull, JL; Ortiz Oficialdegui, P | 1 |
Bergin, P; Cieslik, L; Dagan, M; Hare, JL; Kaye, DM; Lankaputhra, M; Leet, A; Patel, HC; Taylor, AJ; Warner, V; Yeung, T | 1 |
Banai, S; Frydman, S; Granot, Y; Havakuk, O; Hochstadt, A; Ketchker, L; Korotetski, L; Laufer-Perl, M; Milwidsky, A; Sadeh, B; Sapir, O; Topilsky, Y | 1 |
Li, M; Li, Y; Qu, T; Wan, Q; Yuan, F; Zhang, Y | 1 |
Cheng, Z; Cui, X; Dong, X; Han, Y; Hong, Y; Huang, X; Li, Y; Mu, Y; Wang, Z; Zhang, L | 1 |
Freimark, D; Grupper, A; Itelman, E; Kassif, Y; Kogan, A; Lavee, J; Lotan, D; Morgan, A; Segev, A; Shemesh, Y | 1 |
Araszkiewicz, A; Grygier, J; Jankiewicz, S; Lesiak, M; Mularek-Kubzdela, T; Sławek-Szmyt, S | 1 |
Biasucci, LM; Conte, C; Cribari, F; D'Aiello, A; Liuzzo, G; Narducci, ML; Pedicino, D; Ruggio, A | 1 |
Banach, J; Dobosiewicz, M; Gilewski, W; Grześk, G; Hertmanowski, W; Kowalkowska, M; Rogowicz, D; Wołowiec, Ł | 1 |
Afzal, O; Akhtar, MS; Altamimi, A; Hassan, MZ; Hassan, Q; Mohammad, AAS; Sharma, AK; Tabassum, F | 1 |
Afzal, O; Ahsan, MJ; Akhtar, MS; Alavudeen, SS; Altamimi, ASA; Hassan, MQ; Khurana, M; Rahman, SO; Sharma, AK; Siddiqui, A; Tabassum, F | 1 |
Hyllen, S; Lindstedt, S | 1 |
Carvalho, T; Correia, C; Cruz Ferreira, R; Ferreira Reis, J; Ilhão Moreira, R; Pereira da Silva, T; Pombo, D; Santos, C; Timóteo, AT; Valentim Gonçalves, A | 1 |
Abecia, A; Castrodeza, J; Cobo-Marcos, M; Codina, P; de Frutos, F; de Juan-Baguda, J; Diez-Lopez, C; Dobarro, D; Donoso-Trenado, V; Escolar, V; Garcia-Pinilla, JM; Gómez-Otero, I; González-Babarro, E; Gonzalez-Costello, J; Lopez-Fernandez, S; Marzoa-Rivas, R; Melendo-Viu, M; Méndez-Fernández, AB; Moliner-Abós, C; Pastor, F; Rodriguez, M; Ruiz-Bustillo, S; Sagasti-Aboitiz, I; Solé-González, E; Tobar, J; Vaqueriza-Cubillo, D | 1 |
Borbély, A; Csanádi, Z; Édes, I; Horváth, B; Nánási, PP; Papp, Z; Ráduly, AP; Sárkány, F; Szentandrássy, N; Tóth, A | 1 |
Gruchała, M; Książczyk, M; Lelonek, M; Stopczyńska, I | 1 |
Aydın, C; Kaplangoray, M | 1 |
Abdelshafy, M; Berchtold-Herz, M; Caliskan, K; de By, TMMH; Elkoumy, A; Elsherbini, H; Elzomor, H; Gollmann-Tepeköylü, C; Gummert, J; Kimman, JR; Loforte, A; Meyns, B; Mohacsi, P; Paluszkiewicz, L; Reineke, D; Schoenrath, F; Simpkin, AJ; Soliman, O | 1 |
Amani-Beni, R; GhasempourDabaghi, G; RabieeRad, M; Zare, MM | 1 |
Lin, X; Liu, G | 1 |
Li, D; Li, J; Zhang, L; Zhou, S | 1 |
Dong, N; Guo, Q; Lan, H; Li, C; Shi, J; Wang, G; Xiong, T; Zhang, J; Zheng, Q | 1 |
Capolupo, I; Columbo, C; De Rose, DU; Di Chiara, L; Dotta, A; Gandolfo, C; Giliberti, P; Landolfo, F; Martini, L; Pugnaloni, F; Ronchetti, MP; Santisi, A; Toscano, A | 1 |
Bayes-Genis, A; Codina, P; De Frutos, F; de Juan-Bagudá, J; Dobarro, D; Gonzalez-Costello, J; Lupón, J | 1 |
Amour, J; Cholley, B; Fellahi, JL; Levy, B; Longrois, D; Mebazaa, A; Ouattara, A | 1 |
Caliskan, K; Yalcin, YC | 1 |
Buttà, C; Miceli, G; Petrantoni, R; Pinto, A; Roberto, M; Tuttolomondo, A; Zappia, L | 1 |
Campo Sien, C; Comín-Colet, J; Delgado Jimenez, JF; Díez López, C; Enjuanes Grau, C; González Costello, J; Manito Lorite, N; Rubio-Rodríguez, D; Rubio-Terrés, C; Segovia-Cubero, J | 1 |
Di Chiara, L; Di Molfetta, A; Haiberger, R; Iacobelli, R; Marinari, E; Ricci, Z; Toscano, A | 1 |
Bugajski, J; Duszańska, A; Feusette, P; Gierlotka, M; Płonka, J | 1 |
Affronti, A; Bellani, G; Feri, M; Guarracino, F; Marini, M; Quacquarelli, A; Sangalli, F; Vitale, D; Volpi, F | 1 |
Arribas Ynsaurriaga, F; de Juan Bagudá, JS; Delgado Jiménez, JF; García-Cosío Carmena, MD; Ponz de Antonio, I; Rodríguez Chaverri, A | 1 |
Dobarro, D; Ribera-Solé, A | 1 |
Dabrowski, W; Jaroszynski, A; Piasek, E; Schlegel, TT; Siwicka-Gieroba, D | 1 |
Araújo, I; Campos, L; Cunha, GJL; Fernandes, L; Ferraz, M; Fonseca, C; Gomes, RV; Morais, R; Rocha, BML | 1 |
Chen, Y; Cui, D; Li, G; Liao, Y | 1 |
Mamalyga, LM; Mamalyga, ML | 1 |
Aimo, A; Arzilli, C; Emdin, M; Rapezzi, C; Vergaro, G | 1 |
Agostoni, P; Alvarez, J; Bettex, D; Bouchez, S; Brito, D; Černý, V; Comin-Colet, J; Crespo-Leiro, MG; Delgado, JF; Édes, I; Eremenko, AA; Farmakis, D; Fedele, F; Fonseca, C; Fruhwald, S; Girardis, M; Guarracino, F; Harjola, VP; Heringlake, M; Herpain, A; Heunks, LMA; Husebye, T; Ivancan, V; Karason, K; Kaul, S; Kivikko, M; Kubica, J; Lewinski, DV; Masip, J; Matskeplishvili, S; Mebazaa, A; Nieminen, MS; Oliva, F; Papp, JG; Papp, Z; Parissis, J; Parkhomenko, A; Põder, P; Pollesello, P; Pölzl, G; Reinecke, A; Ricksten, SE; Riha, H; Rudiger, A; Sarapohja, T; Schwinger, RHG; Toller, W; Tritapepe, L; Tschöpe, C; Vrtovec, B; Wikström, G | 1 |
Bugajski, J; Deja, M; Depukat, R; Gierlotka, M; Gruchała, M; Grześk, G; Kasprzak, JD; Kubica, J; Kucewicz-Czech, E; Leszek, P; Płonka, J; Sobkowicz, B; Stępińska, J; Straburzyńska-Migaj, E; Tycińska, A; Wilk, K; Zawiślak, B; Zymliński, R | 1 |
Bottio, T; Gerosa, G; Piperata, A | 1 |
Amarelli, C; Cacciatore, F; Golino, P; Maiello, C; Palmieri, V | 1 |
Masarone, D; Pacileo, G | 1 |
Fu, M; Liu, Y; Wang, Z | 1 |
Bachorzewska-Gajewska, H; Chlabicz, M; Dobrzycki, S; Kuźma, Ł; Zalewska-Adamiec, M | 1 |
Beitzke, D; Gremmel, F; Hülsmann, M; Kammerlander, A; Laggner, R; Loewe, C; Nolz, R; Senn, D; Wielandner, A | 1 |
Gruchała, M; Korościk, E; Lelonek, M; Stopczyńska, I; Straburzyńska-Migaj, E | 1 |
Alvarez, J; Bettex, D; Bouchez, S; Fruhwald, S; Girardis, M; Grossini, E; Guarracino, F; Heringlake, M; Herpain, A; Pollesello, P; Toller, W; Tritapepe, L | 1 |
Borlaug, BA; Burkhoff, D; Chung, ES; Lewis, GD; Majure, DT; Mazurek, JA; Preston, IR; Raza, F; Rich, JD; Rich, S; Shah, SJ; Simon, MA; Tedford, RJ; Thenappan, T; Zamanian, RT; Zolty, R | 1 |
Filipiak, KJ; Gasecka, A; Jaguszewski, MJ; Szarpak, L; Targonski, R | 1 |
Cui, DY; Hu, S; Hu, Y; Kuang, X; Liu, ZZ; Long, YX | 1 |
Luo, B; Wang, M | 1 |
Borlaug, BA; Brener, MI; Burkhoff, D; Hamid, NB; Rich, S; Shah, SJ; Sunagawa, K | 1 |
Häberle, HA | 1 |
Astuto, M; La Via, L; Merola, F; Sanfilippo, F | 1 |
Conti, N; Diemberger, I; Gatti, M; Potena, L; Raschi, E | 1 |
Altenberger, J; Baholli, L; Beltrán, P; Borbély, A; Bover, R; Comin-Colet, J; Delgado, JF; Fedele, F; Fontana, A; Fruhwald, F; Garcia-González, MJ; Giamouzis, G; Giannakoulas, G; Gustafsson, F; Kaikkonen, K; Kivikko, M; Kubica, J; Löfman, I; Malfatto, G; Manito, N; Martínez-Sellés, M; Masip, J; Merkely, B; Morandi, F; Mølgaard, H; Oliva, F; Pantev, E; Papp, Z; Perna, GP; Pfister, R; Piazza, V; Pollesello, P; Pölzl, G; Rangel-Sousa, D; Recio-Mayoral, A; Reinecke, A; Rieth, A; Sarapohja, T; Schmidt, G; Seidel, M; Störk, S; von Lewinski, D; Vrtovec, B; Wikström, G; Yerly, P | 1 |
Shang, G; Shang, Y; Song, D; Tang, M; Ti, Y; Wang, Z; Yang, X; Zhang, W; Zhang, Y; Zhong, M | 1 |
Andersen, A; Bogaard, HJ; Hansen, MS; Happé, C; Holmboe, S; Nielsen-Kudsk, JE; Ringgaard, S; Schultz, JG; Simonsen, U | 1 |
López, J; Rodríguez-Santamarta, M; Sayago, I | 1 |
De Carlo, M; Fiorelli, F; Giannini, C; Guarracino, F; Liga, R; Marraccini, E; Petronio, AS; Pieroni, A; Spontoni, P | 1 |
Hao, Y; Huang, S; Jia, L; Li, X; Ma, Y; Mao, Y; Qiu, J; Wang, M | 1 |
Altenberger, J; Gustafsson, F; Harjola, VP; Karason, K; Kindgen-Milles, D; Kivikko, M; Malfatto, G; Papp, Z; Parissis, J; Pollesello, P; Pölzl, G; Tschöpe, C | 1 |
Almeida, I; Caetano, F; Costa, M; Fernandes, A; Gonçalves, L; Madeira, M; Reis, L | 1 |
Belletti, A; Fontana, A; Pollesello, P; Silvetti, S | 1 |
Gong, SG; He, J; Jiang, R; Liu, JM; Luo, CJ; Qiu, HL; Wang, L; Wu, WH; Yuan, P; Zhang, R; Zhao, QH | 1 |
Abbate, A; Van Tassell, BW | 1 |
Brossier, D; Goyer, I; Toledano, B | 1 |
Muehlschlegel, JD; Varelmann, DJ | 1 |
Almenar, L; Blasco, T; Bruguera, J; Comín-Colet, J; Crespo-Leiro, MG; Delgado, J; García Pinilla, JM; Gonzalez-Vilchez, F; Grau, M; Lambert-Rodríguez, JL; Manito, N; Pascual-Figal, D; Segovia-Cubero, J; Sionis, A | 1 |
Hage, C; Haugen Löfman, I; Lund, LH; Manouras, A; Najjar, E; Ottenblad, E; Stålhberg, M | 1 |
Li, J; Zhang, L; Zhou, S | 1 |
Altenberger, J; Pölzl, G | 1 |
Chen, D; Matter, A; Sivakumar, N; Teneggi, V | 1 |
Bettex, D; Jacky, A; Krüger, B; Paal, S; Rudiger, A; Seifert, B; Spahn, DR; Wilhelm, MJ | 1 |
Apostolopoulou, SC; Kakava, F; Rammos, S; Tsoutsinos, A; Vagenakis, GA | 1 |
Grebenshchikov, OA; Lar'kov, RN; Likhvantsev, VV; Marchenko, DN; Ovezov, AM; Philippovskaya, ZS; Skripkin, YV; Sungurov, VA; Timoshin, SS; Ubasev, YV; Zabelina, TS | 1 |
Anker, SD; Balligand, JL; Bauersachs, J; Brutsaert, D; Carrier, L; Chlopicki, S; Cleland, JG; de Boer, RA; de Keulenaer, G; Dietl, A; Eschenhagen, T; Fischmeister, R; Hamdani, N; Harjola, VP; Heinzel, FR; Heymans, S; Hilfiker-Kleiner, D; Holzmeister, J; Limongelli, G; Linke, WA; Lund, LH; Lyon, AR; Maack, C; Manstein, DJ; Masip, J; Mebazaa, A; Metra, M; Metzger, J; Mueller, C; Papp, Z; Pieske, B; Ponikowski, P; Ristić, A; Ruschitzka, F; Seferović, PM; Skouri, H; Tocchetti, CG; Yilmaz, MB; Zimmermann, WH | 1 |
Andersson, B; Bartfay, SE; Bergh, N; Bollano, E; Dahlberg, P; Gilljam, T; Hjalmarsson, C; Karason, K; Lannemyr, L; Ljungman, C; Ricksten, SE; Rundqvist, B | 1 |
Allipour Birgani, S; Altenberger, J; Comín-Colet, J; Delgado, JF; Fedele, F; García-Gonzáles, MJ; Gustafsson, F; Masip, J; Papp, Z; Pölzl, G; Störk, S; Ulmer, H; Vrtovec, B; Wikström, G | 1 |
Bouchez, S; Fedele, F; Giannakoulas, G; Gustafsson, F; Harjola, VP; Karason, K; Kivikko, M; Oliva, F; Papp, Z; Parissis, J; Pollesello, P; Pölzl, G; Tschöpe, C; von Lewinski, D | 1 |
Iotti, GA; Mojoli, F; Tavazzi, G; Via, G | 1 |
Bergounioux, J; Essid, A; Haegy, I; Josseran, L; Mbieleu, B; Sumanaru, D | 1 |
Almeida, GR; Bernardo, WM; Buzzini, RF; Floriano, I; Silvinato, A | 1 |
Li, J; Li, Y; Wang, XY; Yang, F; Yang, J; Yang, ZY; Yuan, P | 1 |
Akin, Y; Aygun, E; Beyazal, OF; Demirkan, B; Karahan, M; Kervan, U; Kocabeyoglu, SS; Pac, M; Sert, DE; Unal, EU | 1 |
Cameli, M; Incampo, E; Lunghetti, S; Mandoli, GE; Mondillo, S; Navarri, R; Palmerini, E; Righini, FM; Sciaccaluga, C; Sisti, N | 1 |
Hou, ZQ; Hu, B; Shang, DY; Su, CY; Sun, ZX; Tan, H; Zhong, X; Zhou, Y | 1 |
Kivikko, M; Kurttila, M; Laitinen, T; Magga, J; Miettinen, K; Parviainen, I; Peuhkurinen, K; Punnonen, K; Timonen, K; Timonen, P; Tuomainen, PO; Uusaro, A; Vanninen, E; Vuolteenaho, O | 1 |
Banasiak, W; Biegus, J; Jankowska, EA; Kulej, K; Ponikowski, P; Szachniewicz, J; Zymliński, R | 1 |
Cully, M | 1 |
Huang, LQ; Huang, X; Jiang, RL; Lei, S; Xia, GL; Zhi, YH; Zhu, MF | 1 |
Dipchand, AI; Mohseni-Bod, H; Tosoni, A | 1 |
Bagalas, V; Boutou, AK; Paspala, A; Pitsiou, G; Stanopoulos, I | 1 |
Angadi, U; Chowdhry, MF; Westrope, C | 1 |
Elisha, N; Paret, G; Rubinsthein, M; Salem, I | 1 |
Aldea-Perona, A; Cordero, M; de Mora-Martín, M; del Mar García-Saiz, M; García-González, MJ; Lara-Padrón, A; López-Díaz, J; López-Fernández, S; Marrero-Rodríguez, F; Martínez-Sellés, M; Romero-García, J | 1 |
Barrett, NA; Berry, WT; Hewson, RW; Langrish, CJ; McKenzie, CA | 1 |
Ata, Y; Eris, C; Turk, T; Yavuz, S | 1 |
Hajj-Chahine, J | 1 |
Desimonas, NA | 1 |
Andersson, KB; Christensen, G; Golz, S; Hillestad, V; Knorr, A; Kramer, F | 1 |
Franz, WM; Grabmaier, U; Hagl, C; Kaczmarek, I; Kreissl, N; Sodian, R; Steinbeck, G; Theiss, HD | 1 |
Alibaz-Oner, F; Erguney, M; Gurbuz, OZ; Oner, E; Yurdakul, S | 1 |
Bacaksiz, A; Erdogan, E; Ergelen, M; Erturk, M; Karakurt, H; Sonmez, O; Tasal, A; Turfan, M; Uyarel, H; Vatankulu, MA | 1 |
de Lurdes, CM; Di Prima, AL; Greco, T; Landoni, G; Mucchetti, M; Pasin, L; Scandroglio, M; Silvetti, S; Zangrillo, A | 1 |
Pollesello, P | 1 |
Høydal, MA; Kolseth, SM; Nordhaug, DO; Rolim, NP; Salvesen, Ø; Wahba, A | 1 |
Andersen, GØ; Ata, SH; Dahl, CP; Levy, FO; Orstavik, O; Osnes, JB; Qvigstad, E; Riise, J; Skomedal, T | 1 |
Acarturk, E; Bacaksiz, A; Bozkurt, A; Demir, M; Eker, RA; Kanadasi, M; Sahin, DY; Tasal, A; Vatankulu, MA | 1 |
Califf, RM | 1 |
Colucci, W; Delgado-Herrera, L; Fisher, L; Garratt, C; Huang, B; Massie, BM; Packer, M; Padley, RJ; Salon, J; Sarapohja, T; Teerlink, JR; Thakkar, R; Young, J | 1 |
O'Connor, C | 2 |
Yeo, PSD | 1 |
Barisin, A; Barisin, S; Djuzel, V; Rudez, I | 1 |
Blengino, S; Branzi, G; Della Rosa, F; Facchini, M; Giglio, A; Malfatto, G; Parati, G; Rella, V; Villani, A | 1 |
Firlinger, F; Gegenhuber, A; Lenz, K; Lohr, G; Piringer, P | 1 |
Guo, M; Jia, Z; Liang, HQ; Song, Y; Zhang, LY; Zhang, YQ | 2 |
Cruz Mañas, J; Galán Ortega, M; Guerrero Orriach, JL; Iglesias, P; Navarro Arce, I; Rubio Navarro, M | 1 |
Altenberger, J; Ben-Gal, T; Böhmer, A; Comin-Colet, J; Dickstein, K; Edes, I; Fedele, F; Fonseca, C; García-González, MJ; Giannakoulas, G; Iakobishvili, Z; Jääskeläinen, P; Karavidas, A; Kettner, J; Kivikko, M; Lund, LH; Matskeplishvili, ST; Metra, M; Morandi, F; Nieminen, MS; Oliva, F; Parissis, J; Parkhomenko, A; Pollesello, P; Pölzl, G; Schwinger, RH; Segovia, J; Seidel, M; Vrtovec, B; Wikström, G | 1 |
Benson, L; Dahlström, U; Edner, M; Hagerman, I; Lund, LH; Thorvaldsen, T | 1 |
Akturk, IF; Birant, A; Erturk, M; Karakurt, H; Kurtar Mansıroglu, A; Oner, E; Somuncu, MU; Uzun, F; Yalcin, AA; Yildirim, A | 1 |
Altenberger, J; Avgeropoulou, E; Costard-Jaeckle, A; Dimopoulos, L; Ebner, C; Karavidas, A; Parissis, JT; Poelzl, G; Sihorsch, K; Ulmer, H; Weber, T; Winter, A | 1 |
Chivite, D; Corbella, X; Formiga, F | 1 |
Haddad, F; Hrovat, E; Knezevic, I; Oman, A; Pintar, T; Poglajen, G; Vrtovec, B; Wu, JC | 1 |
De Luca, L | 1 |
Makris, D; Papanikolaou, J; Tsolaki, V; Zakynthinos, E | 1 |
Cismowski, MJ; de Tombe, P; Guggilam, A; Lucchesi, PA; Sadayappan, S; Trask, AJ; West, TA; Wilson, K; Zhang, X | 1 |
Aliabadi, A; Buchberger, E; de Martin, R; Demyanets, S; Gröger, M; Hofer-Warbinek, R; Huber, K; Kastl, SP; Kaun, C; Krychtiuk, KA; Maurer, G; Pisoni, J; Rauscher, S; Speidl, WS; Watzke, L; Wojta, J; Zuckermann, A | 1 |
Andersen, GØ; Arnesen, H; Bjørnerheim, R; Eritsland, J; Husebye, T; Mangschau, A; Seljeflot, I | 1 |
Henriques-Coelho, T; Leite-Moreira, AF; Lourenço, AP; Moreno, N; Oliveira-Pinto, J; Tavares-Silva, M | 1 |
Martín Herranz, MI; Martínez Roca, C; Vilaboa Pedrosa, C; Yáñez Gómez, P | 1 |
Bistola, V; Farmakis, D; Filippatos, G; Frogoudaki, A; Ikonomidis, I; Kremastinos, D; Lekakis, J; Paraskevaidis, I; Parissis, JT; Rafouli-Stergiou, P; Vasiliadis, K | 1 |
Favilli, R; Lunghetti, S; Mondillo, S; Palmerini, E; Söderberg, S | 1 |
Li, JX; Niu, LL; Yi, GY; Zhang, CY; Zhang, J | 1 |
Adam, M; Baldus, S; Costard-Jäckle, A; Klinke, A; Knors, H; Meyer, S; Radunski, UK; Rudolph, TK; Rudolph, V; Spin, JM; Tsao, PS | 1 |
Acea, AB; Ferrer Hita, JJ; García-González, MJ; Jiménez-Sosa, A; Jorge-Pérez, P; Lacalzada Almeida, JB | 1 |
Freeman, LJ; Rafiq, I | 1 |
Ben-Gal, T; Buerke, M; Comín-Colet, J; Fedele, F; Karavidas, A; Kivikko, M; Nieminen, MS; Parissis, J; Pollesello, P; Severino, P; Wikström, G | 1 |
Gong, B; Li, Z; Yat Wong, PC | 1 |
Huang, J; Qian, J; Yao, Y; Zhang, D | 1 |
Çavuşoğlu, Y; Demirtaş, S; Gencer, E; Güneş, H; Kalaycı, S; Korkmaz, Ş; Mert, UK; Mutlu, F; Özdemir, S; Şaşmaz, H; Yılmaz, MB | 1 |
Nieminen, MS; Silvetti, S | 1 |
Ji, F; Wen, Y | 1 |
Andersen, A; Andersen, S; Hillgaard, TK; Nielsen, JM; Nielsen-Kudsk, JE; Ringgaard, S; Vildbrad, MD | 1 |
Irving, M; Pineda-Sanabria, SE; Robertson, IM; Sun, YB; Sykes, BD | 1 |
Ertl, G; Pauschinger, M; von Scheidt, W | 1 |
Kumar, A; Kushwah, S; Sahana, KS | 1 |
Harjola, VP; Kivikko, M; Nieminen, MS; Pollesello, P; Sarapohja, T; Tarvasmäki, T | 1 |
Huang, Q; Qin, X; Yang, H | 1 |
Buerke, M; Cohen-Solál, A; Costa, S; Édes, I; Erlikh, A; Franco, F; Gibson, C; Gorjup, V; Guarracino, F; Gustafsson, F; Harjola, VP; Husebye, T; Karason, K; Katsytadze, I; Kaul, S; Kivikko, M; Marenzi, G; Masip, J; Matskeplishvili, S; Mebazaa, A; Møller, JE; Nessler, B; Nessler, J; Nieminen, MS; Ntalianis, A; Oliva, F; Pichler-Cetin, E; Põder, P; Pollesello, P; Recio-Mayoral, A; Rex, S; Rokyta, R; Strasser, RH; Zima, E | 1 |
Mauriat, P; Séguéla, PE; Tafer, N; Thambo, JB | 1 |
Alvarez, J; Brito, D; Farmakis, D; Fedele, F; Fonseca, C; Gal, TB; Gordon, AC; Gotsman, I; Grossini, E; Guarracino, F; Harjola, VP; Hellman, Y; Heunks, L; Ivancan, V; Karavidas, A; Kivikko, M; Lomivorotov, V; Longrois, D; Masip, J; Metra, M; Morelli, A; Nikolaou, M; Papp, Z; Parissis, J; Parkhomenko, A; Poelzl, G; Pollesello, P; Ravn, HB; Rex, S; Ricksten, SE; Riha, H; Schwinger, RHG; Vrtovec, B; Yilmaz, MB; Zielinska, M | 1 |
Asif, M | 1 |
Birant, A; Eksik, A; Erturk, M; Kalkan, AK; Karakurt, H; Mansiroglu, AK; Oner, E; Ozturk, D; Somuncu, MU | 1 |
Fruhwald, F; Fruhwald, S; Pollesello, P | 1 |
Andersen, GØ; Bjørnerheim, R; Eritsland, J; Husebye, T | 1 |
Ciambellotti, F; Facchini, M; Giglio, A; Malfatto, G; Oldani, M; Ortis, B; Parati, G; Villani, A | 1 |
Anastasiou-Nana, M; Dimopoulos, S; Gerovasili, V; Kaldara, E; Kourtidou, S; Nanas, J; Nanas, S; Pierrakos, C; Roussos, C; Sarafoglou, S; Venetsanakos, J | 1 |
Kapralou, A; Katsaragakis, S; Markogiannakis, H; Theodorou, D; Toufektzian, L | 1 |
Andreadou, I; Bistola, V; Filippatos, G; Kremastinos, DT; Paraskevaidis, I; Parissis, JT | 1 |
Beck-da-Silva, L; Fuchs, FD | 1 |
Osório, AP; Rosa, EM; Scopel, L | 1 |
Harjola, VP; Lassus, J; Melin, J; Nieminen, MS; Peuhkurinen, K; Rossinen, J; Siirila-Waris, K | 1 |
Frick, M; Grander, W; Jonetzko, P; Metzler, B; Pachinger, O; Poelzl, G; Roithinger, FX; Ulmer, H; Zwick, RH | 1 |
Akyuz, S; Alioglu, E; Bozkaya, YT; Duygu, H; Gunduz, R; Kirilmaz, B; Ozdogan, O; Payzin, S; Turk, U; Turkoglu, C | 1 |
Harjola, VP; Jurkko, R; Nieminen, MS; Oikarinen, L; Puttonen, J; Sarapohja, T; Sundberg, S; Toivonen, L | 1 |
Bagshaw, SM; Bradford, C; Delaney, A; Lee, R; McCaffrey, J | 2 |
Francis, GS; Unzek, S | 1 |
Bistola, V; Filippatos, G; Ikonomidis, I; Kremastinos, DT; Papadopoulos, C; Paraskevaidis, IA; Parissis, JT | 1 |
Belenkov, Y; Cleland, JG; Eha, J; Kivikko, M; Nieminen, MS; Põder, P; Sarapohja, T | 1 |
Bistola, V; Farmakis, D; Filippatos, G; Iliodromitis, EK; Kremastinos, DT; Paraskevaidis, IA; Parissis, JT | 1 |
Endoh, M | 3 |
Altinay, L; Cicekcioglu, F; Katircioglu, SF; Parlar, AI; Yay, K | 1 |
Akilli, A; Akin, M; Duygu, H; Ergene, O; Erturk, U; Nalbantgil, S; Nazli, C; Ozerkan, F; Zoghi, M | 1 |
Economides, C; Kota, B; Prasad, AS; Singh, BN | 1 |
Mebazaa, A; Paraskevaidis, I; Parissis, JT; Rafouli-Stergiou, P | 1 |
Kass, DA | 1 |
Tagarakis, GI; Tsilimingas, NB | 1 |
Cleland, JG; Cohen-Solal, A; Filippatos, GS; Huang, B; Mebazaa, A; Nieminen, MS; Padley, RJ; Salon, JE; Thakkar, R | 1 |
Erdem, A; Karadas, F; Tandogan, I; Turgut, OO; Yalta, K; Yilmaz, A; Yilmaz, MB; Yontar, C | 2 |
Bonios, M; Drakos, SG; Kaldara, E; Kanakakis, JV; Katsaros, F; Nanas, JN; Nanas, S; Pantsios, C | 1 |
Carrio, ML; Farrero, E; Miralles, A; Rodriguez-Castro, D; Ruiz-Majoral, A; Torrado, H; Ventura, JL | 1 |
Antoniades, C; Antonopoulos, AS; Bakogiannis, C; Stefanadi, E; Stefanadis, C; Tousoulis, D | 1 |
Beyan, C; Ifran, A; Kaptan, K | 1 |
Beiras-Fernandez, A; Kaczmarek, I; Kur, F; Reichart, B; Schmoeckel, M; Sodian, R; Weis, F; Weis, M | 1 |
Abreu-Lima, C; Amorim, S; Damasceno, A; Ferreira, J; Ferreira, R; Fonseca, C; Ilídio-Moreira, J; Lousada, N; Martins-de-Campos, J; Oliveira-Soares, A; Rabaçal, C; Seabra-Gomes, R; Silva-Cardoso, J | 1 |
Chay Woodward, T; de Lissovoy, G; Fraeman, K; Salon, J; Sterz, R | 1 |
Cai, D; Cohen-Solal, A; Huang, B; Logeart, D; Mebazaa, A; Nieminen, MS | 1 |
de Lissovoy, G; Durtschi, A; Fraeman, K; Mullahy, J; Padley, RJ; Salon, J; Sterz, R; Teerlink, JR | 1 |
Kirkeby-Garstad, I; Kolseth, SM; Nordhaug, DO; Sellevold, O; Stenseth, R; Wahba, A | 1 |
Jaykumar, I; Kamath, SR; Matha, S | 1 |
Finckenberg, P; Forsten, H; Kaheinen, P; Kytö, V; Leskinen, H; Levijoki, J; Louhelainen, M; Merasto, S; Mervaala, E; Tikkanen, I; Vahtola, E | 1 |
Ambrosio, G; De Maria, R; Di Lenarda, A; Fedele, F; Gabrielli, D; Metra, M; Oliva, F; Perna, G; Senni, M | 1 |
Kiviniemi, V; Kurola, J; Leppikangas, H; Lindgren, L; Ruokonen, E; Rutanen, J | 1 |
Filippatos, G; Parissis, JT | 1 |
Kytö, V; Latva-Hirvelä, J; Levijoki, J; Saraste, A; Saukko, P; Vuorinen, T | 1 |
Ertmer, C; Morelli, A; Pietropaoli, P; Westphal, M | 1 |
Bilgehan, K; Duman, D; Palit, F; Sacide, A; Simsek, E | 1 |
Cao, DX; Cao, MH; He, B; He, WX; Li, J; Peng, SL; Xia, SX; Xu, ZD; Yang, T; Zhao, YF | 1 |
Cas, LD; Cotter, G; Gheorghiade, M; Metra, M; Sabbah, HN; Teerlink, JR; Zacà, V | 1 |
Despas, F; Franchitto, N; Galinier, M; Labrunee, M; Pathak, A; Senard, JM; Trouillet, C | 1 |
Grande, DB; Hidalgo, RL; Morales, SC; Moyano, AP | 1 |
Altenberger, J; Parissis, JT; Poelzl, G; Ulmer, H | 1 |
Liaudet, L; Rusca, M | 1 |
Omerovic, E; Swedberg, K; Waagstein, F | 1 |
Andersson, B; Bergh, CH; Dahlström, U; Forfang, K; Kivikko, M; Sarapohja, T; Ullman, B; Wikström, G | 1 |
Duman, D; Fotbolcu, H | 1 |
Dexeus, D; Hoffman, RS; Lugassy, DM; Nelson, LS; Stefan, A | 1 |
Alexander, PM; Butt, WW; Penny, DJ; Ryerson, LM; Shann, FA; Shekerdemian, LS | 1 |
Busani, S; Cobelli, M; Girardis, M; Pasetto, A; Rinaldi, L; Severino, C | 1 |
Ata, N; Beyaztas, A; Birdane, A; Cavusoglu, Y | 1 |
Polanczyk, CA; Ribeiro, RA; Rohde, LE | 1 |
Arutiunov, AG; Arutiunov, GP; Volkova, AL | 1 |
Branzi, G; Ciambellotti, F; Facchini, M; Giglio, A; Malfatto, G; Parati, G; Revera, M; Rosa, FD; Villani, A | 1 |
Campia, U; Gheorghiade, M; Nodari, S | 1 |
Banach, M; Kowalczyk, M; Kozłowski, D; Lip, GY; Mikhailidis, DP; Rysz, J | 1 |
Buerke, M; Lemm, H; Russ, M; Schlitt, A; Werdan, K | 1 |
Wikström, BG | 1 |
Ayub-Ferreira, SM; Bacal, F; Bocchi, EA; Mangini, S; Marcondes-Braga, FG | 1 |
Batur, MK; Kurt, IH; Yavuzer, K | 1 |
Tandoğan, I; Yalta, K; Yilmaz, MB; Yontar, OC | 1 |
Biala, A; Finckenberg, P; Kaheinen, P; Levijoki, J; Louhelainen, M; Luft, FC; Martonen, E; Merasto, S; Mervaala, E; Muller, DN | 1 |
Andrade Acuña, G; Dekhuijzen, PN; Heunks, LM; Linkels, M; van Hees, HW | 1 |
Alsina, E; Brogly, N; Gilsanz, F; Guasch, E; López, T; Puertas, L | 1 |
Buerke, U; Buerkem, B; Dietz, S; Krohe, K; Lemm, H; Raaz, U; Russ, M; Schlitt, A; Werdan, K | 1 |
Cui, L; Hao, YM; Jiang, DJ; Li, GP; Li, HM; Liu, J; Qi, GX; Wang, L; Wang, WZ; Wei, JP; Zhang, YD | 1 |
Apostolakis, S; Lazaridis, K; Spandidos, DA; Tzoras, S; Zaravinos, A | 1 |
Fox, CJ; Kaye, AD; Liu, H; Zhang, S | 1 |
Fields, AM; Milligan, DJ | 1 |
Erdem, A; Tandogan, I; Yalta, K; Yilmaz, MB; Yontar, OC | 1 |
Colucci, WS; Karlsson, MO; Kivikko, M; Pohjanjousi, P; Sundberg, S | 1 |
Anastasiou-Nana, M; Bistola, V; Ikonomidis, I; Papadopoulos, C; Paraskevaidis, IA; Parissis, J; Stassinos, V | 1 |
Ata, N; Birdane, A; Cavuşoğlu, Y; Demirüstü, C; Göktekin, Ö; Görenek, B; Tek, M; Ünalır, A | 1 |
Bongo, AS; Lazzero, M; Lupi, A; Rognoni, A; Rognoni, G | 1 |
Auteri, A; Di Renzo, M; Maffei, S; Pasqui, AL; Pompella, G; Puccetti, L | 1 |
Böhm, M; Cai, D; Cohen Solal, A; Filippatos, GS; Huang, B; Kivikko, M; Link, A; Mebazaa, A; Nieminen, MS; Padley, RJ; Salem, R | 1 |
Bautista-Hernandez, V; Fynn-Thompson, F; Portela, F; Sanchez-Andres, A | 1 |
Harjola, VP; Jalanko, M; Kivikko, M; Laine, M; Nieminen, MS | 1 |
Feola, M; Lombardo, E; Piccolo, S; Taglieri, C; Vallauri, P; Valle, R | 1 |
Hoffman, TM | 1 |
Bettari, L; Bugatti, S; Carubelli, V; Danesi, R; Dei Cas, L; Lazzarini, V; Lombardi, C; Metra, M; Monti, A; Villa, C | 1 |
Cheng, CP; Cheng, HJ; Little, WC; Masutani, S; Tachibana, H | 1 |
Beggino, C; Caimmi, PP; Crosio, E; Giustini, G; Grossini, E; Kapetanakis, EI; Micalizzi, E; Molinari, C; Reposo, G; Vacca, G | 1 |
Kiviniemi, V; Lahtinen, P; Pitkänen, O; Pölönen, P; Turpeinen, A; Uusaro, A | 1 |
Brasolin, B; Bruno, N; Caira, C; D'Ambrosi, A; Fedele, F; Mancone, M | 1 |
Kaheinen, P; Lakkisto, J; Lakkisto, P; Levijoki, J; Louhelainen, M; Merasto, S; Mervaala, E; Storvik, M; Tikkanen, I; Vahtola, E | 1 |
Kantor, PF; Timberlake, K | 1 |
Gautreux Minaya, S; Lobo Martínez, P; Oulego Erroz, I; Rodríguez Fernández, LM | 1 |
Bellmann, R; Bertocchi, C; Bijuklic, K; Dunzendorfer, S; Hasslacher, J; Joannidis, M; Kountchev, J | 1 |
Dzhaiani, NA; Gnidkina, NA; Kositsyna, IV; Tereshchenko, SN | 1 |
Bakır, F; Berker, D; Cetin, M; Çetin, ZG; Ciçekçioğlu, H; Güler, S; Işık, S; Ozuğuz, U; Uçar, O | 1 |
Bocchi, EA; Carvalho, VO; Cruz, F; Guimarães, GV; Issa, VS; Moura, LZ | 1 |
Mebazaa, A; Yilmaz, MB | 1 |
Biala, A; Finckenberg, P; Korpi, A; Levijoki, J; Loytainen, M; Martonen, E; Mervaala, E | 1 |
Lehmann, A; Radke, J; Sack, FU | 1 |
Favilli, R; Focardi, M; Guarino, E; Lunghetti, S; Maffei, S; Mondillo, S; Palmerini, E; Urselli, R | 1 |
Kilo, J; Schermer, E; Schweigmann, U; Velik-Salchner, C | 1 |
Bignami, E; Biondi-Zoccai, G; Greco, M; Greco, T; Guarracino, F; Landoni, G; Morelli, A; Zangrillo, A | 1 |
Bersani, I; Conti, G; De Carolis, MP; De Rosa, G; Pardeo, M; Piastra, M; Romagnoli, C; Stival, E; Tempera, A | 1 |
Allegaert, K; Thewissen, L | 1 |
Jovicić, B; Kosutić, J; Nikolić, L; Prijić, S; Rakić, S; Stajević, M; Vukomanović, V | 1 |
Borlu, F; Dal, MS; Oztekin, E; Paksoy, F; Tursun, I; Ulaş, T | 1 |
Aro, S; Høydal, M; Kirkeby-Garstad, I; Kolseth, SM; Nordgaard, H; Nordhaug, D; Rognmo, Ø; Wahba, A | 1 |
Gongadze, NV; Sukoyan, GV | 1 |
An, T; Huang, Y; Lü, R; Qing, EM; Qing, P; Wei, BQ; Zhang, J; Zhang, YH; Zhou, Q; Zou, CH | 1 |
Bai, XJ; Huang, Y; Jiang, YN; Li, H; Liu, WX; Qing, EM; Qu, P; Sun, YX; Wei, BQ; Zhang, J; Zhang, L; Zhang, YH; Zhou, Q | 1 |
Barillà, F; Dominici, T; Giordano, F; Jacomelli, I; Pellicano, M | 1 |
Amir, O; Zafrir, B | 1 |
Arai, M | 1 |
Büyüklü, M; Kürüm, AT; Set, T; Tatlý, E | 1 |
Aydoğdu, S; Cetin, M; Cicekçioğlu, H; Güven Cetin, Z; Sahin, M; Uçar, O; Vasfi Ulusoy, F | 1 |
Colucci, WS; Kivikko, M; Mebazaa, A; Nieminen, MS; Pohjanjousi, P; Pollesello, P; Teerlink, JR | 1 |
Branzi, G; Della Rosa, F; Facchini, M; Malfatto, G; Parati, G; Rella, V; Villani, A | 1 |
Cohen, A; Hasin, Y; Nahir, M; Qarawani, D | 1 |
Cai, D; Cohen-Solal, A; Deye, N; Kivikko, M; Laribi, S; Laterre, PF; Mebazaa, A; Nikolaou, M; Parissis, J; Paugam-Burtz, C; Poder, P; Pohjanjousi, P; Seronde, MF; Yilmaz, MB | 1 |
Bacchini, S; Bongo, AS; Cavallino, C; Lupi, A; Rognoni, A; Rosso, R; Secco, GG; Veia, A | 1 |
Apajasalo, M; D'Ambrosi, A; Fedele, F; Lucioni, C; Mazzi, S; Pollesello, P | 1 |
Andersen, GØ; Arnesen, H; Bjørnerheim, R; Eritsland, J; Husebye, T; Mangschau, A; Müller, C; Sandvik, L; Seljeflot, I | 1 |
Ambrosy, AP; Butler, J; Gheorghiade, M; Greene, SJ; Vaduganathan, M | 1 |
Coats, AJ | 1 |
Andrejevs, N; Golikov, AP; Kobalava, ZD; Laine, T; Lazebnik, LB; Lehtonen, LA; Lie, KI; Moiseyev, VS; Nieminen, MS; Põder, P; Ruda, MY | 1 |
Antila, S; Eha, J; Kivikko, M; Lehtonen, L; Pentikäinen, PJ | 2 |
Young, JB | 1 |
Colucci, WS; Kivikko, M; Lehtonen, L | 1 |
Borghi, C; Greenberg, B; Perrone, S | 1 |
Apajasalo, M; Cleland, JG; Kobelt, G; Takala, A; Zethraeus, N | 1 |
Gattis, WA; Gheorghiade, M; Jain, P; Klein, L; Massie, BM | 1 |
Teerlink, JR | 2 |
Bouali, R; Dubois, MJ; Verdant, CL | 1 |
Gronda, E; Mangiavacchi, M | 1 |
Antila, S; Jonsson, EN; Karlsson, MO; Lehtonen, L; McFadyen, L | 1 |
Erhardt, L; Mebazaa, A | 1 |
Antila, S; Eha, J; Heinpalu, M; Lehtonen, L; Loogna, I; Planken, U; Põder, P; Rantanen, S; Sundberg, S | 2 |
Frishman, WH | 1 |
Boldt, J; Kirchner, J; Lehmann, A | 1 |
McBride, BF; White, CM | 1 |
Erhardt, LR | 1 |
Nieminen, MS; Sandell, EP | 1 |
Follath, F | 2 |
Anifantakis, A; Athanassopoulos, G; Chatzigeorgiou, G; Cokkinos, DV; Iakovis, P; Karatasakis, G; Koutsogiannis, N; Manginas, A; Maounis, T; Papadakis, M; Spargias, KS | 1 |
Cavana, M; Fraticelli, A; Mebazaa, A; Pignataro, C | 1 |
Innes, CA; Wagstaff, AJ | 1 |
Krum, H; Liew, D | 1 |
Borges, A; Braun, JP; Dohmen, P; Döpfmer, U; Kastrup, M; Kox, W; Roots, I; Schneider, M; Spies, C | 1 |
Antila, S; Eha, J; Heikkilä, A; Kivikko, M; Lehtonen, L; Pentikäinen, PJ; Pohjanjousi, P | 1 |
Delle Karth, G; Heinz, G | 1 |
Cleland, JG; McGowan, J; Nikitin, N | 1 |
Riggs, JM | 1 |
Adamopoulos, S; Antoniades, C; Iliodromitis, E; Kostakis, G; Kremastinos, D; Kyrzopoulos, S; Parissis, JT; Rigas, A | 1 |
Battagliese, A; Bucciarelli Ducci, C; Celotto, A; De Luca, L; Fedele, F; Palombaro, GL; Proietti, P | 1 |
Lehtonen, L; Lilleberg, J; Toivonen, L; Ylönen, V | 1 |
Graham, CA | 1 |
Kwok, BW | 1 |
Baixas, C; Couderc, P; Delay, M; Galinier, M; Maury, P; Pathak, A; Roncalli, J | 1 |
Eriksson, O; Haikala, H; Pollesello, P | 1 |
Anker, SD; Diller, GP; von Haehling, S | 1 |
Cheng, CP; Cheng, HJ; Igawa, A; Little, WC; Tachibana, H; Ukai, T; Zhang, ZS | 1 |
Agrios, N; Anastasiou-Nana, MI; Christodoulou, K; Dalianis, A; Kanakakis, J; Nanas, JN; Papazoglou, PP; Terrovitis, JV; Tsagalou, EP; Tsolakis, E | 1 |
Pollesello, P; Solaro, RJ; Sorsa, T | 1 |
Abreu e Lima, C; Cardoso, JS; Damasceno, A; de Campos, JM; de Sá, EP; Ferreira, J; Ferreira, R; Fonseca, C; Lousada, N; Moreira, JI; Rabaçal, C; Seabra-Gomes, R | 1 |
Kivikko, M; Lehtonen, L | 1 |
Alexopoulos, GP; Anastasiou-Nana, MI; Kanakakis, J; Nanas, JN; Nanas, SN; Ntalianis, A; Papazoglou, P; Terrovitis, JV; Tsagalou, EP; Tsolakis, E | 1 |
Adamopoulos, S; Degiannis, D; Iliodromitis, E; Kostakis, G; Kremastinos, DT; Kyrzopoulos, S; Parissis, JT; Rassias, J | 1 |
Farmakis, D; Kremastinos, DT; Parissis, JT | 2 |
Chatterjee, K; Foster, E; Gerber, IL; Jordan, MV; Kostal, M; McKeown, B; Michaels, AD; Vakharia, KT | 1 |
Brixius, K; Schwinger, RH | 1 |
Csapó, K; Edes, I; Haikala, H; Papp, Z; Pollesello, P | 1 |
Andreadou, I; Androulakis, A; Avgeropoulou, C; Demopoulou, M; Kallikazaros, I; Markantonis-Kyroudis, S; Missovoulos, P | 1 |
Gegenhuber, A; Haltmayer, M; Mueller, T | 1 |
Paraskevaidis, IA; Parissis, JT; Th Kremastinos, D | 1 |
Bonnefoy, E; Trindade, PT | 1 |
Erhardt, L | 1 |
Lehtonen, L | 2 |
Barretto, AC; Canaviera, R; Follador, W; Martins, ML; Oliveira, MT; Scipioni, A; Tsuji, RL | 1 |
Adamopoulos, S; Farmakis, D; Filippatos, G; Kremastinos, DT; Lekakis, J; Panou, F; Paraskevaidis, I; Parissis, JT; Venetsanou, K | 1 |
Reingardiene, D | 1 |
Berger, R; Bojic, A; Huelsmann, M; Moertl, D; Pacher, R | 1 |
Kaplinsky, EJ; Perrone, SV | 1 |
MacGowan, GA | 2 |
Colucci, WS; Maytin, M | 1 |
Gheorghiade, M; Mebazaa, A; Teerlink, JR | 1 |
Barraud, D; Mebazaa, A; Welschbillig, S | 1 |
Cardoso, JS; Follath, F; Franco, F | 1 |
Earl, GL; Fitzpatrick, JT | 1 |
Dernellis, J; Panaretou, M | 1 |
Herzig, S; Hoppe, UC; Michels, G | 1 |
Huang, SJ; McLean, AS; Nalos, M; Ting, I | 1 |
Adamopoulos, S; Farmakis, D; Filippatos, G; Kremastinos, D; Paraskevaidis, I; Parissis, JT | 1 |
Nanas, JN; Tsagalou, EP | 1 |
Akhter, MW; Ng, TM | 1 |
Rasmussen, T; Schmidt, H | 1 |
Chalikias, GK; Hatseras, DI; Hatzinikolaou, HI; Kaski, JC; Kortsaris, AX; Maltezos, E; Papanas, N; Stakos, DA; Tentes, IK; Tziakas, DN | 1 |
Brixius, K; Hoyer, HK; Schwinger, RH | 1 |
Flaim, BD; MacIsaac, AI; Prior, DL; Yii, MY | 1 |
McLachlan, CS; Mossop, P | 1 |
Mehra, MR | 1 |
Atar, D; Hodt, A; Steine, K | 1 |
Böttiger, BW; Motsch, J; Rauch, H | 1 |
Francis, D | 1 |
Domínguez Rodríguez, A; García González, MJ | 1 |
Colucci, WS; De Luca, L; Gheorghiade, M; Massie, BM; Nieminen, MS | 1 |
Antoniades, C; Karamitros, I; Latsios, G; Stefanadis, C; Tentolouris, C; Tousoulis, D; Trikas, A; Vasiliadou, K | 1 |
Adamopoulos, S; Farmakis, D; Filippatos, GS; Gheorghiade, M; Iliodromitis, EK; Karatzas, D; Kremastinos, DT; Paraskevaidis, I; Parissis, JT; Tsiapras, D | 1 |
Hennersdorf, M; Müller, K; Peters, A; Strauer, BE; Zeus, T | 1 |
Kivikko, M; Kupari, M; Laine, M; Lilleberg, J; Palkama, T; Pohjanjousi, P | 1 |
Ahmadi, R; Berger, R; Bojic, A; Heissenberger, I; Huelsmann, M; Moertl, D; Pacher, R | 1 |
Munger, MA | 1 |
Brimioulle, S; Demester, JP; Fesler, P; Huez, S; Kerbaul, F; Naeije, R; Rondelet, B | 1 |
Giannakoulas, G; Giannoglou, G; Kalpidis, P; Louridas, G; Martiadou, K; Parharidis, G; Vassilikos, V | 1 |
Feres, GA; Garcia, JA; Hansen, MH; Holanda, GS; Salluh, JI; Simvoulidis, LF; Soares, M; Souza, RC; Toscano, L | 1 |
Caimmi, PP; Grossini, E; Molinari, C; Teodori, G; Vacca, G | 1 |
Adamopoulos, S; Farmakis, D; Filippatos, G; Iliodromitis, E; Kremastinos, DT; Panou, F; Paraskevaidis, I; Parissis, JT | 1 |
Bistola, V; Farmakis, D; Filippatos, G; Kourea, K; Kremastinos, D; Nikolaou, M; Panou, F; Paraskevaidis, I; Parissis, JT | 1 |
Flevari, P; Kourea, K; Kremastinos, DT; Leftheriotis, D; Panou, F; Parissis, JT | 1 |
Lechner, E; Mair, R; Moosbauer, W; Pinter, M; Tulzer, G | 1 |
Adamopoulos, S; Bistola, V; Farmakis, D; Kremastinos, DT; Parissis, JT | 1 |
Agewall, S; Atar, D | 1 |
Akilli, A; Akin, M; Duygu, H; Ergene, O; Nalbantgil, S; Nazli, C; Ozerkan, F; Zoghi, M | 1 |
Cam, N; Kasikcioglu, HA | 1 |
Benezet-Mazuecos, J; de la Hera, J | 1 |
Antoniades, C; Koumallos, N; Marinou, K; Stefanadis, C; Tousoulis, D | 1 |
Lehtonen, L; Põder, P | 1 |
Cavusoglu, Y | 1 |
Barraud, D; Damy, T; Faivre, V; Gayat, E; Heymes, C; Mebazaa, A; Payen, D; Shah, AM; Welschbillig, S | 1 |
Erdem, A; Karadas, F; Tandogan, I; Yilmaz, MB | 1 |
De Keulenaer, B; Powell, BP | 1 |
Cohen-Solal, A; Kivikko, M; Kleber, FX; Mebazaa, A; Nieminen, MS; Packer, M; Padley, RJ; Pocock, SJ; Põder, P; Thakkar, R | 1 |
Farmakis, D; Nieminen, M; Parissis, JT | 1 |
Arapi, S; Bistola, V; Farmakis, D; Filippatos, G; Karavidas, A; Korres, D; Kremastinos, DT; Matsakas, E; Paraskevaidis, IA; Parissis, JT | 1 |
Izumi, T; Shinagawa, H | 1 |
Iwama, Y; Takagi, A | 1 |
Kajimoto, K; Kawana, M; Watanabe, H | 1 |
Yasumura, Y | 1 |
Antila, S; Lehtonen, LA; Sundberg, S | 1 |
Bistola, V; Farmakis, D; Filippatos, G; Kremastinos, D; Nikolaou, M; Papadopoulos, C; Paraskevaidis, I; Parissis, JT | 1 |
Bunc, M; Vrtovec, B; Yazdanbakhsh, AP; Zemljic, G | 1 |
Knez, I; Toller, W | 1 |
Carbajosa-Dalmau, J; Carrasco-Moreno, R; Climent-Payá, V; Diéguez-Zaragoza, S; Fernández-Cañadas, J; Laghzaoui, F; Llorens-Soriano, P; Murcia-Zaragoza, J | 1 |
Ma, J; Song, ZZ | 1 |
Butler, J; Giamouzis, G; Giannakoulas, G | 1 |
Andreadou, I; Bistola, V; Filippatos, G; Iliodromitis, EK; Kremastinos, DT; Louka, A; Markantonis, SL; Paraskevaidis, I; Parissis, JT; Pyriochou, A | 1 |
Graudins, A; Najafi, J; Rur-SC, MP | 1 |
Akilli, A; Akin, M; Duygu, H; Ergene, O; Nalbantgil, S; Nazli, C; Ozerkan, F; Yildiz, A; Zoghi, M | 1 |
Damman, K; Voors, AA | 1 |
Simes, DC | 1 |
Bistola, V; Filippatos, G; Ikonomidis, I; Kourea, K; Kremastinos, DT; Lekakis, J; Paraskevaidis, I; Parissis, JT | 1 |
Tang, WH | 1 |
Angus, JA; Royse, AG; Royse, CF; Soeding, PE; Wright, CE | 1 |
Felker, GM; Petersen, JW | 1 |
Khouadja, H; Mebazaa, A; Rezlan, E; Tavares, M; Vostroknoutova, I | 1 |
Cheng, CP; Cheng, HJ; Heikkilä, A; Hyttilä-Hopponen, M; Levijoki, J; Little, WC; Masutani, S; Vuorela, A | 1 |
Archan, S; Toller, W | 1 |
Antoniades, C; Koumallos, N; Shirodaria, C; Stefanadis, C; Tousoulis, D | 1 |
Best, M; Dembo, L; Driscoll, GO; Parle, NM; Thomas, MD | 1 |
Birhan, M; Yilmaz, MB | 1 |
Böhm, M; De Luca, L; Dickstein, K; El-Banayosy, A; Filippatos, G; Gheorghiade, M; Mebazaa, A; Nieminen, M; Parissis, JT; Rhodes, A; Voors, AA; Zannad, F | 1 |
Rabasseda, X | 1 |
Albuquerque, D; Baima, J; Barretto, AC; Bocchi, EA; Lage, S; Moreira, Mda C; Rassi, S; Ribeiro, JP; Vilas-Boas, F | 1 |
Andrade, AC; Mebazaa, A; Tavares, M | 1 |
Ghazwinian, N; Hochmair, N; Mueller, T; Plöchl, W; Ponschab, M | 1 |
Kapralou, A; Katsaragakis, S; Kofinas, G; Larentzakis, A; Markogiannakis, H; Menenakos, E; Theodoraki, EM; Theodorou, D | 1 |
Ertmer, C; Pinto, BB; Rehberg, S; Westphal, M | 1 |
Garrido Bravo, IP; Manzano-Fernández, S; Marín, F; Pascual Figal, DA | 1 |
Agha, SA; Butler, J; Georgiopoulou, V; Giamouzis, G; Giannakoulas, G; Kalogeropoulos, A; Karvounis, H; Tsarpalis, K | 1 |
Celik, T; Iyisoy, A; Kardesoglu, E; Yuksel, UC | 1 |
Papp, JG; Udvary, E; Végh, A | 1 |
Antila, S; Eha, J; Heinpalu, M; Lehtonen, L; Loogna, I; Mesikepp, A; Planken, U; Sandell, EP | 1 |
Antila, S; Hayha, M; Heikkinen, P; Lehtonen, LA; Ottoila, P; Pentikainen, PJ; Sandell, EP | 1 |
Akkila, J; Lehtonen, L; Mills-Owens, P | 1 |
Katz, SD; Mathew, L | 1 |
Castell, M; Hasenfuss, G; Just, H; Kretschmann, B; Maier, LS; Pieske, B | 1 |
Cleland, JG; Gomes, UC | 1 |
Colucci, WS; Gottlieb, SS; Greenberg, BH; Haeusslein, E; Hare, J; Hutchins, S; Leier, CV; LeJemtel, TH; Loh, E; Nicklas, J; Ogilby, D; Singh, BN; Slawsky, MT; Smith, W | 1 |
Akkila, J; Hasenfuss, G; Kleber, FX; Lehtonen, LA; Mitrovic, V; Nieminen, MS; Nyquist, O; Remme, WJ | 1 |
Akkila, J; Iida, H; Karanko, M; Knuuti, J; Lehikoinen, P; Lehtonen, L; Någren, K; Saraste, M; Ukkonen, H; Voipio-Pulkki, LM | 1 |
Orrù, P; Porcu, M | 1 |
Lehtonen, LA | 1 |
Figgitt, DP; Gillies, PS; Goa, KL | 1 |
Brixius, K; Reicke, S; Schwinger, RH | 1 |
Chin, BS; Lip, GY | 1 |
Cleland, JG; McGowan, J | 1 |
Laine, M; Lehtonen, L; Nieminen, MS | 1 |
138 review(s) available for simendan and Heart Failure
Article | Year |
---|---|
The importance of pharmacokinetics, pharmacodynamic and repetitive use of levosimendan.
Topics: Calcium; Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Pyridazines; Simendan | 2022 |
Levosimendan: mechanistic insight and its diverse future aspects in cardiac care.
Topics: Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Myocytes, Cardiac; Pyridazines; Simendan; Stroke Volume | 2023 |
Novel Treatments of Hypertrophic Cardiomyopathy in GDMT for Heart Failure: A State-of-art Review.
Topics: Cardiomyopathy, Hypertrophic; Heart Failure; Humans; Simendan; Stroke Volume | 2023 |
Effect of Levosimendan on B-type Natriuretic Peptide Levels in Patients with Heart Failure: A Systematic Review and Meta-Analysis.
Topics: Heart Failure; Humans; Natriuretic Peptide, Brain; Patients; Simendan | 2023 |
The anti-inflammatory and haemodynamic effects of levosimendan on advanced heart failure patients: a meta-analysis of published studies.
Topics: Anti-Inflammatory Agents; Databases, Factual; Heart Failure; Hemodynamics; Humans; Interleukin-6; Simendan | 2023 |
Levosimendan in the light of the results of the recent randomized controlled trials: an expert opinion paper.
Topics: Cardiotonic Agents; Expert Testimony; Heart Failure; Humans; Perioperative Medicine; Randomized Controlled Trials as Topic; Simendan | 2019 |
Levosimendan Can Improve the Level of B-Type Natriuretic Peptide and the Left Ventricular Ejection Fraction of Patients with Advanced Heart Failure: A Meta-analysis of Randomized Controlled Trials.
Topics: Cardiotonic Agents; Heart Failure; Hemodynamics; Humans; Natriuretic Peptide, Brain; Peptide Fragments; Randomized Controlled Trials as Topic; Simendan; Stroke Volume; Ventricular Function, Left | 2021 |
Levosimendan Efficacy and Safety: 20 Years of SIMDAX in Clinical Use.
Topics: Cardiotonic Agents; Heart Failure; Humans; Myocardial Contraction; Patient Safety; Simendan; Treatment Outcome; Vasodilation; Vasodilator Agents | 2020 |
An update on levosimendan in acute cardiac care: applications and recommendations for optimal efficacy and safety.
Topics: Adrenergic beta-Antagonists; Cardiac Surgical Procedures; Cardiotonic Agents; Critical Care; Dobutamine; Heart Failure; Hemodynamics; Humans; Shock, Cardiogenic; Simendan | 2021 |
Efficacy and safety of levosimendan and dobutamine in heart failure: A systematic review and meta-analysis.
Topics: Cardiotonic Agents; Dobutamine; Heart Failure; Humans; Hydrazones; Pyridazines; Simendan; Treatment Outcome | 2021 |
Effect of Levosimendan on Ventricular Systolic and Diastolic Functions in Heart Failure Patients: A Meta-Analysis of Randomized Controlled Trials.
Topics: Cardiotonic Agents; Diastole; Echocardiography; Heart Failure; Humans; Randomized Controlled Trials as Topic; Simendan; Stroke Volume; Systole; Ventricular Function, Left; Ventricular Function, Right | 2021 |
[Levosimendan - a 20-Year Experience].
Topics: Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Pyridazines; Simendan | 2021 |
Evidence and Current Use of Levosimendan in the Treatment of Heart Failure: Filling the Gap.
Topics: Adenosine Triphosphate; Cardiotonic Agents; Heart Failure; Humans; Phosphodiesterase 3 Inhibitors; Simendan; Vasodilator Agents | 2021 |
Repetitive use of levosimendan in advanced heart failure: need for stronger evidence in a field in dire need of a useful therapy.
Topics: Administration, Oral; Cardiotonic Agents; Clinical Trials as Topic; Consensus Development Conferences as Topic; Drug Administration Schedule; Europe; Evidence-Based Medicine; Heart Failure; Humans; Hydrazones; Infusions, Intravenous; Pyridazines; Rome; Simendan | 2017 |
Effects of Levosimendan on Patients with Heart Failure Complicating Acute Coronary Syndrome: A Meta-Analysis of Randomized Controlled Trials.
Topics: Acute Coronary Syndrome; Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Prognosis; Pyridazines; Randomized Controlled Trials as Topic; Shock, Cardiogenic; Simendan | 2017 |
Efficacy and safety of levosimendan in patients with acute right heart failure: A meta-analysis.
Topics: Acute Disease; Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Pyridazines; Randomized Controlled Trials as Topic; Simendan; Treatment Outcome; Vasodilator Agents | 2017 |
Levosimendan in Acute and Advanced Heart Failure: An Appraisal of the Clinical Database and Evaluation of Its Therapeutic Applications.
Topics: Acute Disease; Cardiotonic Agents; Chronic Disease; Clinical Decision-Making; Congresses as Topic; Databases, Factual; Heart Failure; Humans; Myocardial Contraction; Patient Selection; Recovery of Function; Risk Factors; Simendan; Treatment Outcome; Vasodilation; Vasodilator Agents | 2018 |
Rehospitalization after intermittent levosimendan treatment in advanced heart failure patients: a meta-analysis of randomized trials.
Topics: Cause of Death; Dose-Response Relationship, Drug; Drug Administration Schedule; Global Health; Heart Failure; Humans; Hydrazones; Patient Readmission; Pyridazines; Randomized Controlled Trials as Topic; Simendan; Survival Rate; Vasodilator Agents | 2017 |
Noteworthy Literature published in 2017 for Cardiothoracic Anesthesiologists.
Topics: Adrenal Cortex Hormones; Anesthesiologists; Anti-Arrhythmia Agents; Cardiac Surgical Procedures; Heart Failure; Heart-Assist Devices; Humans; Hydrazones; Methylprednisolone; Pyridazines; Simendan; Thrombelastography; Transcatheter Aortic Valve Replacement | 2018 |
Effect of levosimendan in patients with acute decompensated heart failure : A meta-analysis.
Topics: Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Prospective Studies; Pyridazines; Simendan | 2019 |
Drugs' development in acute heart failure: what went wrong?
Topics: Acute Disease; Cardiotonic Agents; Drug Approval; Drug Development; Heart Failure; Humans; Natriuretic Peptide, Brain; Simendan | 2018 |
Levosimendan in Acute and Advanced Heart Failure: an Expert Perspective on Posology and Therapeutic Application.
Topics: Acute Disease; Cardiotonic Agents; Chronic Disease; Congresses as Topic; Evidence-Based Medicine; Heart Failure; Humans; Kidney; Myocardial Contraction; Recovery of Function; Simendan; Time Factors; Treatment Outcome; Vasodilator Agents | 2018 |
Decompensated congestive heart failure - treatment with levosimendan.
Topics: Brazil; Cardiomyopathy, Dilated; Cardiotonic Agents; Clinical Decision-Making; Heart Failure; Humans; Reproducibility of Results; Risk Factors; Simendan; Treatment Outcome | 2019 |
Effects of levosimendan in heart failure: The role of echocardiography.
Topics: Cardiotonic Agents; Echocardiography; Heart Failure; Heart Ventricles; Humans; Simendan; Stroke Volume; Systole; Ventricular Function, Left | 2019 |
Levosimendan versus dobutamine in critically ill patients: a meta-analysis of randomized controlled trials.
Topics: Arrhythmias, Cardiac; Cardiotonic Agents; Comorbidity; Critical Illness; Dobutamine; Evidence-Based Medicine; Heart Failure; Humans; Hydrazones; Hypotension; Pyridazines; Randomized Controlled Trials as Topic; Risk Factors; Simendan; Survival Rate; Treatment Outcome | 2013 |
The use of levosimendan in children with cancer with severe acute cardiac dysfunction: case series and a review of the literature.
Topics: Acute Disease; Antineoplastic Agents; Cardiotonic Agents; Child, Preschool; Female; Heart Failure; Humans; Hydrazones; Leukemia, Myeloid, Acute; Neuroblastoma; Pyridazines; Severity of Illness Index; Simendan | 2014 |
Is levosimendan effective in paediatric heart failure and post-cardiac surgeries?
Topics: Age Factors; Benchmarking; Cardiac Surgical Procedures; Cardiovascular Agents; Child, Preschool; Evidence-Based Medicine; Heart Failure; Hemodynamics; Humans; Hydrazones; Pyridazines; Recovery of Function; Simendan; Treatment Outcome; Ventricular Function, Left | 2013 |
Intermittent levosimendan improves mid-term survival in chronic heart failure patients: meta-analysis of randomised trials.
Topics: Administration, Intravenous; Adult; Cardiotonic Agents; Chronic Disease; Heart Failure; Humans; Hydrazones; Pyridazines; Randomized Controlled Trials as Topic; Simendan; Survival Rate; Time Factors | 2014 |
[Organ-protection therapy. A new therapeutic approach for acute heart failure?].
Topics: Acute Disease; Amides; Benzazepines; Cardio-Renal Syndrome; Dobutamine; Fumarates; Heart Failure; Humans; Hydrazones; Inflammation; Kaplan-Meier Estimate; Multicenter Studies as Topic; Natriuretic Peptide, Brain; Prognosis; Pyridazines; Randomized Controlled Trials as Topic; Recombinant Proteins; Relaxin; Simendan; Therapies, Investigational; Tolvaptan | 2014 |
Levosimendan: The current situation and new prospects.
Topics: Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Pyridazines; Simendan | 2014 |
Repetitive infusion of levosimendan in patients with chronic heart failure: a meta-analysis.
Topics: Chronic Disease; Clinical Trials as Topic; Follow-Up Studies; Heart Failure; Humans; Hydrazones; Pyridazines; Simendan; Stroke Volume | 2015 |
Levosimendan Treatment for Heart Failure: A Systematic Review and Meta-Analysis.
Topics: Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Pyridazines; Randomized Controlled Trials as Topic; Simendan; Treatment Outcome | 2015 |
Repeated or intermittent levosimendan treatment in advanced heart failure: An updated meta-analysis.
Topics: Cardiotonic Agents; Drug Administration Schedule; Heart Failure; Humans; Hydrazones; Pyridazines; Randomized Controlled Trials as Topic; Simendan; Treatment Outcome | 2016 |
Long-term intravenous inotropes in low-output terminal heart failure?
Topics: Administration, Intravenous; Cardiac Output; Cardiac Output, Low; Cardiotonic Agents; Chi-Square Distribution; Dobutamine; Drug Administration Schedule; Heart Failure; Heart Transplantation; Humans; Hydrazones; Milrinone; Odds Ratio; Practice Guidelines as Topic; Pyridazines; Risk Factors; Simendan; Time Factors; Treatment Outcome; Waiting Lists | 2016 |
The role of levosimendan in acute heart failure complicating acute coronary syndrome: A review and expert consensus opinion.
Topics: Acute Coronary Syndrome; Anti-Arrhythmia Agents; Drug Synergism; Heart Failure; Humans; Hydrazones; Practice Guidelines as Topic; Prognosis; Pyridazines; Simendan | 2016 |
[Use of levosimendan in children].
Topics: Cardiac Output, Low; Cardiotonic Agents; Child; Extracorporeal Circulation; Heart Failure; Humans; Hydrazones; Postoperative Complications; Pyridazines; Simendan | 2016 |
Levosimendan beyond inotropy and acute heart failure: Evidence of pleiotropic effects on the heart and other organs: An expert panel position paper.
Topics: Acute Disease; Anti-Arrhythmia Agents; Cardiotonic Agents; Clinical Trials as Topic; Expert Testimony; Heart; Heart Failure; Humans; Hydrazones; Muscle Contraction; Pyridazines; Simendan; Treatment Outcome | 2016 |
A Review on Role of the Calcium Sensitive Inotropic Agent, Levosimendan and Its Metabolites.
Topics: Calcium; Calmodulin; Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Muscle Relaxation; Myocardial Contraction; Myosin Light Chains; Potassium Channels; Pyridazines; Simendan; Troponin C; Vascular Resistance | 2018 |
Advanced heart failure: an appraisal of the potential of levosimendan in this end-stage scenario and some related ethical considerations.
Topics: Cardiotonic Agents; Heart Failure; Heart-Assist Devices; Humans; Hydrazones; Pyridazines; Quality of Life; Simendan | 2016 |
Novel biologic mechanisms of levosimendan and its effect on the failing heart.
Topics: Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Myocardial Contraction; Oxidative Stress; Pyridazines; Randomized Controlled Trials as Topic; Simendan; Treatment Outcome | 2008 |
Levosimendan for the treatment of acute severe heart failure: a meta-analysis of randomised controlled trials.
Topics: Acute Disease; Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Pyridazines; Randomized Controlled Trials as Topic; Severity of Illness Index; Simendan | 2010 |
Management of heart failure: a brief review and selected update.
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Cardiotonic Agents; Diuretics; Heart Failure; Hemofiltration; Humans; Hydrazones; Natriuretic Peptide, Brain; Pacemaker, Artificial; Pyridazines; Simendan; Tolvaptan; Vasodilator Agents | 2008 |
Cardiac Ca2+ signaling and Ca2+ sensitizers.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Agonists; Angiotensin II; Animals; Azocines; Calcium; Calcium Signaling; Cardiotonic Agents; Cholinergic Agonists; Dihydropyridines; Endothelins; Heart Failure; Humans; Hydrazones; Myocardial Contraction; Myocardium; Phosphodiesterase Inhibitors; Pyridazines; Quinolines; Simendan; Thiadiazines; Troponin C | 2008 |
Levosimendan and calcium sensitization of the contractile proteins in cardiac muscle: impact on heart failure.
Topics: Calcium; Cardiotonic Agents; Contractile Proteins; Headache; Heart Failure; Humans; Hydrazones; Hypotension; Myocardium; Pyridazines; Randomized Controlled Trials as Topic; Simendan | 2008 |
Levosimendan for heart-operated patients: what is the state of the art?
Topics: Cardiac Surgical Procedures; Cardiotonic Agents; Clinical Trials as Topic; Heart Failure; Humans; Hydrazones; Pyridazines; Simendan | 2009 |
Relationship between the pharmacokinetics of levosimendan and its effects on cardiovascular system.
Topics: Animals; Calcium; Cardiotonic Agents; Clinical Trials as Topic; Heart Failure; Humans; Hydrazones; Potassium Channels; Pyridazines; Simendan; Vasodilation | 2009 |
Levosimendan.
Topics: Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Pyridazines; Simendan | 2009 |
[Inotrope therapy in acute heart failure: a critical review of clinical and scientific evidence for levosimendan in the context of traditional treatment].
Topics: Acute Disease; Algorithms; Calcium; Cardiotonic Agents; Clinical Trials as Topic; Evidence-Based Medicine; Heart Failure; Humans; Hydrazones; Myocardial Contraction; Patient Selection; Prognosis; Pyridazines; Randomized Controlled Trials as Topic; Severity of Illness Index; Simendan; Treatment Outcome | 2009 |
[Effect of levosimendan on B-type natriuretic peptide levels in patients with advanced heart failure: a meta-analysis].
Topics: Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Natriuretic Peptide, Brain; Pyridazines; Simendan | 2009 |
Agents with inotropic properties for the management of acute heart failure syndromes. Traditional agents and beyond.
Topics: Acute Disease; Cardiotonic Agents; Digoxin; Dobutamine; Etiocholanolone; Exercise Test; Heart Failure; Hemodynamics; Hospitals, Group Practice; Humans; Hydrazones; Prognosis; Pyrazines; Pyridazines; Quinolines; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Simendan; Treatment Outcome; Urea; Vasodilator Agents | 2009 |
A promising new inotrope: levosimendan.
Topics: Calcium; Cardiac Output; Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Potassium Channels; Pyridazines; Simendan; Treatment Outcome; Ventricular Dysfunction | 2010 |
Levosimendan in acute decompensated heart failure: systematic review and meta-analysis.
Topics: Brazil; Heart Failure; Hospitalization; Humans; Hydrazones; Pyridazines; Randomized Controlled Trials as Topic; Risk Factors; Simendan; Treatment Outcome; Vasodilator Agents | 2010 |
Levosimendan - a calcium sensitising agent with potential anti-arrhythmic properties.
Topics: Anti-Arrhythmia Agents; Anti-Inflammatory Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Pyridazines; Randomized Controlled Trials as Topic; Simendan | 2010 |
[Therapeutic strategies in acute decompensated heart failure and cardiogenic shock].
Topics: Aged; Cardiac Output, Low; Cardiotonic Agents; Combined Modality Therapy; Comorbidity; Critical Care; Cross-Sectional Studies; Diuretics; Emergency Service, Hospital; Heart Failure; Hospitalization; Humans; Hydrazones; Multicenter Studies as Topic; Myocardial Revascularization; Population Dynamics; Pyridazines; Risk Factors; Shock, Cardiogenic; Simendan; Vasodilator Agents | 2010 |
Cardiovascular pharmacology: an update.
Topics: Animals; Cardiovascular Agents; Cardiovascular Diseases; Diastole; Heart Failure; Humans; Hydrazones; Muscle Contraction; Myofibrils; Natriuretic Peptide, Brain; Nicardipine; Pyridazines; Pyridines; Sarcomeres; Simendan; Urea | 2010 |
Levosimendan: calcium sensitizer and inodilator.
Topics: Animals; Calcium; Cardiopulmonary Bypass; Clinical Trials as Topic; Heart Failure; Humans; Hydrazones; Nitric Oxide; Pyridazines; Simendan; Vasodilator Agents; Ventricular Function, Left | 2010 |
Levosimendan: from basic science to clinical trials.
Topics: Acute Disease; Animals; Calcium Channels; Cardiovascular Agents; Chronic Disease; Evidence-Based Medicine; Heart Failure; Humans; Hydrazones; Myocardial Contraction; Myocardium; Oxygen Consumption; Potassium Channels; Pyridazines; Simendan; Translational Research, Biomedical; Treatment Outcome; Ventricular Function | 2011 |
Current pharmacologic management of pediatric heart failure in congenital heart disease.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Child; Diuretics; Heart Defects, Congenital; Heart Failure; Hemodynamics; Humans; Hydrazones; Incidence; Natriuretic Peptide, Brain; Pyridazines; Simendan | 2011 |
Newer inotropes in pediatric heart failure.
Topics: Cardiotonic Agents; Child; Clinical Trials as Topic; Drug Administration Schedule; Etiocholanolone; Heart Failure; Humans; Hydrazones; Milrinone; Myocardial Contraction; Pyridazines; Simendan; Treatment Outcome | 2011 |
Effects of levosimendan on mortality and hospitalization. A meta-analysis of randomized controlled studies.
Topics: Cardiac Surgical Procedures; Critical Care; Critical Illness; Female; Heart Failure; Hospital Mortality; Hospitalization; Humans; Hydrazones; Prognosis; Pyridazines; Randomized Controlled Trials as Topic; Risk Assessment; Simendan; Treatment Outcome | 2012 |
Beta blocker therapy, decompensated heart failure, and inotropic interactions: current perspectives.
Topics: Acute Disease; Adrenergic beta-Antagonists; Cardiotonic Agents; Chronic Disease; Dobutamine; Drug Interactions; Drug Therapy, Combination; Heart Failure; Hospitalization; Humans; Hydrazones; Phosphodiesterase Inhibitors; Practice Guidelines as Topic; Pyridazines; Simendan | 2012 |
[Calcium mobilizers and calcium sensitizers].
Topics: Calcium; Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Myocardial Contraction; Pyridazines; Simendan | 2011 |
The clinical effects of levosimendan are not attenuated by sulfonylureas.
Topics: Aged; Diabetes Mellitus; Drug Interactions; Female; Heart Failure; Hemodynamics; Humans; Hydrazones; Hypoglycemic Agents; KATP Channels; Logistic Models; Male; Middle Aged; Multivariate Analysis; Propensity Score; Proportional Hazards Models; Pyridazines; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Simendan; Sulfonylurea Compounds; Treatment Outcome; Vasodilator Agents | 2012 |
Levosimendan preoperative.
Topics: Cardiac Surgical Procedures; Combined Modality Therapy; Heart Failure; Humans; Hydrazones; Preoperative Care; Pyridazines; Simendan; Vasodilator Agents | 2013 |
The disconnect between phase II and phase III trials of drugs for heart failure.
Topics: Animals; Benzazepines; Cardiovascular Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Evidence-Based Medicine; Heart Failure; Humans; Hydrazones; Natriuretic Peptide, Brain; Patient Readmission; Patient Selection; Pyridazines; Pyridines; Risk Assessment; Risk Factors; Simendan; Tetrazoles; Time Factors; Tolvaptan; Treatment Outcome; Xanthines | 2013 |
New therapeutic choices in the management of acute congestive heart failure.
Topics: Acute Disease; Heart Failure; Humans; Hydrazones; Milrinone; Natriuretic Agents; Natriuretic Peptide, Brain; Pyridazines; Quinolones; Simendan; Treatment Outcome; Vasodilator Agents | 2001 |
Pharmacotherapeutic approaches for decompensated heart failure: a role for the calcium sensitiser, levosimendan?
Topics: Calcium Channel Blockers; Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Pyridazines; Simendan; United States; Vasodilator Agents; Ventricular Dysfunction, Left | 2003 |
Current medical treatment for the exacerbation of chronic heart failure resulting in hospitalization.
Topics: Aged; Diuretics; Dobutamine; Enalaprilat; Female; Heart Failure; Hemodynamics; Hospitalization; Humans; Hydrazones; Injections, Intravenous; Male; Milrinone; Natriuretic Agents; Natriuretic Peptide, Brain; Nitroprusside; Pulmonary Wedge Pressure; Pyridazines; Renal Agents; Simendan; Vasodilator Agents | 2003 |
Dyspnea as an end point in clinical trials of therapies for acute decompensated heart failure.
Topics: Acute Disease; Drug Approval; Dyspnea; Forecasting; Heart Failure; Hospitalization; Humans; Hydrazones; Natriuretic Agents; Natriuretic Peptide, Brain; Pyridazines; Pyridines; Randomized Controlled Trials as Topic; Severity of Illness Index; Simendan; Tetrazoles; Treatment Outcome; Vasodilator Agents | 2003 |
The development of new medical treatments for acute decompensated heart failure.
Topics: Acute Disease; Cardiotonic Agents; Cohort Studies; Heart Failure; Hemodynamics; Humans; Hydrazones; Multicenter Studies as Topic; Natriuretic Agents; Natriuretic Peptide, Brain; Placebos; Pyridazines; Pyridines; Randomized Controlled Trials as Topic; Receptors, Endothelin; Simendan; Tetrazoles; Time Factors; Vasodilator Agents | 2002 |
[Inotropic agents in advanced and refractory heart failure].
Topics: Cardiotonic Agents; Dobutamine; Dopamine; Drug Administration Schedule; Heart Failure; Humans; Hydrazones; Phosphodiesterase Inhibitors; Pyridazines; Simendan; Treatment Failure; Treatment Outcome | 2003 |
Levosimendan: a new dual-action drug in the treatment of acute heart failure.
Topics: Acute Disease; Cardiotonic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Heart Failure; Humans; Hydrazones; Pyridazines; Randomized Controlled Trials as Topic; Simendan; Survival Analysis; Treatment Outcome | 2003 |
The role of Ca++-sensitizers for the treatment of heart failure.
Topics: Calcium; Cardiotonic Agents; Chronic Disease; Clinical Trials as Topic; Dobutamine; Heart Failure; Hemodynamics; Humans; Hydrazones; Myocardial Ischemia; Pyridazines; Simendan | 2003 |
Levosimendan: implications for clinicians.
Topics: Calcium; Cardiotonic Agents; Chronic Disease; Controlled Clinical Trials as Topic; Drug Interactions; Heart Failure; Humans; Hydrazones; Pyridazines; Simendan | 2003 |
Is calcium sensitization the best strategy to improve myocardial contractility in acute heart failure?
Topics: Acute Disease; Calcium; Calcium Channels, L-Type; Cardiac Output; Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Myocardial Contraction; Pulmonary Wedge Pressure; Pyridazines; Simendan; Vascular Resistance; Vasodilator Agents | 2003 |
Considerations on the efficacy and safety of levosimendan in ischemic heart failure.
Topics: Calcium Channels, L-Type; European Union; Heart Failure; Humans; Hydrazones; Morbidity; Myocardial Contraction; Myocardial Ischemia; Pyridazines; Simendan; Treatment Outcome; United States; Vasodilator Agents | 2003 |
The clinical experience with levosimendan in anesthesiology and in the intensive care unit.
Topics: Adrenergic beta-Antagonists; Anesthesia; Calcium Channels, L-Type; Cardiac Output, Low; Cardiac Surgical Procedures; Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Intensive Care Units; Myocardial Contraction; Pyridazines; Shock, Cardiogenic; Simendan; Systole; Ventricular Dysfunction, Left | 2003 |
Levosimendan: a review of its use in the management of acute decompensated heart failure.
Topics: Acute Disease; Animals; Cardiotonic Agents; Heart Failure; Hemodynamics; Humans; Hydrazones; Pyridazines; Randomized Controlled Trials as Topic; Simendan | 2003 |
New and emerging drug therapies for the management of acute heart failure.
Topics: Antidiuretic Hormone Receptor Antagonists; Heart Failure; Humans; Hydrazones; Natriuretic Agents; Natriuretic Peptide, Brain; Pyridazines; Pyridines; Simendan; Tetrazoles; Treatment Outcome; Vasodilator Agents; Vasopressins | 2003 |
[Levosimendan. Clinical indications of a new vasoactive substance].
Topics: Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Pyridazines; Salvage Therapy; Simendan | 2004 |
[Levosimendan in cardiology and intensive care medicine].
Topics: Cardiotonic Agents; Critical Care; Heart Failure; Hemodynamics; Humans; Hydrazones; Myocardial Stunning; Pyridazines; Randomized Controlled Trials as Topic; Simendan; Survival Rate; Vasodilator Agents | 2004 |
Levosimendan: first in a new class of inodilator for acute and chronic severe heart failure.
Topics: Cardiotonic Agents; Drug Interactions; Female; Follow-Up Studies; Heart Failure; Hemodynamics; Humans; Hydrazones; Infusions, Intravenous; Male; Middle Aged; Multicenter Studies as Topic; Pyridazines; Randomized Controlled Trials as Topic; Safety; Simendan; Time Factors; Vasodilator Agents | 2004 |
New therapies for heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Agents; Diuretics; Drug Therapy, Combination; Eplerenone; Heart Failure; Humans; Hydrazones; Natriuretic Agents; Natriuretic Peptide, Brain; Neurotransmitter Agents; Pyridazines; Simendan; Spironolactone; Treatment Outcome; United States | 2004 |
New positive inotropic agents in the treatment of left ventricular dysfunction.
Topics: Cardiotonic Agents; Diastole; Heart Failure; Humans; Hydrazones; Milrinone; Myocardial Ischemia; Phosphodiesterase Inhibitors; Pyrazines; Pyridazines; Quinolines; Simendan; Ventricular Dysfunction, Left; Ventricular Function, Left | 2004 |
Pharmacological therapy of acute cardiogenic pulmonary oedema in the emergency department.
Topics: Acute Disease; Analgesics, Opioid; Angiotensin-Converting Enzyme Inhibitors; Cardiotonic Agents; Critical Illness; Developed Countries; Diuretics; Emergency Service, Hospital; Emergency Treatment; Evidence-Based Medicine; Furosemide; Heart Failure; Humans; Hydrazones; Natriuretic Agents; Natriuretic Peptide, Brain; Nitroprusside; Oxygen Inhalation Therapy; Patient Selection; Pulmonary Edema; Pyridazines; Pyridines; Simendan; Tetrazoles; Treatment Outcome; Vasodilator Agents | 2004 |
The contractile apparatus as a target for drugs against heart failure: interaction of levosimendan, a calcium sensitiser, with cardiac troponin c.
Topics: Animals; Calcium; Cardiotonic Agents; Dose-Response Relationship, Drug; Heart Failure; Humans; Hydrazones; Myocardial Contraction; Myocardium; Myocytes, Cardiac; Protein Binding; Pyridazines; Simendan; Tropomyosin; Troponin C; Troponin I; Troponin T | 2004 |
Levosimendan: a new inodilatory drug for the treatment of decompensated heart failure.
Topics: Administration, Oral; Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Injections, Intravenous; Pyridazines; Randomized Controlled Trials as Topic; Simendan; Time Factors; Vasodilator Agents | 2005 |
[If the myofilaments become sensitive: Ca2+-sensitizer for the therapy of heart insufficiency].
Topics: Actin Cytoskeleton; Calcium; Cardiotonic Agents; Heart; Heart Failure; Humans; Hydrazones; Myocardium; Oxygen Consumption; Pyridazines; Quinolines; Simendan; Thiadiazines | 2005 |
Pharmacological mechanisms contributing to the clinical efficacy of levosimendan.
Topics: Animals; Chronic Disease; Heart Failure; Humans; Hydrazones; Pyridazines; Simendan; Treatment Outcome | 2005 |
Anti-inflammatory and anti-apoptotic effects of levosimendan in decompensated heart failure: a novel mechanism of drug-induced improvement in contractile performance of the failing heart.
Topics: Animals; Anti-Inflammatory Agents; Apoptosis; Contraindications; Heart Failure; Humans; Hydrazones; Pyridazines; Simendan | 2005 |
[Levosimendan, a revolution in the world of inotropic agents?].
Topics: Anti-Arrhythmia Agents; Heart Failure; Hemodynamics; Humans; Hydrazones; Myocardial Contraction; Myocardial Ischemia; Pyridazines; Simendan | 2005 |
An emerging role for calcium sensitisation in the treatment of heart failure.
Topics: Animals; Calcium Signaling; Clinical Trials as Topic; Drugs, Investigational; Heart Failure; Humans; Hydrazones; Myocytes, Cardiac; Pyridazines; Simendan | 2005 |
Levosimendan: a calcium-sensitizing agent for the treatment of patients with decompensated heart failure.
Topics: Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Heart Failure; Heart Function Tests; Humans; Hydrazones; Infusions, Intravenous; Male; Maximum Tolerated Dose; Prognosis; Prospective Studies; Pyridazines; Randomized Controlled Trials as Topic; Risk Assessment; Severity of Illness Index; Simendan; Survival Analysis; Treatment Outcome; Vasodilator Agents | 2004 |
[The novelty in the treatment of heart failure].
Topics: Adolescent; Adrenergic beta-Agonists; Adult; Aged; Cardiotonic Agents; Child; Child, Preschool; Dobutamine; Heart Failure; Hemodynamics; Humans; Hydrazones; Infant; Infant, Newborn; Infusions, Intravenous; Injections, Intravenous; Middle Aged; Multicenter Studies as Topic; Pyridazines; Randomized Controlled Trials as Topic; Retrospective Studies; Simendan; Vasodilator Agents | 2005 |
Calcium sensitizer agents: a new class of inotropic agents in the treatment of decompensated heart failure.
Topics: Arrhythmias, Cardiac; Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Pyridazines; Simendan | 2005 |
The myofilament force-calcium relationship as a target for positive inotropic therapy in congestive heart failure.
Topics: Actin Cytoskeleton; Animals; Calcium; Cardiotonic Agents; Energy Metabolism; Heart Failure; Humans; Hydrazones; Mice; Mice, Transgenic; Myocardial Contraction; Myocardium; Phosphorylation; Pyridazines; Simendan; Ventricular Function, Left | 2005 |
Cardioprotection: a new paradigm in the management of acute heart failure syndromes.
Topics: Acute Disease; Animals; Cardiotonic Agents; Cells, Cultured; Heart Failure; Humans; Hydrazones; Hydrogen Peroxide; Myocytes, Cardiac; Oxidative Stress; Pyridazines; Rats; Simendan; Syndrome | 2005 |
Pharmacology of new agents for acute heart failure syndromes.
Topics: Acute Disease; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Cardiotonic Agents; Clinical Trials as Topic; Endothelin Receptor Antagonists; Heart Failure; Humans; Hydrazones; Pyridazines; Pyridines; Simendan; Syndrome; Tetrazoles; Tolvaptan; Vasodilator Agents | 2005 |
Randomized clinical trials with levosimendan.
Topics: Acute Disease; Cardiotonic Agents; Dobutamine; Heart Failure; Humans; Hydrazones; Pyridazines; Randomized Controlled Trials as Topic; Simendan; Syndrome | 2005 |
European experience on the practical use of levosimendan in patients with acute heart failure syndromes.
Topics: Acute Disease; Cardiotonic Agents; Europe; Heart Failure; Humans; Hydrazones; Pyridazines; Randomized Controlled Trials as Topic; Simendan; Syndrome | 2005 |
Levosimendan: a novel inotropic agent for treatment of acute, decompensated heart failure.
Topics: Acute Disease; Cardiotonic Agents; Clinical Trials as Topic; Heart Failure; Humans; Hydrazones; Pyridazines; Simendan; Treatment Outcome | 2005 |
[Levosimendan].
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Cardiotonic Agents; Cyclic Nucleotide Phosphodiesterases, Type 3; Heart Failure; Humans; Hydrazones; Phosphodiesterase Inhibitors; Pyridazines; Simendan; Vasodilator Agents | 2005 |
Levosimendan for the treatment of acute heart failure syndromes.
Topics: Acute Disease; Animals; Heart Failure; Humans; Hydrazones; Pyridazines; Radiography; Simendan; Syndrome | 2005 |
Levosimendan: dual mechanisms for acute heart failure...and beyond?
Topics: Acute Disease; Calcium; Cardiac Output; Clinical Trials as Topic; Heart Failure; Humans; Hydrazones; Pulmonary Wedge Pressure; Pyridazines; Randomized Controlled Trials as Topic; Simendan; Treatment Outcome; Vasodilator Agents | 2005 |
[Levosimendan--an alternative to conventional inotropic treatment of patients with acute heart failure?].
Topics: Cardiotonic Agents; Heart Failure; Hemodynamics; Humans; Hydrazones; Phosphodiesterase Inhibitors; Pyridazines; Simendan | 2006 |
Ca2+-sensitisers--a promising option to treat heart failure?
Topics: Calcium; Heart Failure; Humans; Hydrazones; Pyridazines; Simendan | 2005 |
Optimizing outcomes in the patient with acute decompensated heart failure.
Topics: Biomarkers; Cardiotonic Agents; Diuretics; Heart Failure; Hemodynamics; Humans; Hydrazones; Milrinone; Natriuretic Agents; Natriuretic Peptide, Brain; Nitroglycerin; Pyridazines; Pyridines; Risk Assessment; Simendan; Tetrazoles; Therapeutics; Troponin; Vasodilator Agents; Ventricular Function, Left; Ventricular Pressure | 2006 |
[Medical and ventilatory treatment of acute heart failure].
Topics: Acute Disease; Adrenergic beta-Agonists; Cardiotonic Agents; Continuous Positive Airway Pressure; Diuretics; Dobutamine; Furosemide; Heart Failure; Humans; Hydrazones; Isosorbide Dinitrate; Natriuretic Agents; Natriuretic Peptide, Brain; Nitric Oxide Donors; Oxygen Inhalation Therapy; Practice Guidelines as Topic; Pyridazines; Simendan; Vasodilator Agents | 2006 |
Newer approaches to the pharmacological management of heart failure.
Topics: Calcium Signaling; Cardiotonic Agents; Cardiovascular Agents; Endothelins; Enzyme Inhibitors; Heart Failure; Humans; Hydrazones; Natriuretic Peptide, Brain; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase; Pyridazines; Pyridines; Simendan; Tetrazoles | 2006 |
Pharmacologic treatment of heart failure due to ventricular dysfunction by myocardial stunning: potential role of levosimendan.
Topics: Adenosine Triphosphate; Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Models, Biological; Myocardial Stunning; Potassium Channels; Pyridazines; Randomized Controlled Trials as Topic; Simendan; Ventricular Dysfunction | 2006 |
Evidence-based use of levosimendan in different clinical settings.
Topics: Administration, Oral; Adult; Arrhythmias, Cardiac; Cardiotonic Agents; Child; Heart Failure; Humans; Hydrazones; Intraoperative Care; Myocardial Ischemia; Pyridazines; Randomized Controlled Trials as Topic; Shock, Cardiogenic; Simendan | 2006 |
A review of levosimendan in the treatment of heart failure.
Topics: Anti-Arrhythmia Agents; Anti-Inflammatory Agents; Cardiotonic Agents; Coronary Circulation; Drug Therapy, Combination; Heart Failure; Humans; Hydrazones; Matrix Metalloproteinases; Myocardial Contraction; Myocardial Stunning; Neurosecretory Systems; Practice Guidelines as Topic; Pyridazines; Simendan; Treatment Outcome; Ventricular Remodeling | 2006 |
Levosimendan: beyond its simple inotropic effect in heart failure.
Topics: Calcium; Cardiac Output; Cardiotonic Agents; Drug Interactions; Heart Failure; Humans; Hydrazones; Potassium Channels; Pyridazines; Simendan; Vasodilation; Vasodilator Agents | 2007 |
The utility of levosimendan in the treatment of heart failure.
Topics: Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Pyridazines; Simendan; Stroke Volume; Survival Rate; Treatment Outcome; Vasodilation | 2007 |
The use of levosimendan in comparison and in combination with dobutamine in the treatment of decompensated heart failure.
Topics: Aged; Biological Availability; Calcium Channels; Cardiotonic Agents; Dobutamine; Half-Life; Heart Failure; Hospitalization; Humans; Hydrazones; Prognosis; Pyridazines; Randomized Controlled Trials as Topic; Simendan; Tissue Distribution; Treatment Outcome | 2007 |
Classical inotropes and new cardiac enhancers.
Topics: Algorithms; Cardiotonic Agents; Dobutamine; Dopamine; Heart Failure; Humans; Hydrazones; Milrinone; Practice Guidelines as Topic; Pyridazines; Randomized Controlled Trials as Topic; Simendan; Treatment Outcome | 2007 |
[Calcium sensitizer: characteristics, mechanisms of action, pharmacokinetics, indication, contraindication, clinical data, and side effects].
Topics: Calcium; Cardiotonic Agents; Clinical Trials as Topic; Contraindications; Heart Failure; Humans; Hydrazones; Phosphodiesterase Inhibitors; Pyridazines; Simendan; Stimulation, Chemical; Survival Rate | 2007 |
[Calcium sensitizer agents in heart failure therapy].
Topics: Calcium; Cardiotonic Agents; Clinical Trials as Topic; Heart Failure; Humans; Hydrazones; Myocardial Contraction; Myocardium; Phosphodiesterase Inhibitors; Pyridazines; Simendan; Stimulation, Chemical | 2007 |
[Combination therapy with PDE III inhibitor for heart failure].
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Chronic Disease; Clinical Trials as Topic; Cyclic Nucleotide Phosphodiesterases, Type 3; Dobutamine; Drug Therapy, Combination; Heart Failure; Humans; Hydrazones; Milrinone; Phosphodiesterase Inhibitors; Pyridazines; Simendan | 2007 |
[Levosimendan for treatment of heart failure].
Topics: Blood Pressure; Calcium; Cardiotonic Agents; Clinical Trials as Topic; Cytokines; Heart Failure; Heart Rate; Humans; Hydrazones; Inflammation Mediators; Natriuretic Peptide, Brain; Pyridazines; Shock, Cardiogenic; Simendan | 2007 |
Clinical pharmacology of levosimendan.
Topics: Area Under Curve; Cardiotonic Agents; Clinical Trials as Topic; Half-Life; Heart Failure; Humans; Hydrazones; Infusions, Intravenous; Molecular Structure; Pyridazines; Simendan; Treatment Outcome | 2007 |
Medical support and surgery of the failing heart: levosimendan.
Topics: Cardiac Surgical Procedures; Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Intraoperative Care; Pyridazines; Simendan | 2007 |
Pharmacologic therapy for acute heart failure.
Topics: Antidiuretic Hormone Receptor Antagonists; Catecholamines; Heart Failure; Humans; Hydrazones; Myocardial Contraction; Natriuretic Agents; Natriuretic Peptide, Brain; Natriuretic Peptides; Pyridazines; Randomized Controlled Trials as Topic; Simendan; Sodium Potassium Chloride Symporter Inhibitors; Treatment Outcome; Vasodilator Agents | 2007 |
Inoprotection: the perioperative role of levosimendan.
Topics: Animals; Cardiotonic Agents; Clinical Trials as Topic; Coronary Artery Bypass; Heart Failure; Humans; Hydrazones; Ischemic Preconditioning, Myocardial; Myocardial Contraction; Perioperative Care; Potassium Channels; Pyridazines; Simendan | 2007 |
Inotropes in the management of acute heart failure.
Topics: Acute Disease; Cardiac Myosins; Cardiotonic Agents; Heart Failure; Hemodynamics; Humans; Hydrazones; Patient Selection; Pyridazines; Simendan | 2008 |
New pharmacologic therapies for acute heart failure.
Topics: Acute Disease; Adenosine; Adenosine Triphosphatases; Antidiuretic Hormone Receptor Antagonists; Cardiac Myosins; Cardiotonic Agents; Endothelin Receptor Antagonists; Heart Failure; Humans; Hydrazones; Natriuretic Peptides; Pyridazines; Simendan | 2008 |
Levosimendan: current status and future prospects.
Topics: Acute Disease; Adrenergic beta-Antagonists; Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Postoperative Complications; Pyridazines; Shock, Septic; Simendan; Ventricular Dysfunction, Right | 2008 |
Levosimendan: a novel agent in heart failure.
Topics: Animals; Apoptosis; Cardiotonic Agents; Heart Failure; Hemodynamics; Humans; Hydrazones; Pyridazines; Simendan; Vasodilator Agents | 2006 |
Overview of emerging pharmacologic agents for acute heart failure syndromes.
Topics: Adenosine; Cardiovascular Agents; Endothelin-1; Etiocholanolone; Heart Failure; Hemodynamics; Humans; Hydrazones; Natriuretic Peptide, Brain; Perhexiline; Pyridazines; Randomized Controlled Trials as Topic; Simendan; Sodium-Potassium-Exchanging ATPase; Syndrome; Vasodilator Agents | 2008 |
Levosimendan use in several scenarios of acute heart failure.
Topics: Acute Disease; Adrenergic beta-Antagonists; Cardiotonic Agents; Contraindications; Heart Failure; Hemodynamics; Humans; Hydrazones; Hypotension; Ischemia; Phosphodiesterase Inhibitors; Pyridazines; Simendan; Syndrome; Vasodilator Agents | 2008 |
Role of levosimendan in sepsis and septic shock.
Topics: Animals; Calcium; Dose-Response Relationship, Drug; Drug Interactions; Endotoxemia; Heart Failure; Humans; Hydrazones; Potassium Channels; Pyridazines; Sepsis; Shock, Septic; Simendan | 2008 |
Calcium sensitising agents in heart failure.
Topics: Aged; Animals; Calcium; Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Pyridazines; Simendan | 1998 |
[Ca2+ sensitizers].
Topics: Animals; Calcium; Cardiotonic Agents; Cyclic AMP; Dihydropyridines; Drug Design; Heart Failure; Humans; Hydrazones; Myocardium; Pyridazines; Signal Transduction; Simendan | 2000 |
Levosimendan: A promising agent for the treatment of hospitalized patients with decompensated heart failure.
Topics: Animals; Cardiotonic Agents; Heart Failure; Hemodynamics; Humans; Hydrazones; Myocardial Contraction; Pyridazines; Simendan; Vasodilator Agents | 2000 |
Levosimendan: a parenteral calcium-sensitising drug with additional vasodilatory properties.
Topics: Calcium; Drug and Narcotic Control; Heart Failure; Hydrazones; Pyridazines; Simendan; Vasodilator Agents | 2001 |
Levosimendan.
Topics: Biological Availability; Cardiotonic Agents; Coronary Circulation; Half-Life; Heart Failure; Humans; Hydrazones; Protein Binding; Pyridazines; Randomized Controlled Trials as Topic; Simendan | 2001 |
New pharmacological strategies for the treatment of heart failure.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atrial Natriuretic Factor; Bosentan; Calcium; Cardiotonic Agents; Clinical Trials as Topic; Endothelin-1; Heart Failure; Humans; Hydrazones; Muscle Proteins; Neprilysin; Phosphodiesterase Inhibitors; Pyridazines; Simendan; Sulfonamides; Tumor Necrosis Factor-alpha | 2001 |
Levosimendan: a new era for inodilator therapy for heart failure?
Topics: Cardiotonic Agents; Dose-Response Relationship, Drug; Heart Failure; Hemodynamics; Humans; Hydrazones; Pyridazines; Simendan; Treatment Outcome; Vasodilator Agents; Ventricular Dysfunction, Left | 2002 |
109 trial(s) available for simendan and Heart Failure
Article | Year |
---|---|
Repetitive use of LEvosimendan in Ambulatory Heart Failure patients (LEIA-HF) - The rationale and study design.
Topics: Cardiotonic Agents; Double-Blind Method; Heart Failure; Humans; Simendan; Stroke Volume; Treatment Outcome | 2022 |
Efficacy and safety of intermittent repeated levosimendan infusions in advanced heart failure patients: the LAICA study.
Topics: Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Pyridazines; Simendan | 2021 |
Use of levosimendan combined with Shenfu injection to treat acute heart failure patients with hypotension: a prospective randomized controlled single-blind study.
Topics: Cardiotonic Agents; Drugs, Chinese Herbal; Heart Failure; Humans; Hydrazones; Hypotension; Prospective Studies; Pyridazines; Simendan; Single-Blind Method | 2022 |
Economic analysis of intermittent intravenous outpatient treatment with levosimendan in advanced heart failure in Spain.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Ambulatory Care; Cardiotonic Agents; Costs and Cost Analysis; Female; Heart Failure; Humans; Hydrazones; Male; Middle Aged; Outpatients; Risk Factors; Simendan; Spain; Treatment Outcome | 2020 |
Effects of Xinkeshu combined with levosimendan on perioperative heart failure in oldest-old patients with hip fractures.
Topics: Aged; Aged, 80 and over; Drug Therapy, Combination; Drugs, Chinese Herbal; Endothelin-1; Female; Heart Failure; Hip Fractures; Humans; Male; Malondialdehyde; Natriuretic Peptide, Brain; Nitric Oxide; Simendan; Treatment Outcome | 2020 |
Levosimendan Improves Hemodynamics and Exercise Tolerance in PH-HFpEF: Results of the Randomized Placebo-Controlled HELP Trial.
Topics: Exercise Tolerance; Female; Heart Failure; Hemodynamics; Humans; Male; Simendan; Stroke Volume | 2021 |
Effects of levosimendan in patients with severe functional mitral regurgitation undergoing MitraClip implantation.
Topics: Aged; Aged, 80 and over; Cardiotonic Agents; Female; Heart Failure; Heart Valve Prosthesis Implantation; Humans; Hydrazones; Male; Middle Aged; Mitral Valve Insufficiency; Pyridazines; Simendan | 2017 |
Efficacy and safety of intermittent intravenous outpatient administration of levosimendan in patients with advanced heart failure: the LION-HEART multicentre randomised trial.
Topics: Aged; Cardiotonic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Heart Failure; Heart Ventricles; Humans; Injections, Intravenous; Male; Middle Aged; Natriuretic Peptide, Brain; Outpatients; Peptide Fragments; Protein Precursors; Retrospective Studies; Simendan; Stroke Volume; Treatment Outcome | 2018 |
Haemodynamic effects of levosimendan in advanced but stable chronic heart failure.
Topics: Cardiotonic Agents; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heart Failure; Hemodynamics; Humans; Infusions, Intravenous; Male; Middle Aged; Prospective Studies; Simendan; Treatment Outcome | 2018 |
Comparison of Levosimendan and Milrinone for ECLS Weaning in Patients After Cardiac Surgery-A Retrospective Before-and-After Study.
Topics: Aged; Cardiac Surgical Procedures; Cardiotonic Agents; Extracorporeal Membrane Oxygenation; Female; Follow-Up Studies; Heart Failure; Humans; Incidence; Male; Middle Aged; Milrinone; Postoperative Care; Retrospective Studies; Shock, Cardiogenic; Simendan; Switzerland | 2018 |
PREVENTION OF HEART FAILURE PATIENTS WITH DECREASED EJECTION FRACTION IN NON-CARDIAC SURGERY: LEVOSIMENDAN OR ANESTHETIC CARDIOPROTECTION?.
Topics: Aged; Anesthesia, General; Aorta; Cardiac Output, Low; Cardiopulmonary Bypass; Cardiotonic Agents; Female; Heart Failure; Humans; Hydrazones; Male; Perioperative Period; Prospective Studies; Pyridazines; Retrospective Studies; Simendan; Treatment Outcome | 2016 |
Differential Effects of Levosimendan and Dobutamine on Glomerular Filtration Rate in Patients With Heart Failure and Renal Impairment:A Randomized Double-Blind Controlled Trial.
Topics: Aged; Cardio-Renal Syndrome; Cardiotonic Agents; Dobutamine; Double-Blind Method; Female; Glomerular Filtration Rate; Heart Failure; Hemodynamic Monitoring; Hemodynamics; Humans; Male; Middle Aged; p-Aminohippuric Acid; Renal Circulation; Renal Insufficiency; Renal Plasma Flow; Simendan | 2018 |
Repetitive levosimendan infusions for patients with advanced chronic heart failure in the vulnerable post-discharge period.
Topics: Cardiotonic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Follow-Up Studies; Heart Failure; Humans; Infusions, Intravenous; Patient Discharge; Simendan; Stroke Volume; Treatment Outcome | 2019 |
Effect of levosimendan on estimated glomerular filtration rate in hospitalized patients with decompensated heart failure and renal dysfunction.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Biomarkers; Blood Pressure; Cardiotonic Agents; Chi-Square Distribution; China; Double-Blind Method; Female; Glomerular Filtration Rate; Heart Failure; Heart Rate; Hospitalization; Humans; Hydrazones; Infusions, Intravenous; Kidney Diseases; Linear Models; Male; Middle Aged; Natriuretic Peptide, Brain; Prospective Studies; Pyridazines; Simendan; Stroke Volume; Time Factors; Treatment Outcome; Urination; Ventricular Function, Left | 2013 |
Intermittent levosimendan treatment in patients with severe congestive heart failure.
Topics: Aged; Cardiotonic Agents; Drug Administration Schedule; Exercise Test; Exercise Tolerance; Heart Failure; Humans; Hydrazones; Infusions, Intravenous; Longitudinal Studies; Male; Middle Aged; Oxygen; Pyridazines; Severity of Illness Index; Simendan; Surveys and Questionnaires; Treatment Outcome | 2013 |
Rationale and design of a randomized, double-blind, placebo controlled multicenter trial to study efficacy, security, and long term effects of intermittent repeated levosimendan administration in patients with advanced heart failure: LAICA study.
Topics: Cardiotonic Agents; Double-Blind Method; Drug Administration Schedule; Heart Failure; Hospitalization; Humans; Hydrazones; Pyridazines; Simendan | 2013 |
Impact of levosimendan on right ventricular functions by using novel tissue Doppler derived indices in patients with ischaemic left ventricular failure.
Topics: Cardiotonic Agents; Echocardiography, Doppler; Female; Heart Failure; Humans; Hydrazones; Male; Middle Aged; Pyridazines; Simendan; Ventricular Dysfunction, Right | 2013 |
Comparison of single-dose and repeated levosimendan infusion in patients with acute exacerbation of advanced heart failure.
Topics: Aged; Biomarkers; Dose-Response Relationship, Drug; Echocardiography; Female; Heart Failure; Heart Ventricles; Humans; Hydrazones; Infusions, Intravenous; Interleukin-1beta; Interleukin-2; Interleukin-6; Male; Middle Aged; Natriuretic Peptide, Brain; Pyridazines; Simendan; Tumor Necrosis Factor-alpha; Turkey; Vasodilator Agents | 2014 |
Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure.
Topics: Cardiotonic Agents; Double-Blind Method; Female; Heart Failure; Humans; Hydrazones; Male; Middle Aged; Prospective Studies; Pyridazines; Simendan | 2013 |
Efficacy of intravenous levosimendan in patients with heart failure complicated by acute myocardial infarction.
Topics: Cardiotonic Agents; Female; Heart Failure; Humans; Hydrazones; Infusions, Intravenous; Male; Middle Aged; Myocardial Ischemia; Pyridazines; Simendan; Single-Blind Method; Treatment Outcome | 2014 |
Assessment of sustained effects of levosimendan and dobutamine on left ventricular systolic functions by using novel tissue Doppler derived indices in patients with advanced heart failure.
Topics: Aged; Biomarkers; Cardiotonic Agents; Dobutamine; Echocardiography, Doppler; Female; Heart Failure; Humans; Hydrazones; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Predictive Value of Tests; Pyridazines; Recovery of Function; Simendan; Stroke Volume; Systole; Time Factors; Treatment Outcome; Turkey; Ventricular Dysfunction, Left; Ventricular Function, Left | 2015 |
Efficacy and safety of the pulsed infusions of levosimendan in outpatients with advanced heart failure (LevoRep) study: a multicentre randomized trial.
Topics: Aged; Aged, 80 and over; Ambulatory Care; Cardiotonic Agents; Disease-Free Survival; Double-Blind Method; Female; Heart Failure; Humans; Hydrazones; Infusions, Intravenous; Male; Middle Aged; Pyridazines; Quality of Life; Severity of Illness Index; Simendan; Treatment Outcome | 2014 |
The effects of levosimendan on renal function early after heart transplantation: results from a pilot randomized trial.
Topics: Adult; Cardiotonic Agents; Combined Modality Therapy; Female; Follow-Up Studies; Glomerular Filtration Rate; Graft Survival; Heart Failure; Heart Transplantation; Hemodynamics; Humans; Hydrazones; Kidney; Kidney Function Tests; Male; Middle Aged; Pilot Projects; Prognosis; Pyridazines; Risk Factors; Simendan; Survival Rate | 2014 |
Association of interleukin 8 and myocardial recovery in patients with ST-elevation myocardial infarction complicated by acute heart failure.
Topics: Aged; Biomarkers; C-Reactive Protein; Cardiotonic Agents; Female; Heart Failure; Humans; Hydrazones; Intercellular Adhesion Molecule-1; Interleukin-6; Interleukin-8; Male; Matrix Metalloproteinase 9; Middle Aged; Morpholines; Myocardial Contraction; Myocardial Infarction; Pyridazines; Receptors, Interleukin-6; Recovery of Function; Simendan; Tumor Necrosis Factor-alpha; Vascular Cell Adhesion Molecule-1; Ventricular Function, Left | 2014 |
Levosimendan and nesiritide as a combination therapy in patients with acute heart failure.
Topics: Acute Disease; Aged; Aged, 80 and over; Cardiotonic Agents; Drug Monitoring; Drug Synergism; Drug Therapy, Combination; Female; Heart Failure; Humans; Hydrazones; Infusions, Intravenous; Male; Middle Aged; Mortality; Natriuretic Peptide, Brain; Patient Readmission; Pyridazines; Severity of Illness Index; Simendan; Treatment Outcome | 2015 |
Levosimendan improves hemodynamic status in critically ill patients with severe aortic stenosis and left ventricular dysfunction: an interventional study.
Topics: Aged; Aged, 80 and over; Aortic Valve Stenosis; Cardiovascular Agents; Critical Illness; Female; Heart Failure; Hemodynamics; Humans; Hydrazones; Infusions, Intravenous; Male; Middle Aged; Pyridazines; Recovery of Function; Severity of Illness Index; Simendan; Spain; Stroke Volume; Time Factors; Treatment Outcome; Ventricular Dysfunction, Left; Ventricular Function, Left | 2015 |
Levosimendan Improves Clinical Outcomes of Refractory Heart Failure in Elderly Chinese Patients.
Topics: Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Asian People; China; Creatinine; Female; Heart Failure; Humans; Hydrazones; Male; Natriuretic Peptide, Brain; Peptide Fragments; Prospective Studies; Pyridazines; Simendan; Stroke Volume; Treatment Outcome | 2015 |
Ischemia-modified albumin levels in patients with acute decompensated heart failure treated with dobutamine or levosimendan: IMA-HF study.
Topics: Adolescent; Adult; Aged; Biomarkers; Cardiotonic Agents; Dobutamine; Female; Heart Failure; Humans; Hydrazones; Infusions, Intravenous; Male; Middle Aged; Prospective Studies; Pyridazines; Serum Albumin; Serum Albumin, Human; Simendan; Treatment Outcome; Turkey; Young Adult | 2015 |
Effect of baseline characteristics on mortality in the SURVIVE trial on the effect of levosimendan vs dobutamine in acute heart failure: Sub-analysis of the Finnish patients.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Dobutamine; Drug Therapy, Combination; Female; Finland; Heart Failure; Humans; Hydrazones; Male; Middle Aged; Proportional Hazards Models; Pyridazines; Retrospective Studies; Simendan; Survival Analysis; Treatment Outcome | 2016 |
Systolic mitral annulus velocity is a sensitive index for changes in left ventricular systolic function during inotropic therapy in patients with acute heart failure.
Topics: Acute Disease; Aged; Blood Flow Velocity; Cardiotonic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Echocardiography, Doppler, Color; Electrocardiography; Feasibility Studies; Female; Follow-Up Studies; Heart Failure; Heart Ventricles; Humans; Hydrazones; Infusions, Intravenous; Male; Mitral Valve; Pyridazines; Reproducibility of Results; Simendan; ST Elevation Myocardial Infarction; Systole; Time Factors; Treatment Outcome; Ventricular Function, Left | 2018 |
Safety and effectiveness of levosimendan in patients with predominant right heart failure.
Topics: Cardiotonic Agents; Female; Heart Failure; Humans; Hydrazones; Male; Middle Aged; Pyridazines; Simendan; Treatment Outcome; Ventricular Dysfunction, Right | 2008 |
Levosimendan versus dobutamine in heart failure patients treated chronically with carvedilol.
Topics: Adrenergic beta-Antagonists; Blood Pressure; Carbazoles; Cardiotonic Agents; Carvedilol; Dobutamine; Drug Therapy, Combination; Female; Heart Failure; Heart Rate; Humans; Hydrazones; Infusions, Intravenous; Male; Middle Aged; Propanolamines; Pyridazines; Simendan; Time Factors; Treatment Outcome | 2008 |
The hemodynamic and pharmacokinetic interactions between chronic use of oral levosimendan and digoxin in patients with NYHA Classes II-III heart failure.
Topics: Acetamides; Administration, Oral; Aged; Area Under Curve; Cardiotonic Agents; Chronic Disease; Digoxin; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Female; Heart Failure; Hemodynamics; Humans; Hydrazones; Magnetocardiography; Male; Middle Aged; Pyridazines; Simendan | 2008 |
Oral levosimendan in patients with severe chronic heart failure --the PERSIST study.
Topics: Aged; Biomarkers; Cardiotonic Agents; Chronic Disease; Disease Progression; Double-Blind Method; Female; Heart Failure; Humans; Hydrazones; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Psychometrics; Pyridazines; Quality of Life; Severity of Illness Index; Simendan; Surveys and Questionnaires | 2008 |
Plasma B-type natriuretic peptide reduction predicts long-term response to levosimendan therapy in acutely decompensated chronic heart failure.
Topics: Acute Disease; Aged; Biomarkers; Cardiotonic Agents; Chronic Disease; Disease-Free Survival; Female; Follow-Up Studies; Heart Failure; Heart Function Tests; Humans; Hydrazones; Kaplan-Meier Estimate; Male; Middle Aged; Natriuretic Peptide, Brain; Patient Readmission; Predictive Value of Tests; Pyridazines; Sensitivity and Specificity; Simendan; Ultrasonography | 2010 |
Effects of levosimendan on left atrial functions in patients with ischemic heart failure.
Topics: Aged; Atrial Function, Left; Blood Pressure; Cardiotonic Agents; Dobutamine; Female; Heart Failure; Humans; Hydrazones; Male; Middle Aged; Myocardial Ischemia; Pyridazines; Simendan; Stroke Volume; Ventricular Function, Left; Ventricular Pressure | 2008 |
Levosimendan vs. dobutamine: outcomes for acute heart failure patients on beta-blockers in SURVIVE.
Topics: Acute Disease; Adrenergic beta-Antagonists; Aged; Cardiotonic Agents; Cause of Death; Dobutamine; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Heart Failure; Humans; Hydrazones; Infusions, Intravenous; Male; Middle Aged; Pyridazines; Simendan; Stroke Volume; Survival Rate; Treatment Outcome | 2009 |
Comparative effects of levosimendan and dobutamine on right ventricular function in patients with biventricular heart failure.
Topics: Aged; Cardiotonic Agents; Diastole; Dobutamine; Dose-Response Relationship, Drug; Echocardiography; Female; Follow-Up Studies; Heart Failure; Heart Ventricles; Humans; Hydrazones; Infusions, Intravenous; Male; Middle Aged; Pyridazines; Simendan; Stroke Volume; Systole; Treatment Outcome; Ventricular Dysfunction, Right; Ventricular Function, Right | 2009 |
Effectiveness and safety of levosimendan in clinical practice.
Topics: Acute Disease; Female; Heart Failure; Humans; Hydrazones; Male; Middle Aged; Prospective Studies; Pyridazines; Simendan; Systole; Vasodilator Agents | 2009 |
The costs of treating acute heart failure: an economic analysis of the SURVIVE trial.
Topics: Acute Disease; Aged; Aged, 80 and over; Cardiotonic Agents; Cost-Benefit Analysis; Dobutamine; Female; Health Expenditures; Heart Failure; Humans; Hydrazones; Length of Stay; Male; Middle Aged; Patient Admission; Pyridazines; Simendan | 2008 |
Hospital costs for treatment of acute heart failure: economic analysis of the REVIVE II study.
Topics: Adult; Aged; Aged, 80 and over; Australia; Cardiotonic Agents; Cost-Benefit Analysis; Female; Heart Failure; Hospital Costs; Humans; Hydrazones; Israel; Length of Stay; Male; Middle Aged; Pyridazines; Randomized Controlled Trials as Topic; Simendan; Survival Analysis; Treatment Outcome; United States; Young Adult | 2010 |
Effects of levosimendan versus dobutamine on left atrial function in decompensated heart failure.
Topics: Adult; Aged; Aged, 80 and over; Atrial Function, Left; Cardiotonic Agents; Dobutamine; Dose-Response Relationship, Drug; Echocardiography; Electrocardiography; Female; Follow-Up Studies; Heart Failure; Humans; Hydrazones; Infusions, Intravenous; Male; Middle Aged; Prospective Studies; Pyridazines; Simendan; Single-Blind Method; Treatment Outcome; Young Adult | 2009 |
Levosimedan improves hemodynamics functions without sympathetic activation in severe heart failure patients: direct evidence from sympathetic neural recording.
Topics: Acute Disease; Cardiotonic Agents; Drug Monitoring; Echocardiography; Electromyography; Female; Heart Failure; Hemodynamics; Humans; Hydrazones; Infusions, Intravenous; Male; Microelectrodes; Middle Aged; Plethysmography; Pyridazines; Simendan; Single-Blind Method; Statistics, Nonparametric; Sympathetic Nervous System; Treatment Outcome | 2010 |
Rationale and design of the multicentre randomized trial investigating the efficacy and safety of pulsed infusions of levosimendan in outpatients with advanced heart failure (LevoRep study).
Topics: Cardiotonic Agents; Double-Blind Method; Female; Health Status Indicators; Heart Failure; Humans; Hydrazones; Kaplan-Meier Estimate; Male; Outpatients; Pulsatile Flow; Pyridazines; Quality of Life; Research Design; Simendan; Surveys and Questionnaires | 2010 |
Intravenous levosimendan vs. dobutamine in acute decompensated heart failure patients on beta-blockers.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Aged; Analysis of Variance; Antihypertensive Agents; Cardiotonic Agents; Confidence Intervals; Dobutamine; Double-Blind Method; Female; Heart Failure; Hemodynamics; Humans; Hydrazones; Male; Myocardial Perfusion Imaging; Natriuretic Peptide, Brain; Odds Ratio; Perfusion; Pulmonary Wedge Pressure; Pyridazines; Simendan; Vasodilator Agents | 2010 |
[Study evaluating the impact of a combination of inotropic support and heart rate control on prognosis and stabilization rate in patients with decompensated chronic heart failure (LEGION)].
Topics: Benzazepines; Blood Pressure; Cardiotonic Agents; Catheterization, Swan-Ganz; Dopamine; Drug Therapy, Combination; Female; Heart Failure; Heart Rate; Humans; Hydrazones; Ivabradine; Male; Middle Aged; Monitoring, Physiologic; Myocardial Contraction; Pilot Projects; Prognosis; Prospective Studies; Pyridazines; Simendan; Treatment Outcome | 2010 |
Acute effects of levosimendan on mitral regurgitation and diastolic function in patients with advanced chronic heart failure.
Topics: Aged; Cardiography, Impedance; Cardiotonic Agents; Chronic Disease; Diastole; Echocardiography, Doppler; Female; Heart Failure; Hemodynamics; Humans; Hydrazones; Infusions, Intravenous; Italy; Male; Middle Aged; Mitral Valve Insufficiency; Natriuretic Peptide, Brain; Pilot Projects; Pyridazines; Severity of Illness Index; Simendan; Stroke Volume; Systole; Time Factors; Treatment Outcome; Vasodilator Agents; Ventricular Function, Left | 2010 |
Short-term effect of levosimendan on free light chain kappa and lambda levels in patients with decompensated chronic heart failure.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Cardiotonic Agents; Chronic Disease; Down-Regulation; Female; Heart Failure; Humans; Hydrazones; Immunoglobulin kappa-Chains; Immunoglobulin lambda-Chains; Male; Middle Aged; Natriuretic Peptide, Brain; Pyridazines; Severity of Illness Index; Simendan; Stroke Volume; Time Factors; Treatment Outcome; Turkey | 2010 |
[Efficacy and safety of intravenous levosimendan compared with dobutamine in decompensated heart failure].
Topics: Aged; Cardiotonic Agents; Dobutamine; Female; Heart Failure; Humans; Hydrazones; Injections, Intravenous; Male; Middle Aged; Pyridazines; Simendan; Treatment Outcome | 2010 |
Levosimendan reduces plasma cell-free DNA levels in patients with ischemic cardiomyopathy.
Topics: Aged; Anti-Arrhythmia Agents; Biomarkers; Cardiomyopathies; DNA; Female; Heart Failure; Humans; Hydrazones; Male; Middle Aged; Myocardial Ischemia; Pyridazines; Simendan; Ventricular Dysfunction, Left | 2011 |
Acute effects of levosimendan and dobutamine on QRS duration in patients with heart failure.
Topics: Aged; Cardiotonic Agents; Chi-Square Distribution; Dobutamine; Female; Heart Conduction System; Heart Failure; Humans; Hydrazones; Male; Muscle Contraction; Pyridazines; Simendan; Statistics, Nonparametric | 2010 |
Acetylation status does not affect levosimendan's hemodynamic effects in heart failure patients.
Topics: Acetamides; Acetylation; Double-Blind Method; Female; Follow-Up Studies; Heart Failure; Hemodynamics; Humans; Hydrazones; Male; Middle Aged; Pyridazines; Severity of Illness Index; Simendan; Treatment Outcome; Vasodilator Agents | 2011 |
[Levosimendan and dobutamine have a similar profile for potential risk for cardiac arrhythmias during 24-hour infusion in patients with acute decompensated heart failure].
Topics: Acute Disease; Aged; Arrhythmias, Cardiac; Atrial Fibrillation; Cardiotonic Agents; Dobutamine; Electrocardiography, Ambulatory; Female; Heart Failure; Heart Rate; Humans; Hydrazones; Infusions, Parenteral; Male; Middle Aged; Pyridazines; Risk Factors; Simendan; Tachycardia, Ventricular; Ventricular Premature Complexes | 2010 |
Levosimendan improves pro/anti-inflammatory cytokines imbalance in male patients with advanced heart failure. A randomized, double-blind, placebo-controlled study.
Topics: Cytokines; Double-Blind Method; Heart Failure; Humans; Hydrazones; Male; Placebos; Pyridazines; Simendan; Treatment Outcome; Vasodilator Agents | 2011 |
Beneficial association of β-blocker therapy on recovery from severe acute heart failure treatment: data from the Survival of Patients With Acute Heart Failure in Need of Intravenous Inotropic Support trial.
Topics: Acute Disease; Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Cardiotonic Agents; Confidence Intervals; Dobutamine; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Heart Failure; Hospital Mortality; Humans; Hydrazones; Infusions, Intravenous; International Cooperation; Kaplan-Meier Estimate; Male; Middle Aged; Patient Discharge; Proportional Hazards Models; Pyridazines; Reference Values; Risk Assessment; Severity of Illness Index; Simendan; Survival Analysis; Treatment Outcome | 2011 |
Oral levosimendan improves filling pressure and systolic function during long-term treatment.
Topics: Administration, Oral; Aged; Blood Pressure; Chronic Disease; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Heart Failure; Heart Rate; Humans; Hydrazones; Male; Middle Aged; Prospective Studies; Pyridazines; Severity of Illness Index; Simendan; Systole; Time Factors; Treatment Outcome; Vasodilator Agents | 2011 |
Effects of levosimendan/furosemide infusion on plasma brain natriuretic peptide, echocardiographic parameters and cardiac output in end-stage heart failure patients.
Topics: Aged; Cardiac Output; Case-Control Studies; Echocardiography; Female; Follow-Up Studies; Furosemide; Heart Failure; Humans; Hydrazones; Infusions, Intravenous; Male; Natriuretic Peptide, Brain; Pyridazines; Simendan; Time Factors | 2011 |
Levosimendan reduces heart failure after cardiac surgery: a prospective, randomized, placebo-controlled trial.
Topics: Aged; Cardiotonic Agents; Coronary Artery Bypass; Female; Heart Failure; Heart Valve Diseases; Hemodynamics; Humans; Hydrazones; Male; Middle Aged; Prospective Studies; Pyridazines; Simendan | 2011 |
[Efficacy of levosimendan vs dopamine in patients with resistant cardiac failure].
Topics: Aged; Aged, 80 and over; Cardiotonic Agents; Dopamine; Female; Heart Failure; Hemodynamics; Humans; Hydrazones; Male; Middle Aged; Pilot Projects; Prognosis; Pyridazines; Simendan | 2011 |
Effects of the recombinant form of the natural human B-type natriuretic peptide and levosimendan on pulmonary hyperventilation and chemosensivity in heart failure.
Topics: Adult; Brazil; Cardiovascular Agents; Chemoreceptor Cells; Chronic Disease; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Female; Heart Failure; Hemodynamics; Humans; Hydrazones; Hypercapnia; Hyperventilation; Hypoxia; Infusions, Intravenous; Lung; Male; Middle Aged; Natriuretic Peptide, Brain; Prospective Studies; Pyridazines; Recombinant Proteins; Respiratory Rate; Simendan; Time Factors; Treatment Outcome | 2013 |
[The effect of levosimendan and dobutamine treatment on QT dispersion in patients with decompensated heart failure: a prospective study].
Topics: Aged; Arrhythmias, Cardiac; Cardiotonic Agents; Cohort Studies; Dobutamine; Female; Heart Failure; Humans; Hydrazones; Infusions, Intravenous; Male; Prospective Studies; Pyridazines; Simendan; Treatment Outcome | 2012 |
[Hemodynamic and efficacies of domestic levosimendan versus dobutamine in patients with acute decompensated heart failure].
Topics: Adolescent; Adult; Dobutamine; Double-Blind Method; Female; Heart Failure; Hemodynamics; Humans; Hydrazones; Male; Middle Aged; Pyridazines; Simendan; Treatment Outcome; Young Adult | 2012 |
[Comparison on efficacy and safety between domestic levosimendan versus dobutamine for patients with acute decompensated heart failure].
Topics: Aged; Dobutamine; Female; Heart Failure; Humans; Hydrazones; Male; Middle Aged; Pyridazines; Simendan; Treatment Outcome | 2012 |
Intermittent levosimendan infusions in advanced heart failure: favourable effects on left ventricular function, neurohormonal balance, and one-year survival.
Topics: Aged; Calcium; Chronic Disease; Data Interpretation, Statistical; Diuretics; Drug Administration Schedule; Female; Furosemide; Heart Failure; Heart Function Tests; Hemodynamics; Humans; Hydrazones; Infusions, Intravenous; Male; Mortality; Natriuretic Peptide, Brain; Pyridazines; Severity of Illness Index; Simendan; Treatment Outcome; Ventricular Function | 2012 |
Levosimendan in acute heart failure following primary percutaneous coronary intervention-treated acute ST-elevation myocardial infarction. Results from the LEAF trial: a randomized, placebo-controlled study.
Topics: Acute Disease; Aged; Cardiotonic Agents; Double-Blind Method; Echocardiography; Female; Heart Failure; Humans; Hydrazones; Male; Middle Aged; Myocardial Contraction; Myocardial Infarction; Norway; Percutaneous Coronary Intervention; Pyridazines; Simendan; Treatment Outcome | 2013 |
Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN).
Topics: Acute Disease; Aged; Analysis of Variance; Cardiotonic Agents; Double-Blind Method; Drug Evaluation; Endpoint Determination; Female; Heart Failure; Humans; Hydrazones; Hypotension; Male; Myocardial Infarction; Prospective Studies; Pyridazines; Risk Factors; Safety; Simendan; Survival Analysis; Treatment Outcome; Ventricular Dysfunction, Left | 2002 |
Pharmacokinetics of levosimendan and its metabolites during and after a 24-hour continuous infusion in patients with severe heart failure.
Topics: Blood Pressure; Cardiotonic Agents; Female; Heart Failure; Heart Rate; Humans; Hydrazones; Infusions, Intravenous; Male; Middle Aged; Pyridazines; Simendan; Time Factors | 2002 |
Sustained hemodynamic effects of intravenous levosimendan.
Topics: Cardiotonic Agents; Double-Blind Method; Female; Heart Failure; Hemodynamics; Humans; Hydrazones; Infusions, Intravenous; Kinetics; Male; Middle Aged; Pyridazines; Simendan; Stroke Volume; Vasodilator Agents | 2003 |
Intravenous levosimendan treatment is cost-effective compared with dobutamine in severe low-output heart failure: an analysis based on the international LIDO trial.
Topics: Aged; Cardiac Output, Low; Cardiotonic Agents; Cost-Benefit Analysis; Dobutamine; Double-Blind Method; Europe; Female; Follow-Up Studies; Heart Failure; Humans; Hydrazones; Infusions, Intravenous; Length of Stay; Life Expectancy; Male; Middle Aged; Patient Admission; Pyridazines; Randomized Controlled Trials as Topic; Risk Factors; Sensitivity and Specificity; Severity of Illness Index; Simendan; Survival Analysis; Treatment Outcome | 2003 |
Population pharmacokinetics of levosimendan in patients with congestive heart failure.
Topics: Adrenergic beta-Antagonists; Cardiotonic Agents; Digoxin; Double-Blind Method; Heart Failure; Humans; Hydrazones; Infusions, Intravenous; Pyridazines; Simendan | 2003 |
Pharmacokinetic-pharmacodynamic interrelationships of intravenous and oral levosimendan in patients with severe congestive heart failure.
Topics: Administration, Oral; Adult; Aged; Blood Pressure; Electric Stimulation; Female; Heart Failure; Heart Rate; Humans; Hydrazones; Infusions, Intravenous; Male; Middle Aged; Myocardial Contraction; Pyridazines; Simendan; Time Factors; Vasodilation | 2003 |
Levosimendan in patients with low-output heart failure: lessons from the LIDO trial.
Topics: Adrenergic beta-Agonists; Calcium Channels, L-Type; Cardiac Output, Low; Cardiotonic Agents; Death, Sudden, Cardiac; Dobutamine; Dose-Response Relationship, Drug; Double-Blind Method; Europe; Heart Failure; Heart Rate; Humans; Hydrazones; Infusions, Intravenous; Morbidity; Myocardial Contraction; Pulmonary Wedge Pressure; Pyridazines; Risk Factors; Severity of Illness Index; Shock, Cardiogenic; Simendan; Stroke Volume; Survival Analysis; Time; Treatment Outcome; Vasodilator Agents; Ventricular Dysfunction, Left | 2003 |
Pharmacokinetics of levosimendan and its circulating metabolites in patients with heart failure after an extended continuous infusion of levosimendan.
Topics: Acetamides; Cardiotonic Agents; Female; Heart Failure; Humans; Hydrazones; Infusions, Intravenous; Male; Protein Binding; Pyridazines; Simendan | 2004 |
Effects of levosimendan on circulating pro-inflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure.
Topics: Adjuvants, Immunologic; Aged; Cardiotonic Agents; Fas Ligand Protein; Female; Heart Failure; Humans; Hydrazones; Infusions, Intravenous; Interleukin-6; Male; Membrane Glycoproteins; Pyridazines; Simendan; Ventricular Function, Left | 2004 |
Pharmacodynamics and pharmacokinetics of oral levosimendan and its metabolites in patients with severe congestive heart failure: a dosing interval study.
Topics: Administration, Oral; Analysis of Variance; Double-Blind Method; Drug Administration Schedule; Female; Heart Failure; Humans; Hydrazones; Male; Middle Aged; Pyridazines; Simendan | 2004 |
Hemodynamic effects of levosimendan added to dobutamine in patients with decompensated advanced heart failure refractory to dobutamine alone.
Topics: Administration, Oral; Cardiac Output; Cardiotonic Agents; Diuretics; Dobutamine; Drug Therapy, Combination; Female; Furosemide; Heart Failure; Hemodynamics; Humans; Hydrazones; Infusions, Intravenous; Male; Middle Aged; Pulmonary Wedge Pressure; Pyridazines; Simendan | 2004 |
Levosimendan in daily intensive care practice--the experience of 15 centers. Background, methods and organization of the PORTLAND study.
Topics: Critical Care; Follow-Up Studies; Heart Failure; Humans; Hydrazones; Prospective Studies; Pyridazines; Simendan; Vasodilator Agents | 2004 |
Effects of intravenous levosimendan on human coronary vasomotor regulation, left ventricular wall stress, and myocardial oxygen uptake.
Topics: Adult; Aged; Aged, 80 and over; Coronary Circulation; Coronary Vessels; Female; Heart Failure; Humans; Hydrazones; Male; Middle Aged; Myocardium; Oxygen Consumption; Pyridazines; Regional Blood Flow; Simendan; Vascular Resistance; Vasodilation; Vasomotor System; Ventricular Dysfunction, Left | 2005 |
The Ca2+-sensitizer levosimendan improves oxidative damage, BNP and pro-inflammatory cytokine levels in patients with advanced decompensated heart failure in comparison to dobutamine.
Topics: Adrenergic beta-Agonists; Aged; Aged, 80 and over; Cardiotonic Agents; Dobutamine; Female; Heart Failure; Humans; Hydrazones; Infusions, Intravenous; Interleukin-6; Male; Malondialdehyde; Middle Aged; Natriuretic Peptide, Brain; Oxidative Stress; Pyridazines; Simendan; Time Factors; Tumor Necrosis Factor-alpha | 2005 |
Effects of levosimendan on markers of left ventricular diastolic function and neurohormonal activation in patients with advanced heart failure.
Topics: Aged; Cardiotonic Agents; Chi-Square Distribution; Echocardiography, Doppler; Female; Heart Failure; Humans; Hydrazones; Infusions, Intravenous; Interleukin-6; Male; Middle Aged; Natriuretic Peptide, Brain; Pyridazines; Simendan; Statistics, Nonparametric; Treatment Outcome; Ventricular Dysfunction, Left | 2005 |
Short-term effects of levosimendan and prostaglandin E1 on hemodynamic parameters and B-type natriuretic peptide levels in patients with decompensated chronic heart failure.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alprostadil; Biomarkers; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Heart Failure; Humans; Hydrazones; Infusions, Intravenous; Male; Middle Aged; Natriuretic Peptide, Brain; Phosphodiesterase Inhibitors; Prospective Studies; Pulmonary Wedge Pressure; Pyridazines; Simendan; Stroke Volume; Time Factors; Treatment Outcome; Vasodilator Agents | 2005 |
Levosimendan use reduces matrix metalloproteinase-2 in patients with decompensated heart failure.
Topics: Aged; Cardiotonic Agents; Disease Progression; Female; Heart Failure; Humans; Hydrazones; Injections, Intravenous; Male; Matrix Metalloproteinase 2; Placebos; Pyridazines; Simendan; Treatment Outcome | 2005 |
Long-term effects of levosimendan infusion on inflammatory processes and sFas in patients with severe heart failure.
Topics: Aged; fas Receptor; Female; Heart Failure; Humans; Hydrazones; Inflammation; Infusions, Parenteral; Interleukin-6; Male; Pyridazines; Receptors, Tumor Necrosis Factor, Type I; Simendan; Solubility; Time Factors; Tumor Necrosis Factor-alpha | 2006 |
Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure.
Topics: Aged; Apoptosis; Cardiotonic Agents; Chronic Disease; Dobutamine; Echocardiography; Fas Ligand Protein; Female; Heart Failure; Hemodynamics; Humans; Hydrazones; Infusions, Intravenous; Interleukin-6; Male; Membrane Glycoproteins; Natriuretic Peptide, Brain; Peptide Fragments; Prognosis; Pulmonary Wedge Pressure; Pyridazines; Simendan; Stroke Volume; Treatment Outcome; Tumor Necrosis Factor-alpha; Tumor Necrosis Factors | 2006 |
Duration of the haemodynamic action of a 24-h infusion of levosimendan in patients with congestive heart failure.
Topics: Atrial Natriuretic Factor; Cardiotonic Agents; Double-Blind Method; Echocardiography; Female; Heart Failure; Heart Rate; Humans; Hydrazones; Infusions, Intravenous; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Placebos; Pulmonary Circulation; Pyridazines; Simendan; Systole; Time Factors; Ventricular Dysfunction, Left | 2007 |
Levosimendan and prostaglandin E1 for uptitration of beta-blockade in patients with refractory, advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Alprostadil; Cardiotonic Agents; Drug Interactions; Female; Heart Failure; Humans; Hydrazones; Male; Middle Aged; Natriuretic Peptide, Brain; Prognosis; Pyridazines; Simendan; Stroke Volume; Vasodilator Agents | 2007 |
Effects of serial levosimendan infusions on left ventricular performance and plasma biomarkers of myocardial injury and neurohormonal and immune activation in patients with advanced heart failure.
Topics: Aged; Cardiomyopathies; Cardiotonic Agents; Cytokines; Electrocardiography; Female; Heart Failure; Humans; Hydrazones; Immunity, Cellular; Infusions, Intravenous; Male; Natriuretic Peptide, Brain; Peptide Fragments; Pyridazines; Simendan; Treatment Outcome; Troponin T; Vasodilator Agents; Ventricular Dysfunction, Left | 2006 |
Effects of levosimendan on right ventricular function in patients with advanced heart failure.
Topics: Blood Pressure; Cardiotonic Agents; Echocardiography; Female; Heart Failure; Humans; Hydrazones; Interleukin-10; Interleukin-6; Male; Middle Aged; Natriuretic Peptides; Pulmonary Artery; Pyridazines; Simendan; Vasodilator Agents; Ventricular Dysfunction, Left; Ventricular Function, Right | 2006 |
Effect of levosimendan on ventricular arrhythmias and prognostic autonomic indexes in patients with decompensated advanced heart failure secondary to ischemic or dilated cardiomyopathy.
Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Autonomic Nervous System; Cardiomyopathy, Dilated; Cardiotonic Agents; Female; Heart Failure; Humans; Hydrazones; Male; Natriuretic Peptide, Brain; Pyridazines; Simendan; Stroke Volume; Vasodilator Agents; Ventricular Dysfunction, Left | 2006 |
Effect of levosimendan on E/E' ratio in patients with ischemic heart failure.
Topics: Aged; Cardiotonic Agents; Dobutamine; Echocardiography, Doppler; Female; Heart Failure; Humans; Hydrazones; Male; Middle Aged; Myocardial Ischemia; Prospective Studies; Pyridazines; Simendan; Single-Blind Method | 2008 |
Improvement in Doppler alternans in patients with severe heart failure: Levosimendan versus dobutamin.
Topics: Adult; Aged; Cardiotonic Agents; Dobutamine; Echocardiography, Doppler, Pulsed; Female; Heart Failure; Humans; Hydrazones; Male; Middle Aged; Pyridazines; Simendan; Ventricular Function, Left | 2008 |
Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial.
Topics: Acute Disease; Aged; Cardiotonic Agents; Dobutamine; Double-Blind Method; Female; Heart Failure; Humans; Hydrazones; Infusions, Intravenous; Male; Middle Aged; Natriuretic Peptide, Brain; Pyridazines; Simendan; Survival Analysis | 2007 |
Effects of levosimendan on flow-mediated vasodilation and soluble adhesion molecules in patients with advanced chronic heart failure.
Topics: Aged; Chronic Disease; Endothelium, Vascular; Female; Heart Failure; Humans; Hydrazones; Intercellular Adhesion Molecule-1; Interleukin-6; Male; Middle Aged; Natriuretic Peptide, Brain; Nitroglycerin; Pyridazines; Severity of Illness Index; Simendan; Solubility; Stroke Volume; Vascular Cell Adhesion Molecule-1; Vasodilation; Vasodilator Agents | 2008 |
Effects of levosimendan on quality of life and emotional stress in advanced heart failure patients.
Topics: Aged; Cardiotonic Agents; Exercise Tolerance; Female; Heart Failure; Humans; Hydrazones; Infusions, Intravenous; Length of Stay; Male; Middle Aged; Natriuretic Peptide, Brain; Psychometrics; Pyridazines; Quality of Life; Simendan; Stress, Psychological; Surveys and Questionnaires | 2007 |
Levosimendan improves renal function in patients with advanced chronic heart failure awaiting cardiac transplantation.
Topics: Biomarkers; Cardiotonic Agents; Creatinine; Female; Follow-Up Studies; Heart Failure; Heart Transplantation; Humans; Hydrazones; Infusions, Intravenous; Kidney; Male; Middle Aged; Natriuretic Peptide, Brain; Prospective Studies; Pyridazines; Simendan; Time Factors; Treatment Outcome; Waiting Lists | 2007 |
[Clinical experience with levosimendan in the emergency department of a tertiary care hospital].
Topics: Acute Disease; Aged; Cardiotonic Agents; Emergency Service, Hospital; Emergency Treatment; Female; Heart Failure; Humans; Hydrazones; Male; Prospective Studies; Pyridazines; Simendan | 2007 |
Effects of Levosimendan on circulating markers of oxidative and nitrosative stress in patients with advanced heart failure.
Topics: Aged; Anti-Arrhythmia Agents; Female; Heart Failure; Humans; Hydrazones; Male; Malondialdehyde; Middle Aged; Nitric Oxide; Oxidative Stress; Protein Carbonylation; Pyridazines; Simendan; Stroke Volume; Tyrosine | 2007 |
Effect of levosimendan on right ventricular systolic and diastolic functions in patients with ischaemic heart failure.
Topics: Aged; Cardiotonic Agents; Dobutamine; Female; Heart Failure; Humans; Hydrazones; Male; Middle Aged; Pyridazines; Simendan; Treatment Outcome; Ventricular Function, Right | 2008 |
Levosimendan improves renal function in patients with acute decompensated heart failure: comparison with dobutamine.
Topics: Acute Disease; Aged; Cardiotonic Agents; Dobutamine; Female; Glomerular Filtration Rate; Heart Failure; Humans; Hydrazones; Kidney; Male; Middle Aged; Pyridazines; Simendan; Urination | 2007 |
Effects of levosimendan on coronary artery flow and cardiac performance in patients with advanced heart failure.
Topics: Coronary Circulation; Coronary Vessels; Dose-Response Relationship, Drug; Echocardiography, Doppler; Female; Heart Failure; Humans; Hydrazones; Infusions, Intravenous; Male; Middle Aged; Pyridazines; Regional Blood Flow; Simendan; Treatment Outcome; Vasodilator Agents; Ventricular Function, Left | 2007 |
Repeated infusions of levosimendan: well tolerated and improves functional capacity in decompensated heart failure - a single-centre experience.
Topics: Adult; Aged; Ambulatory Care; Cardiotonic Agents; Female; Heart Failure; Humans; Hydrazones; Infusions, Intravenous; Male; Middle Aged; Natriuretic Peptide, Brain; Prospective Studies; Pyridazines; Simendan | 2008 |
Levosimendan in decompensated heart failure patients: efficacy in a Brazilian cohort. Results of the BELIEF study.
Topics: Adolescent; Adrenergic beta-Agonists; Adult; Brazil; Cardiotonic Agents; Dyspnea; Female; Follow-Up Studies; Heart Failure; Hospitalization; Humans; Hydrazones; Infusions, Intravenous; Kaplan-Meier Estimate; Length of Stay; Male; Middle Aged; Prospective Studies; Pyridazines; Quality of Life; Simendan; Treatment Outcome; Vasodilator Agents; Young Adult | 2008 |
Haemodynamic interactions of a new calcium sensitizing drug levosimendan and captopril.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Captopril; Cardiac Output; Cardiotonic Agents; Cross-Over Studies; Double-Blind Method; Drug Interactions; Echocardiography; Electrocardiography, Ambulatory; Half-Life; Heart Failure; Heart Rate; Hemodynamics; Humans; Hydrazones; Injections, Intravenous; Male; Middle Aged; Myocardial Contraction; Pyridazines; Simendan | 1996 |
Pharmacokinetics of levosimendan in healthy volunteers and patients with congestive heart failure.
Topics: Administration, Oral; Aged; Aged, 80 and over; Blood Proteins; Carbon Radioisotopes; Cardiotonic Agents; Erythrocytes; Feces; Heart Failure; Humans; Hydrazones; Male; Middle Aged; Protein Binding; Pyridazines; Reference Values; Saliva; Simendan; Troponin C | 1995 |
Heart failure update.
Topics: Blood Pressure; Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Myocardial Contraction; Myocardial Infarction; Pyridazines; Safety; Simendan; Survival Rate; Treatment Outcome | 1999 |
Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators.
Topics: Cardiotonic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Female; Heart Failure; Heart Function Tests; Heart Rate; Hemodynamics; Humans; Hydrazones; Infusions, Intravenous; Male; Middle Aged; Pulmonary Wedge Pressure; Pyridazines; Severity of Illness Index; Simendan; Treatment Outcome; Vasodilator Agents | 2000 |
Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure.
Topics: Adult; Aged; Aged, 80 and over; Atrial Natriuretic Factor; Cardiotonic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Female; Heart Failure; Hemodynamics; Humans; Hydrazones; Infusions, Intravenous; Male; Middle Aged; Norepinephrine; Pyridazines; Simendan | 2000 |
Myocardial efficiency during levosimendan infusion in congestive heart failure.
Topics: Cardiotonic Agents; Catheterization, Swan-Ganz; Coronary Vessels; Cross-Over Studies; Double-Blind Method; Female; Heart Failure; Hemodynamics; Humans; Hydrazones; Infusions, Intravenous; Male; Middle Aged; Oxygen Consumption; Pyridazines; Simendan; Tomography, Emission-Computed; Ultrasonography | 2000 |
Pharmacodynamics and safety of a new calcium sensitizer, levosimendan, and its metabolites during an extended infusion in patients with severe heart failure.
Topics: Aged; Analysis of Variance; Blood Pressure; Body Weight; Calcium Channel Blockers; Cardiotonic Agents; Chronic Disease; Electrocardiography; Erythrocyte Indices; Female; Heart Failure; Heart Rate; Humans; Hydrazones; Infusions, Intravenous; Male; Middle Aged; Pyridazines; Simendan | 2002 |
212 other study(ies) available for simendan and Heart Failure
Article | Year |
---|---|
Effect of levosimendan combined with recombinant human brain natriuretic peptide on diuretic resistance.
Topics: Diuretics; Heart Failure; Heart Rate; Humans; Natriuretic Peptide, Brain; Simendan; Treatment Outcome | 2021 |
Hemodynamic Effects of Levosimendan in Outpatients With Advanced Heart Failure: An Echocardiographic Pilot Study.
Topics: Aged; Ambulatory Care; Cardiovascular Agents; Echocardiography, Doppler; Female; Heart Failure; Hemodynamics; Humans; Infusions, Intravenous; Male; Middle Aged; Outpatients; Pilot Projects; Predictive Value of Tests; Recovery of Function; Simendan; Time Factors; Treatment Outcome | 2022 |
Levosimendan and Continuous Outpatient Support With Inotropes in Patients With Advanced Heart Failure: A Single-Centre Descriptive Study.
Topics: Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Outpatients; Retrospective Studies; Simendan | 2022 |
Intermittent inotropic therapy with levosimendan vs. milrinone in advanced heart failure patients.
Topics: Aged; Aged, 80 and over; Heart Failure; Humans; Hydrazones; Male; Middle Aged; Milrinone; Pyridazines; Quality of Life; Simendan; Stroke Volume; Ventricular Function, Left | 2022 |
Comparative Effectiveness and Safety of Milrinone and Levosimendan as Initial Inotrope Therapy in Patients With Acute Heart Failure With Renal Dysfunction.
Topics: Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Kidney Diseases; Milrinone; Pyridazines; Retrospective Studies; Simendan | 2022 |
Effect of levosimendan infusion prior to left ventricular assist device implantation on right ventricular failure.
Topics: Heart Failure; Heart-Assist Devices; Humans; Retrospective Studies; Simendan; Ventricular Dysfunction, Right | 2022 |
Acute‑on‑chronic pulmonary embolism‑induced right ventricular failure salvaged by combined catheter‑directed therapy and levosimendan infusion.
Topics: Catheters; Heart Failure; Humans; Pulmonary Embolism; Simendan; Ventricular Dysfunction, Right | 2022 |
Levosimendan for acute right heart failure in COVID-19: another arrow in our quiver?
Topics: Aged; COVID-19; COVID-19 Drug Treatment; Heart Failure; Humans; Male; SARS-CoV-2; Simendan; Systemic Inflammatory Response Syndrome | 2022 |
Comparative Efficacy of Levosimendan, Ramipril, and Sacubitril/ Valsartan in Isoproterenol-induced Experimental Heart Failure: A Hemodynamic and Molecular Approach.
Topics: Antioxidants; Calcium; Collagen; Heart Failure; Hemodynamics; Humans; Isoproterenol; Myocardial Infarction; Ramipril; Simendan; Valsartan | 2023 |
New insight: particle flow rate from the airways as an indicator of cardiac failure in the intensive care unit.
Topics: Heart Failure; Humans; Intensive Care Units; Simendan; Stroke Volume; Ventricular Function, Left | 2023 |
Levosimendan in outpatients with advanced heart failure: Single-center experience of 200 intermittent perfusions.
Topics: Cardiotonic Agents; Female; Heart Failure; Humans; Hydrazones; Male; Outpatients; Pyridazines; Simendan; Stroke Volume; Ventricular Function, Left | 2023 |
Intermittent inotropic support with levosimendan in advanced heart failure as destination therapy: The LEVO-D registry.
Topics: Cardiotonic Agents; Cardiovascular Agents; Heart Failure; Humans; Registries; Retrospective Studies; Simendan; Treatment Outcome | 2023 |
Omecamtiv mecarbil augments cardiomyocyte contractile activity both at resting and systolic Ca
Topics: Animals; Dogs; Heart Failure; Myocytes, Cardiac; Myosins; Simendan; Stroke Volume | 2023 |
A favorable alliance between repetitive use of levosimendan and advanced heart failure: Polish two-centered inpatient perspective in need of validation.
Topics: Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Inpatients; Poland; Pyridazines; Simendan | 2023 |
[Comparative assessment of the effects of dobutamine and levosimendan on right ventricular ejection fraction in patients with biventricular heart failure].
Topics: Cardiovascular Agents; Cross-Sectional Studies; Dobutamine; Heart Failure; Humans; Prospective Studies; Simendan; Stroke Volume; Ventricular Function, Left; Ventricular Function, Right | 2023 |
Efficacy of levosimendan infusion in patients undergoing a left ventricular assist device implant in a propensity score matched analysis of the EUROMACS registry-the Euro LEVO-LVAD study.
Topics: Adult; Heart Failure; Heart-Assist Devices; Humans; Propensity Score; Registries; Retrospective Studies; Simendan; Treatment Outcome | 2023 |
Preoperative Levosimendan Administration in Heart Transplant Patients with Severe Hepatic and Renal Impairment: A Retrospective Study.
Topics: Dobutamine; Dopamine; Heart Failure; Heart Transplantation; Humans; Renal Insufficiency; Retrospective Studies; Simendan | 2023 |
Use of levosimendan in hemodynamic management of heart failure in two neonates with intracranial arteriovenous shunts: a case series.
Topics: Cardiotonic Agents; Heart Failure; Hemodynamics; Humans; Hydrazones; Infant, Newborn; Pyridazines; Simendan | 2023 |
Heart failure risk scores in advanced heart failure patients: insights from the LEVO-D registry.
Topics: Aged; Female; Heart Failure; Humans; Male; Middle Aged; Registries; Risk Factors; Simendan; Stroke Volume; Ventricular Function, Left | 2023 |
Intermittent levosimendan treatment for late onset right ventricular failure in a patient supported with a left ventricular assist device.
Topics: Cardiotonic Agents; Drug Administration Schedule; Heart Failure; Heart-Assist Devices; Humans; Male; Middle Aged; Recovery of Function; Simendan; Treatment Outcome; Ventricular Dysfunction, Left; Ventricular Dysfunction, Right; Ventricular Function, Left; Ventricular Function, Right | 2020 |
Old and New Drugs for Treatment of Advanced Heart Failure.
Topics: Diuretics; Furosemide; Heart Failure; Humans; Prognosis; Simendan | 2020 |
Effects of levosimendan on ventriculo-arterial coupling and cardiac efficiency in paediatric patients with single-ventricle physiology after surgical palliation: retrospective study.
Topics: Cardiac Output, Low; Cardiotonic Agents; Echocardiography; Female; Heart Failure; Humans; Hypoplastic Left Heart Syndrome; Infant; Infant, Newborn; Male; Retrospective Studies; Simendan; Stroke Volume; Univentricular Heart; Ventricular Function, Left | 2020 |
Levosimendan – a valuable player in the treatment of a right-sided heart failure
Topics: Aged; Cardiotonic Agents; Diabetes Mellitus, Type 2; Heart Failure; Humans; Hydrazones; Male; Pyridazines; Simendan | 2019 |
Levosimendan to facilitate weaning from cardiorespiratory support in critically ill patients: current evidence and future directions.
Topics: Critical Illness; Extracorporeal Membrane Oxygenation; Heart Failure; Humans; Shock, Cardiogenic; Simendan | 2020 |
Levosimendan as bridge to transplant in patients with advanced heart failure.
Topics: Adult; Cardiotonic Agents; Heart Failure; Humans; Middle Aged; Simendan | 2020 |
Ambulatory levosimendan infusions. Effective and efficient in advanced heart failure?
Topics: Cardiotonic Agents; Heart Failure; Humans; Infusions, Intravenous; Simendan; Treatment Outcome | 2020 |
Successful Combination of Landiolol and Levosimendan in Patients with Decompensated Heart Failure.
Topics: Adrenergic beta-Antagonists; Aged; Cardiotonic Agents; Drug Therapy, Combination; Female; Heart Failure; Humans; Male; Morpholines; Simendan; Tachycardia; Urea | 2020 |
Levosimendan with other inotropes or vasopressors: Should you combine them?
Topics: Acute Disease; Aged; Aged, 80 and over; Arterial Pressure; Cardiotonic Agents; Dobutamine; Dopamine; Drug Therapy, Combination; Female; Heart Failure; Heart Rate; Hospital Mortality; Humans; Hypotension; Length of Stay; Male; Middle Aged; Norepinephrine; Simendan; Tachycardia, Supraventricular; Treatment Outcome; Vasoconstrictor Agents | 2020 |
Experimental Study of Heart Functionality during Treatment of Chronic Heart Failure in Rats of Different Age Groups with Levosimendan (Experimental Study).
Topics: Animals; Chronic Disease; Disease Models, Animal; Doxorubicin; Heart; Heart Failure; Heart Function Tests; Male; Myocardium; Rats; Rats, Wistar; Simendan | 2020 |
Safety and efficacy of levosimendan in patients with cardiac amyloidosis.
Topics: Amyloidosis; Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Pyridazines; Simendan; Treatment Outcome | 2020 |
Levosimendan in the treatment of patients with acute cardiac conditions: an expert opinion of the Association of Intensive Cardiac Care of the Polish Cardiac Society.
Topics: Cardiotonic Agents; Expert Testimony; Heart Failure; Humans; Hydrazones; Poland; Pyridazines; Simendan | 2020 |
COVID-19 infection in left ventricular assist device patients.
Topics: Aged; Cardiotonic Agents; COVID-19; Dobutamine; Furosemide; Heart Failure; Heart-Assist Devices; Humans; Male; Middle Aged; Simendan; Ventricular Dysfunction, Right | 2020 |
Repetitive levosimendan in outpatients affected by advanced heart failure: the need for a uniform approach.
Topics: Heart Failure; Humans; Hydrazones; Outpatients; Simendan | 2021 |
Repeated infusion of levosimendan in outpatients with advanced heart failure: to cure sometimes, to relieve often, and to comfort always.
Topics: Heart Failure; Humans; Hydrazones; Outpatients; Simendan | 2021 |
Effectiveness of Levosimendan in an 84-Year-Old Patient with Takotsubo Syndrome Complicated by Acute Heart Failure.
Topics: Aged, 80 and over; Echocardiography; Heart Failure; Heart Ventricles; Humans; Male; Simendan; Takotsubo Cardiomyopathy | 2020 |
Effects of Levosimendan on cardiac function, size and strain in heart failure patients.
Topics: Aged; Cardiotonic Agents; Female; Heart Failure; Humans; Magnetic Resonance Imaging, Cine; Male; Middle Aged; Recovery of Function; Retrospective Studies; Simendan; Stroke Volume; Time Factors; Treatment Outcome; Ventricular Function, Left | 2021 |
Multicenter experiences with levosimendan therapy and its safety in patients with decompensated advanced heart failure.
Topics: Cardiotonic Agents; Female; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Poland; Prospective Studies; Simendan; Stroke Volume; Ventricular Function, Left | 2020 |
Levosimendan is safe to patients with advanced heart failure and hypotension.
Topics: Heart Failure; Humans; Hydrazones; Hypotension; Simendan | 2021 |
Changes in Stressed Blood Volume with Levosimendan in Pulmonary Hypertension from Heart Failure with Preserved Ejection Fraction: Insights Regarding Mechanism of Action From the HELP Trial.
Topics: Blood Volume; Heart Failure; Humans; Hypertension, Pulmonary; Simendan; Stroke Volume | 2021 |
Mortality reduction with levosimendan in patients with heart failure: Current evidence is underpowered.
Topics: Heart Failure; Humans; Hydrazones; Pyridazines; Simendan | 2021 |
Levosimendan Prevents and Reverts Right Ventricular Failure in Experimental Pulmonary Arterial Hypertension.
Topics: Animals; Cardiac Output; Cardiotonic Agents; Heart Failure; Hemodynamics; Hydrazones; Hypertension, Pulmonary; Male; Pyridazines; Rats; Rats, Sprague-Dawley; Simendan; Ventricular Dysfunction, Right | 2017 |
High effectiveness of repeated levosimendan cycles in a patient with advanced heart failure.
Topics: Aged; Cardiotonic Agents; Drug Administration Schedule; Female; Heart Failure; Humans; Simendan | 2017 |
Inotropes and cardiorenal syndrome in acute heart failure - A retrospective comparative analysis.
Topics: Acute Disease; Aged; Cardio-Renal Syndrome; Cardiotonic Agents; Dobutamine; Female; Heart Failure; Humans; Hydrazones; Incidence; Male; Middle Aged; Pyridazines; Retrospective Studies; Simendan | 2017 |
Efficacy and safety of a calcium sensitizer, levosimendan, in patients with right heart failure due to pulmonary hypertension.
Topics: Acute Disease; Adolescent; Adult; Aged; Cardiotonic Agents; China; Dose-Response Relationship, Drug; Heart Failure; Humans; Hydrazones; Hypertension, Pulmonary; Injections, Intravenous; Middle Aged; Prospective Studies; Pulmonary Wedge Pressure; Pyridazines; Receptors, Calcium-Sensing; Simendan; Survival Rate; Treatment Outcome; Ventricular Function, Right; Young Adult | 2018 |
Levosimendan in Advanced Heart Failure: Where Do We Stand?
Topics: Heart Failure; Humans; Hydrazones; Simendan | 2018 |
Hemodynamic support of a 15-year-old waiting for a heart transplant: Is there a role for levosimendan in pediatric heart failure?
Topics: Adolescent; Cardiotonic Agents; Heart Failure; Heart Transplantation; Hemodynamics; Humans; Hydrazones; Intensive Care Units, Pediatric; Male; Pyridazines; Simendan | 2018 |
Repetitive levosimendan for a LION's heart?
Topics: Administration, Intravenous; Ambulatory Care; Heart Failure; Humans; Outpatients; Simendan | 2018 |
Ambulatory Intravenous Inotropic Support and or Levosimendan in Pediatric and Congenital Heart Failure: Safety, Survival, Improvement, or Transplantation.
Topics: Adolescent; Adult; Cardiotonic Agents; Child; Child, Preschool; Dobutamine; Female; Follow-Up Studies; Heart Failure; Heart Transplantation; Humans; Infant; Infusions, Intravenous; Male; Milrinone; Retrospective Studies; Simendan; Survival Rate; Treatment Outcome; Young Adult | 2018 |
Treatments targeting inotropy.
Topics: Acute Disease; Animals; Antioxidants; Calcium; Cardiotonic Agents; Case-Control Studies; Catecholamines; Clinical Trials as Topic; Diastole; Dobutamine; Dogs; Energy Metabolism; Excitation Contraction Coupling; Heart Failure; Humans; Mitochondria; Models, Animal; Myocardial Contraction; Nitrogen Oxides; Oxidation-Reduction; Phosphodiesterase Inhibitors; Placebos; Receptors, Adrenergic; Sarcomeres; Shock, Cardiogenic; Simendan; Swine; Systole; Urea | 2019 |
Does Levosimendan Have Room in Takotsubo Syndrome?
Topics: Heart Failure; Humans; Prognosis; Registries; Shock, Cardiogenic; Simendan; Takotsubo Cardiomyopathy | 2019 |
Levosimendan as Rescue Therapy for Acute Heart Failure in a Patient with Duchenne Muscular Dystrophy.
Topics: Acute Disease; Adult; Cardiomyopathies; Cardiotonic Agents; Heart Failure; Humans; Lactic Acid; Male; Muscular Dystrophy, Duchenne; Natriuretic Peptide, Brain; Pneumonia; Simendan | 2019 |
The efficacy of simendan in the treatment of acute heart failure and its impact on NT-proBNP.
Topics: Acute Disease; Aged; Aged, 80 and over; Calcium; Cardiotonic Agents; Female; Heart Failure; Humans; Hypokalemia; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Potassium; Simendan; Stroke Volume; Ventricular Function, Left | 2019 |
Optimization with levosimendan improves outcomes after left ventricular assist device implantation.
Topics: Adult; Heart Failure; Heart-Assist Devices; Hemodynamics; Humans; Simendan; Thoracic Surgical Procedures; Treatment Outcome | 2020 |
[Application of levosimendan in acute heart failure patients with symptoms of low cardiac output: case series report].
Topics: Adult; Aged; Cardiac Output, Low; Cardiotonic Agents; Heart Failure; Hemodynamics; Humans; Hydrazones; Infusions, Intravenous; Male; Middle Aged; Pyridazines; Simendan | 2013 |
Heart failure. Tardy but intact--publication of REVIVE trial results welcomed.
Topics: Access to Information; Cardiovascular Agents; Clinical Trials as Topic; Heart Failure; Humans; Hydrazones; Information Dissemination; Pyridazines; Research Design; Simendan; Treatment Outcome | 2013 |
Inhaled iloprost plus levosimendan to decompensate right heart failure due to chronic thromboembolic pulmonary hypertension.
Topics: Administration, Inhalation; Critical Care; Diuretics; Furosemide; Heart Failure; Humans; Hydrazones; Hypertension, Pulmonary; Iloprost; Male; Middle Aged; Pyridazines; Simendan; Thromboembolism; Vasodilator Agents; Ventricular Dysfunction, Right | 2013 |
Enteroviral myocarditis requiring extracorporeal membranous oxygenation in a 2 week old girl.
Topics: Cardiopulmonary Resuscitation; Cardiotonic Agents; Echocardiography; Enterovirus B, Human; Enterovirus Infections; Extracorporeal Membrane Oxygenation; Female; Heart Failure; Humans; Hydrazones; Infant, Newborn; Myocarditis; Pyridazines; Severity of Illness Index; Simendan; Treatment Outcome; Ventricular Dysfunction, Left | 2013 |
Levosimendan: a retrospective single-center case series.
Topics: Aged; Cardiotonic Agents; Dobutamine; Female; Heart Failure; Hemodynamics; Hospital Mortality; Humans; Hydrazones; Intensive Care Units; Male; Milrinone; Norepinephrine; Pyridazines; Retrospective Studies; Simendan; Sympathomimetics; Treatment Outcome | 2013 |
eComment. Preoperative levosimendan administration in cardiac surgery patients.
Topics: Cardiac Surgical Procedures; Cardiovascular Agents; Heart Failure; Humans; Hydrazones; Pyridazines; Simendan | 2013 |
eComment. Levosimendan in adult patients undergoing cardiac surgery.
Topics: Cardiac Surgical Procedures; Cardiovascular Agents; Heart Failure; Humans; Hydrazones; Pyridazines; Simendan | 2013 |
eComment. Consider trying levosimendan.
Topics: Cardiac Surgical Procedures; Cardiovascular Agents; Heart Failure; Humans; Hydrazones; Pyridazines; Simendan | 2013 |
Long-term levosimendan treatment improves systolic function and myocardial relaxation in mice with cardiomyocyte-specific disruption of the Serca2 gene.
Topics: Animals; Calcium Signaling; Cardiotonic Agents; Diastole; Disease Models, Animal; Extracellular Matrix Proteins; Fibrosis; Gene Expression Regulation; Heart Failure; Hydrazones; Hypertrophy, Left Ventricular; Mice; Mice, Knockout; Myocytes, Cardiac; Pyridazines; Recovery of Function; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Simendan; Stroke Volume; Systole; Time Factors; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Pressure | 2013 |
Preconditioning with levosimendan before implantation of left ventricular assist devices.
Topics: Aged; Cardiomyopathies; Cardiotonic Agents; Female; Heart Failure; Heart-Assist Devices; Humans; Hydrazones; Male; Middle Aged; Pyridazines; Retrospective Studies; Simendan; Treatment Outcome | 2014 |
Utility of the neutrophil to lymphocyte ratio for predicting in-hospital mortality after levosimendan infusion in patients with acute decompensated heart failure.
Topics: Acute Disease; Aged; Cardiotonic Agents; Disease Progression; Dobutamine; Female; Heart Failure; Hospital Mortality; Humans; Hydrazones; Infusions, Intravenous; Leukocyte Count; Lymphocyte Count; Male; Middle Aged; Neutrophils; Predictive Value of Tests; Pyridazines; Retrospective Studies; Simendan | 2014 |
Drug discovery and development for acute heart failure drugs: are expectations too high?
Topics: Acute Disease; Cardiotonic Agents; Clinical Trials as Topic; Drug Discovery; Heart Failure; Humans; Hydrazones; Pyridazines; Simendan; Urea | 2014 |
Levosimendan improves contractility in vivo and in vitro in a rodent model of post-myocardial infarction heart failure.
Topics: Animals; Calcium; Cardiotonic Agents; Female; Heart Failure; Hydrazones; Myocardial Infarction; Pyridazines; Rats; Rats, Sprague-Dawley; Simendan | 2014 |
Inhibition of phosphodiesterase-3 by levosimendan is sufficient to account for its inotropic effect in failing human heart.
Topics: Adrenergic beta-Agonists; Animals; Calcium; Cardiotonic Agents; Heart; Heart Failure; Humans; Hydrazones; In Vitro Techniques; Isoproterenol; Male; Milrinone; Myocardial Contraction; Phosphodiesterase 3 Inhibitors; Phosphodiesterase 4 Inhibitors; Pyridazines; Quinolines; Quinolones; Rats, Wistar; Rolipram; Simendan; Thiadiazines | 2014 |
Better late than never: a welcome publication of tardy clinical trial results.
Topics: Cardiotonic Agents; Female; Heart Failure; Humans; Hydrazones; Male; Pyridazines; Simendan | 2013 |
Dead letter office.
Topics: Cardiotonic Agents; Female; Heart Failure; Humans; Hydrazones; Male; Pyridazines; Simendan | 2013 |
Levosimendan in end-stage heart failure.
Topics: Cardiotonic Agents; Female; Heart Failure; Humans; Hydrazones; Male; Pyridazines; Simendan | 2013 |
DUCCS and SWANS: when U.S. site-based research was highly successful.
Topics: Cardiotonic Agents; Female; Heart Failure; Humans; Hydrazones; Male; Pyridazines; Simendan | 2013 |
Levosimendan reverses right-heart failure in a 51-year-old patient after heart transplantation.
Topics: Cardiotonic Agents; Heart Failure; Heart Transplantation; Humans; Hydrazones; Male; Middle Aged; Pyridazines; Simendan; Treatment Outcome; Ventricular Dysfunction, Right | 2014 |
Prognostic value of noninvasive hemodynamic evaluation of the acute effect of levosimendan in advanced heart failure.
Topics: Aged; Cardiac Catheterization; Cardiography, Impedance; Cardiotonic Agents; Feasibility Studies; Female; Follow-Up Studies; Heart Failure; Hemodynamics; Humans; Hydrazones; Male; Middle Aged; Monitoring, Physiologic; Natriuretic Peptide, Brain; Neurotransmitter Agents; Prognosis; Pyridazines; Simendan | 2014 |
[Pilot study of levosimendan : Effect on liver blood flow and liver function in acute decompensated heart failure].
Topics: Adult; Aged; Cardiac Output, Low; Cardiotonic Agents; Female; Heart Failure; Hemodynamics; Humans; Hydrazones; Indocyanine Green; Infusions, Intravenous; Liver; Liver Failure; Liver Function Tests; Male; Middle Aged; Pilot Projects; Pyridazines; Regional Blood Flow; Simendan | 2014 |
Preoperative levosimendan for right ventricular dysfunction before heart valve replacement surgery.
Topics: Dose-Response Relationship, Drug; Drug Administration Schedule; Echocardiography; Female; Follow-Up Studies; Heart Failure; Heart Valve Prosthesis Implantation; Humans; Hydrazones; Infusions, Intravenous; Male; Postoperative Complications; Preoperative Care; Pyridazines; Risk Assessment; Simendan; Spain; Treatment Outcome; Ventricular Dysfunction, Right | 2013 |
Repetitive use of levosimendan for treatment of chronic advanced heart failure: clinical evidence, practical considerations, and perspectives: an expert panel consensus.
Topics: Chronic Disease; Heart Failure; Humans; Hydrazones; Practice Guidelines as Topic; Pyridazines; Severity of Illness Index; Simendan; Vasodilator Agents | 2014 |
Planned repetitive use of levosimendan for heart failure in cardiology and internal medicine in Sweden.
Topics: Aged; Aged, 80 and over; Cardiology; Cardiotonic Agents; Drug Administration Schedule; Female; Heart Failure; Humans; Hydrazones; Internal Medicine; Male; Middle Aged; Pyridazines; Registries; Simendan; Survival Rate; Sweden | 2014 |
Inotropic agents in advanced heart failure: repetita iuvant?
Topics: Cardiotonic Agents; Drug Administration Schedule; Heart Failure; Humans; Hydrazones; Pyridazines; Severity of Illness Index; Simendan | 2014 |
Early levosimendan administration may improve outcome in patients with subarachnoid hemorrhage complicated by acute heart failure.
Topics: Acute Disease; Adult; Cardiotonic Agents; Dose-Response Relationship, Drug; Female; Heart Failure; Humans; Hydrazones; Injections, Intravenous; Myocardial Contraction; Pyridazines; Simendan; Subarachnoid Hemorrhage; Time Factors | 2014 |
Effects of a myofilament calcium sensitizer on left ventricular systolic and diastolic function in rats with volume overload heart failure.
Topics: Animals; Arterio-Arterial Fistula; Calcium Signaling; Cardiotonic Agents; Heart Failure; Hydrazones; Male; Myocardial Contraction; Myocytes, Cardiac; Myofibrils; Pyridazines; Rats; Rats, Sprague-Dawley; Sarcomeres; Simendan; Ultrasonography; Ventricular Dysfunction, Left; Ventricular Function, Left | 2014 |
Levosimendan exerts anti-inflammatory effects on cardiac myocytes and endothelial cells in vitro.
Topics: Anti-Inflammatory Agents; Cell Adhesion; Cells, Cultured; Decanoic Acids; E-Selectin; Enzyme-Linked Immunosorbent Assay; Heart Failure; Human Umbilical Vein Endothelial Cells; Humans; Hydrazones; Hydroxy Acids; Inflammation; Intercellular Adhesion Molecule-1; Interleukin-1beta; Interleukin-6; Interleukin-8; Microcirculation; Microscopy, Fluorescence; Muscle Cells; Myocardial Infarction; Myocytes, Cardiac; Necrosis; Neutrophils; NF-kappa B; Phosphorylation; Pyridazines; Reactive Oxygen Species; Simendan; Vasodilator Agents | 2015 |
Experience with levosimendan in 32 paediatric patients.
Topics: Adolescent; Age Factors; Blood Pressure; Cardiotonic Agents; Child; Child, Preschool; Dose-Response Relationship, Drug; Female; Heart Failure; Humans; Hydrazones; Infant; Infant, Newborn; Infusions, Intravenous; Male; Pyridazines; Retrospective Studies; Sex Factors; Simendan; Time Factors; Treatment Outcome | 2015 |
Effects of levosimendan on markers of kidney function in patients with acutely decompensated heart failure and renal impairment.
Topics: Biomarkers; Cardiotonic Agents; Cystatin C; Female; Heart Failure; Humans; Hydrazones; Kidney; Male; Pyridazines; Renal Insufficiency; Simendan | 2017 |
Effects of levosimendan on heart failure in normotensive patients: does loading dose matter?
Topics: Cardiotonic Agents; Drug Administration Schedule; Female; Heart Failure; Hemodynamics; Humans; Hydrazones; Infusions, Intravenous; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Pyridazines; Simendan; Ultrasonography; Vasodilator Agents | 2015 |
Levosimendan displays anti-inflammatory effects and decreases MPO bioavailability in patients with severe heart failure.
Topics: Anti-Inflammatory Agents; Biomarkers; Blood Pressure; Cardiotonic Agents; Cell Degranulation; Female; Heart Failure; Humans; Hydrazones; Inflammation; Leukocytes; Male; Middle Aged; Neutrophils; Nitric Oxide; Peroxidase; Pyridazines; Severity of Illness Index; Simendan; Time Factors | 2015 |
Pulsed levosimendan therapy in the management of chronic end stage cardiac failure in 'adult congenital heart disease'.
Topics: Adult; Cardiac Surgical Procedures; Cardiotonic Agents; Disease Progression; Female; Heart Defects, Congenital; Heart Failure; Humans; Hydrazones; Life Expectancy; Male; Middle Aged; Postoperative Complications; Pyridazines; Quality of Life; Severity of Illness Index; Simendan; Treatment Outcome | 2015 |
Pharmaco-economics of levosimendan in cardiology: a European perspective.
Topics: Acute Disease; Algorithms; Cardiology; Cardiotonic Agents; Cost-Benefit Analysis; Economics, Pharmaceutical; Europe; Heart Failure; Hospitalization; Humans; Hydrazones; Length of Stay; Models, Economic; Mortality; Pyridazines; Quality of Life; Simendan | 2015 |
[Levosimendan-induced liver damage in an elderly patient with heart failure].
Topics: Aged; Chemical and Drug Induced Liver Injury; Heart Failure; Humans; Hydrazones; Pyridazines; Simendan | 2015 |
Levosimendan Prevents Pressure-Overload-induced Right Ventricular Failure.
Topics: Animals; Cardiotonic Agents; Disease Models, Animal; Echocardiography; Heart Failure; Hydrazones; Hypertrophy, Right Ventricular; Magnetic Resonance Imaging; Male; Myocardial Contraction; Pyridazines; Rats; Rats, Wistar; Simendan; Ventricular Dysfunction, Right; Ventricular Function, Right | 2016 |
Probing the mechanism of cardiovascular drugs using a covalent levosimendan analog.
Topics: Animals; Calcium; Cardiovascular Agents; Heart Failure; Humans; Hydrazones; Myocardial Contraction; Nuclear Magnetic Resonance, Biomolecular; Protein Binding; Protein Conformation; Pyridazines; Rats; Simendan; Troponin C; Troponin I | 2016 |
Levosimendan. A promising future drug for refractory cardiac failure in children?
Topics: Cardiomyopathy, Dilated; Cardiotonic Agents; Child; Electrocardiography; Female; Heart Failure; Humans; Hydrazones; Myocardial Contraction; Myocarditis; Pyridazines; Simendan | 2016 |
Levosimendan for Heart Failure.
Topics: Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Pyridazines; Simendan | 2016 |
Assessment of sustained effects of levosimendan on right ventricular systolic functions in patients with advanced heart failure.
Topics: Aged; Biological Availability; Cardiotonic Agents; Disease Progression; Echocardiography, Doppler; Female; Heart Failure; Heart Ventricles; Humans; Hydrazones; Male; Middle Aged; Pyridazines; Simendan; Treatment Outcome; Ventricular Function, Right | 2016 |
Intermittent levosimendan infusions in advanced heart failure: a real world experience.
Topics: Aged; Aged, 80 and over; Cardiotonic Agents; Echocardiography; Female; Heart Failure; Humans; Hydrazones; Infusions, Intravenous; Length of Stay; Male; Pyridazines; Retrospective Studies; Simendan; Stroke Volume; Survival Analysis; Treatment Outcome; Ventricular Function, Left | 2017 |
Inotropic agents improve the peripheral microcirculation of patients with end-stage chronic heart failure.
Topics: Adrenergic beta-Agonists; Brachial Artery; Cardiotonic Agents; Case-Control Studies; Chronic Disease; Dobutamine; Female; Heart Failure; Humans; Hydrazones; Male; Microcirculation; Middle Aged; Muscle, Skeletal; Myocardial Reperfusion; Oxygen Consumption; Prognosis; Prospective Studies; Pyridazines; Simendan; Spectroscopy, Near-Infrared; Vasodilator Agents | 2008 |
Perioperative cardiac evaluation: the importance of cardiac failure management.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cardiotonic Agents; Diuretics; Heart Failure; Humans; Hydrazones; Myocardial Ischemia; Postoperative Complications; Pyridazines; Simendan | 2008 |
BELIEF: believe it or not.
Topics: Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Pyridazines; Simendan | 2008 |
Levosimendan in patients with decompensated heart failure.
Topics: Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Pyridazines; Simendan | 2008 |
The use of more than one inotrope in acute heart failure is associated with increased mortality: a multi-centre observational study.
Topics: Acute Disease; Aged; Aged, 80 and over; Cardiotonic Agents; Catecholamines; Female; Finland; Heart Failure; Hospital Mortality; Humans; Hydrazones; Length of Stay; Male; Middle Aged; Pyridazines; Retrospective Studies; Risk Factors; Simendan; Statistics, Nonparametric; Treatment Outcome | 2008 |
Usefulness of dobutamine-induced changes of the two-dimensional longitudinal deformation predict clinical and neurohumoral improvement in men after levosimendan treatment in acutely decompensated chronic heart failure.
Topics: Aged; Cardiotonic Agents; Dobutamine; Echocardiography, Stress; Female; Heart Failure; Heart Ventricles; Humans; Hydrazones; Male; Middle Aged; Natriuretic Peptide, Brain; Pyridazines; Severity of Illness Index; Simendan; Stroke Volume | 2008 |
Tricuspid valve replacement and levosimendan.
Topics: Adult; Aged; Cardiopulmonary Bypass; Cardiotonic Agents; Diastole; Female; Follow-Up Studies; Heart Failure; Heart Rate; Heart Valve Prosthesis; Heart Valve Prosthesis Implantation; Humans; Hydrazones; Pyridazines; Simendan; Systole; Time Factors; Treatment Outcome; Tricuspid Valve; Vasodilator Agents | 2008 |
Levosimendan: from basic science to clinical practice.
Topics: Animals; Cardiotonic Agents; Coronary Circulation; Dobutamine; Heart Failure; Hemodynamics; Humans; Hydrazones; Kidney; Myocardial Contraction; Natriuretic Peptide, Brain; Prognosis; Pyridazines; Quality of Life; Simendan; Vasodilator Agents; Ventricular Dysfunction, Left; Ventricular Function, Right | 2009 |
Rescuing a failing heart: putting on the squeeze.
Topics: Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Clinical Trials as Topic; Heart Failure; Humans; Hydrazones; Middle Aged; Models, Biological; Myocardial Contraction; Pyridazines; Salvage Therapy; Simendan; Survival Analysis | 2009 |
Intermittent inotropic infusions combined with prophylactic oral amiodarone for patients with decompensated end-stage heart failure.
Topics: Administration, Oral; Amiodarone; Anti-Arrhythmia Agents; Cardiotonic Agents; Chronic Disease; Dobutamine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Heart Failure; Humans; Hydrazones; Infusions, Intravenous; Male; Middle Aged; Prospective Studies; Pyridazines; Simendan; Survival Rate; Treatment Outcome | 2009 |
Levosimendan in heart failure after surgical repair of cardiac rupture.
Topics: Aged; Cardiotonic Agents; Female; Heart Failure; Heart Rupture; Humans; Hydrazones; Myocardial Infarction; Pyridazines; Simendan; Treatment Outcome | 2009 |
Do levosimendan have an adverse effect on platelet function?
Topics: Acute Disease; Blood Platelets; Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Meta-Analysis as Topic; Platelet Aggregation; Pyridazines; Randomized Controlled Trials as Topic; Simendan | 2010 |
Levosimendan: a new therapeutic option in the treatment of primary graft dysfunction after heart transplantation.
Topics: Adult; Aged; Cardiotonic Agents; Drug Therapy, Combination; Echocardiography; Echocardiography, Transesophageal; Female; Heart Failure; Heart Transplantation; Hemodynamics; Humans; Hydrazones; Male; Middle Aged; Postoperative Complications; Pyridazines; Simendan; Ventricular Dysfunction, Left | 2009 |
Lowered B-type natriuretic peptide in response to levosimendan or dobutamine treatment is associated with improved survival in patients with severe acutely decompensated heart failure.
Topics: Aged; Cardiotonic Agents; Dobutamine; Female; Heart Failure; Humans; Hydrazones; Male; Middle Aged; Natriuretic Peptide, Brain; Pyridazines; Randomized Controlled Trials as Topic; Retrospective Studies; Simendan | 2009 |
Prophylactic treatment with levosimendan: a retrospective matched-control study of patients with reduced left ventricular function.
Topics: Aged; Cardiopulmonary Bypass; Cardiotonic Agents; Case-Control Studies; Drug Administration Schedule; Drug Evaluation; Female; Heart Failure; Hemodynamics; Humans; Hydrazones; Male; Middle Aged; Norepinephrine; Phosphodiesterase Inhibitors; Preanesthetic Medication; Pyridazines; Retrospective Studies; Simendan; Stroke Volume; Vasodilator Agents; Ventricular Dysfunction, Left | 2009 |
Oral levosimendan prevents postinfarct heart failure and cardiac remodeling in diabetic Goto-Kakizaki rats.
Topics: Administration, Oral; Animals; Apoptosis; Blood Pressure; Cardiomegaly; Cardiotonic Agents; Cyclin-Dependent Kinase Inhibitor p16; Diabetes Complications; Diabetes Mellitus, Type 2; Disease Models, Animal; Heart Failure; Homeodomain Proteins; Hydrazones; Male; Myocardial Infarction; Pyridazines; Rats; Rats, Mutant Strains; Rats, Wistar; RNA, Messenger; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Simendan; STAT1 Transcription Factor; Ventricular Remodeling | 2009 |
Levosimendan as a rescue drug in experimental propranolol-induced myocardial depression: a randomized study.
Topics: Adrenergic beta-Antagonists; Animals; Cardiotonic Agents; Dobutamine; Double-Blind Method; Drug Overdose; Heart Failure; Hemodynamics; Hydrazones; Propranolol; Pyridazines; Random Allocation; Simendan; Survival Analysis; Swine | 2009 |
Levosimendan in viral myocarditis: not only an inodilator but also a cardioprotector?
Topics: Heart Failure; Humans; Hydrazones; Myocarditis; Oxidative Stress; Pyridazines; Simendan; Vasodilator Agents | 2009 |
Effects of levosimendan in experimental acute coxsackievirus myocarditis.
Topics: Animals; Cardiotonic Agents; Coxsackievirus Infections; Heart Failure; Hydrazones; Male; Mice; Mice, Inbred BALB C; Myocarditis; Myocardium; Myocytes, Cardiac; Pyridazines; Simendan; Ventricular Function, Left | 2009 |
Reducing the risk of major elective non-cardiac surgery: is there a role for levosimendan in the preoperative optimization of cardiac function?
Topics: Elective Surgical Procedures; Heart Failure; Humans; Hydrazones; Preoperative Care; Pyridazines; Risk Assessment; Simendan; Vasodilator Agents | 2009 |
[Use of levosimendan in acute heart failure and its effect on renal function].
Topics: Acute Disease; Aged; Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Kidney; Male; Pyridazines; Simendan | 2009 |
[Inotropic agents for treatment of acute heart failure syndromes in intensive care].
Topics: Cardiotonic Agents; Critical Care; Heart Failure; Humans; Hydrazones; Pyridazines; Simendan | 2009 |
Is levosimendan better than dobutamine in acute heart failure in patients on beta-blockade treatment? What is the evidence?
Topics: Acute Disease; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Cardiotonic Agents; Dobutamine; Drug Therapy, Combination; Evidence-Based Medicine; Heart Failure; Humans; Hydrazones; Pyridazines; Simendan | 2010 |
In response to Leppikangas H, et al, Levosimendan as a rescue drug in experimental propranolol-induced myocardial depression: a randomized study.
Topics: Adrenergic beta-Antagonists; Animals; Cardiotonic Agents; Heart Failure; Hemodynamics; Hydrazones; Propranolol; Pyridazines; Simendan; Swine | 2010 |
Rotating inotrope therapy in a pediatric population with decompensated heart failure.
Topics: Adolescent; Cardiotonic Agents; Dobutamine; Drug Therapy, Combination; Echocardiography; Female; Heart Failure; Humans; Hydrazones; Infant; Infant, Newborn; Intensive Care Units, Pediatric; Male; Milrinone; Pyridazines; Retrospective Studies; Simendan; Treatment Outcome | 2011 |
Levosimendan in cardiac failure after subarachnoid hemorrhage.
Topics: Acute Disease; Adult; Cardiotonic Agents; Critical Care; Embolization, Therapeutic; Female; Heart Failure; Humans; Hydrazones; Italy; Myocardial Stunning; Off-Label Use; Patient Selection; Pyridazines; Radiography; Simendan; Stroke Volume; Subarachnoid Hemorrhage; Treatment Outcome; Ventricular Function, Left | 2010 |
Levosimendan and pulmonary hypertension.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Hypertension, Pulmonary; Pulmonary Artery; Pyridazines; Simendan; Treatment Outcome; Vasodilator Agents; Ventricular Function | 2010 |
Acute heart failure with low cardiac output: can we develop a short-term inotropic agent that does not increase adverse events?
Topics: Acute Disease; Animals; Cardiac Output; Cardiotonic Agents; Clinical Trials as Topic; Digoxin; Dobutamine; Etiocholanolone; Genetic Therapy; Heart Failure; Humans; Hydrazones; Pyridazines; Ryanodine Receptor Calcium Release Channel; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Simendan; Sodium-Potassium-Exchanging ATPase; Urea | 2010 |
Correspondence concerning the article: is levosimendan better than dobutamine in acute heart failure in patients on beta blockade treatment? What is the evidence?
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Cardiotonic Agents; Dobutamine; Heart Failure; Humans; Hydrazones; Pyridazines; Simendan | 2010 |
How to treat acute decompensated heart failure in the 'beta-blocker era'?
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Antihypertensive Agents; Cardiotonic Agents; Dobutamine; Heart Failure; Humans; Hydrazones; Pyridazines; Simendan; Vasodilator Agents | 2010 |
Efficacy of levosimendan in patients with chronic heart failure: Does rhythm matter?
Topics: Aged; Atrial Fibrillation; Cardiotonic Agents; Diastole; Echocardiography; Electrocardiography; Female; Heart Failure; Heart Rate; Humans; Hydrazones; Infusions, Intravenous; Male; Middle Aged; Prospective Studies; Pyridazines; Simendan; Stroke Volume | 2010 |
Levosimendan improves cardiac function and survival in rats with angiotensin II-induced hypertensive heart failure.
Topics: Angiotensin II; Angiotensinogen; Animals; bcl-2-Associated X Protein; Blood Pressure; Cardiotonic Agents; Disease Models, Animal; Heart; Heart Failure; Heart Rate; Humans; Hydrazones; Hypertension; Major Histocompatibility Complex; Male; Pyridazines; Rats; Rats, Sprague-Dawley; Rats, Transgenic; Renin; Renin-Angiotensin System; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Simendan | 2010 |
Levosimendan improves calcium sensitivity of diaphragm muscle fibres from a rat model of heart failure.
Topics: Animals; Anti-Arrhythmia Agents; Calcium; Diaphragm; Heart Failure; Humans; Hydrazones; Male; Muscle Contraction; Muscle Fibers, Skeletal; Muscle Weakness; Myosin Heavy Chains; Pyridazines; Rats; Rats, Wistar; Simendan | 2011 |
[Acute early postpartum cardiac failure associated with dilated cardiomyopathy: successful treatment with intra-aortic balloon counter-pulsation and levosimendan].
Topics: Adult; Anti-Arrhythmia Agents; Cardiomyopathy, Dilated; Cesarean Section; Echocardiography; Female; Heart Failure; Humans; Hydrazones; Intra-Aortic Balloon Pumping; Postpartum Period; Pregnancy; Pyridazines; Simendan; Stroke Volume; Ventricular Function, Left | 2010 |
Levosimendan in the treatment of cardiogenic shock.
Topics: Anti-Arrhythmia Agents; Clinical Trials as Topic; Heart Failure; Humans; Hydrazones; Pyridazines; Shock, Cardiogenic; Simendan | 2010 |
Dobutamine-induced changes of left atrial two-dimensional deformation predict clinical and neurohumoral improvement after levosimendan treatment in patients with acutely decompensated chronic heart failure.
Topics: Aged; Atrial Function, Left; Biomarkers; Chronic Disease; Dobutamine; Echocardiography; Echocardiography, Stress; Female; Forecasting; Heart Failure; Humans; Hydrazones; Male; Middle Aged; Natriuretic Peptide, Brain; Neurotransmitter Agents; Pyridazines; Simendan; Treatment Outcome | 2012 |
[Treatment of heart failure patients with inotropic drugs: beyond traditional agents].
Topics: Adrenergic beta-1 Receptor Agonists; Cardiotonic Agents; Dobutamine; Guidelines as Topic; Heart Failure; Hydrazones; Meta-Analysis as Topic; Phosphodiesterase Inhibitors; Pyridazines; Retrospective Studies; Risk Assessment; Simendan | 2010 |
Levosimendan restores the positive force-frequency relation in heart failure.
Topics: Analysis of Variance; Animals; Cardiac Pacing, Artificial; Cardiotonic Agents; Disease Models, Animal; Dogs; Excitation Contraction Coupling; Heart Failure; Heart Rate; Hydrazones; Male; Myocardial Contraction; Pyridazines; Simendan; Stroke Volume; Tachycardia; Time Factors; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Pressure | 2011 |
Management of acute cardiac failure by intracoronary administration of levosimendan.
Topics: Acute Disease; Aged; Aged, 80 and over; Blood Pressure; Cardiac Surgical Procedures; Cardiopulmonary Bypass; Cardiotonic Agents; Female; Heart; Heart Failure; Heart Rate; Hemodynamics; Humans; Hydrazones; Injections, Intra-Arterial; Injections, Intravenous; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Pyridazines; Simendan; Vascular Resistance; Ventricular Function, Left | 2011 |
Cost-effectiveness of levosimendan in patients with acute heart failure.
Topics: Acute Disease; Aged; Cardiotonic Agents; Cost-Benefit Analysis; Dobutamine; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heart Failure; Humans; Hydrazones; Infusions, Intravenous; Length of Stay; Male; Middle Aged; Patient Readmission; Pyridazines; Retrospective Studies; Simendan; Survival Rate | 2011 |
Effects of levosimendan on cardiac gene expression profile and post-infarct cardiac remodelling in diabetic Goto-Kakizaki rats.
Topics: Animals; Diabetes Mellitus, Experimental; Down-Regulation; Gene Expression Profiling; Heart; Heart Failure; Hydrazones; Immunohistochemistry; Microarray Analysis; Myocardial Infarction; Myocardium; Pyridazines; Rats; Rats, Wistar; Renin-Angiotensin System; Simendan; Transcriptome; Up-Regulation; Ventricular Remodeling | 2011 |
Pharmacologic therapy of heart failure in children: part of a special series on paediatric pharmacology, guest edited by Gianvincenzo Zuccotti, Emilio Clementi, and Massimo Molteni.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cardiomyopathies; Cardiotonic Agents; Child; Digoxin; Diuretics; Heart Defects, Congenital; Heart Failure; Humans; Hydrazones; Natriuretic Peptide, Brain; Pyridazines; Simendan | 2011 |
Treatment of acute heart failure using levosimendan for a patient with dilated cardiomyopathy, chronic renal failure, and hypertension.
Topics: Acute Disease; Adolescent; Cardiomyopathy, Dilated; Cardiotonic Agents; Diuresis; Dose-Response Relationship, Drug; Echocardiography, Doppler, Pulsed; Follow-Up Studies; Glycogen Storage Disease Type I; Heart Failure; Humans; Hydrazones; Hypertension; Infusions, Intravenous; Kidney Failure, Chronic; Male; Myocardial Contraction; Pyridazines; Simendan; Stroke Volume | 2011 |
Levosimendan inhibits release of reactive oxygen species in polymorphonuclear leukocytes in vitro and in patients with acute heart failure and septic shock: a prospective observational study.
Topics: Acute Disease; Aged; Aged, 80 and over; Austria; Cardiotonic Agents; Female; Flow Cytometry; Heart Failure; Humans; Hydrazones; In Vitro Techniques; Male; Middle Aged; Neutrophils; Prospective Studies; Pyridazines; Reactive Oxygen Species; Shock, Septic; Simendan | 2011 |
Value of IGF-I levels in the evaluation of response to treatment with levosimendan in patients with severe heart failure.
Topics: Adult; Aged; Aged, 80 and over; Cardiotonic Agents; Cohort Studies; Female; Heart Failure; Humans; Hydrazones; Insulin-Like Growth Factor I; Male; Middle Aged; Natriuretic Peptide, Brain; Predictive Value of Tests; Prospective Studies; Pyridazines; Severity of Illness Index; Simendan; Treatment Outcome; Ultrasonography | 2011 |
In vivo and in vitro evidence for pleiotropic effects of levosimendan in the intensive care setting.
Topics: Cardiotonic Agents; Female; Heart Failure; Humans; Hydrazones; Male; Neutrophils; Pyridazines; Reactive Oxygen Species; Shock, Septic; Simendan | 2011 |
Cardiovascular effects of the combination of levosimendan and valsartan in hypertensive Dahl/Rapp rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Atrial Natriuretic Factor; Blood Pressure; Cardiomegaly; Cardiovascular Diseases; Diet, Sodium-Restricted; Echocardiography; Heart; Heart Failure; Heart Rate; Hydrazones; Hypertension; Kidney; Male; Myocytes, Cardiac; Pyridazines; Rats; Rats, Inbred Dahl; RNA, Messenger; Simendan; Sodium Chloride, Dietary; Sodium, Dietary; Tetrazoles; Valine; Valsartan; Vasodilator Agents; Ventricular Remodeling | 2011 |
Levosimendan--an inoprotective drug or much ado about nothing?
Topics: Cardiotonic Agents; Coronary Artery Bypass; Female; Heart Failure; Heart Valve Diseases; Humans; Hydrazones; Male; Pyridazines; Simendan | 2011 |
Effects of levosimendan without loading dose on systolic and diastolic function in patients with end-stage heart failure.
Topics: Aged; Biomarkers; Cardiotonic Agents; Chi-Square Distribution; Diastole; Female; Heart Failure; Hemodynamics; Humans; Hydrazones; Italy; Male; Middle Aged; Natriuretic Peptide, Brain; Pyridazines; Severity of Illness Index; Simendan; Systole; Treatment Outcome; Ultrasonography; Ventricular Dysfunction, Left; Ventricular Function, Left | 2011 |
How mechanical circulatory support helps not to need it--new strategies in pediatric heart failure.
Topics: Adolescent; Cardiomyopathies; Cardiotonic Agents; Catecholamines; Child, Preschool; Extracorporeal Membrane Oxygenation; Female; Heart Failure; Humans; Hydrazones; Infant; Male; Milrinone; Myocarditis; Natriuretic Agents; Natriuretic Peptide, Brain; Pyridazines; Simendan | 2011 |
Levosimendan in two neonates with ischemic heart failure and pulmonary hypertension.
Topics: Cardiotonic Agents; Female; Heart Failure; Humans; Hydrazones; Hypertension, Pulmonary; Infant, Newborn; Male; Myocardial Ischemia; Pyridazines; Simendan; Treatment Outcome | 2012 |
Inotropic support in the NICU: ever more compounds in search of guidance? Commentary on J. Esch et al.: differential hemodynamic effects of levosimendan in a porcine model of neonatal hypoxia-reoxygenation (Neonatology 2012;101:192–200) and M.P. De Caroli
Topics: Animals; Cardiac Output; Cardiotonic Agents; Female; Fetal Hypoxia; Heart Failure; Humans; Hydrazones; Hypertension, Pulmonary; Male; Myocardial Ischemia; Oxygen; Pyridazines; Simendan; Swine | 2012 |
[Levosimendan treatment of severe acute congestive heart failure refractory to dobutamine/milrinone in children].
Topics: Acute Disease; Adolescent; Cardiotonic Agents; Child, Preschool; Dobutamine; Heart Failure; Humans; Hydrazones; Male; Milrinone; Pyridazines; Simendan | 2011 |
A dose-response study of levosimendan in a porcine model of acute ischaemic heart failure.
Topics: Animals; Cardiotonic Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Heart Failure; Hemodynamics; Hydrazones; Mitochondria, Heart; Myocardial Contraction; Oxygen Consumption; Pyridazines; Simendan; Sus scrofa; Ventricular Function, Left | 2012 |
Mechanism of cardioprotective effect of adenocine and non-glycoside cardiotonic drugs during experimental chronic cardiac insufficiency.
Topics: Acetyldigoxins; Adenosine; Adenosine Triphosphate; Animals; Apoptosis; Cardiotonic Agents; Constriction, Pathologic; Female; Heart; Heart Failure; Heart Ventricles; Hydrazones; Male; Milrinone; Myocardium; Myocytes, Cardiac; NAD; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Pyridazines; Rabbits; Reperfusion; Simendan; Ventricular Function | 2011 |
ST-segment elevation during levosimendan infusion.
Topics: Acute Coronary Syndrome; Cardiotonic Agents; Coronary Angiography; Electrocardiography; Female; Heart Failure; Humans; Hydrazones; Infusions, Intravenous; Middle Aged; Pyridazines; Simendan | 2012 |
Effects of levosimendan on TNF-alpha, BNP and MMP-1 in patients with heart failure with anemia.
Topics: Aged; Anemia; Cardiotonic Agents; Chi-Square Distribution; Female; Heart Failure; Humans; Hydrazones; Infusions, Intravenous; Male; Matrix Metalloproteinase 1; Middle Aged; Natriuretic Peptide, Brain; Pyridazines; Simendan; Statistics, Nonparametric; Treatment Outcome; Tumor Necrosis Factor-alpha | 2012 |
The predictive value of QRS duration in response to levosimendan therapy in patients with decompensated heart failure.
Topics: Biomarkers; Cardiotonic Agents; Chi-Square Distribution; Echocardiography; Electrocardiography; Female; Heart Failure; Humans; Hydrazones; Infusions, Intravenous; Male; Middle Aged; Natriuretic Peptide, Brain; Predictive Value of Tests; Pyridazines; Simendan; Statistics, Nonparametric; Systole; Treatment Outcome | 2012 |
Facilitation of left ventricular function recovery post percutaneous coronary intervention by levosimendan.
Topics: Aged; Aged, 80 and over; Cardiotonic Agents; Case-Control Studies; Female; Follow-Up Studies; Heart Failure; Humans; Hydrazones; Male; Middle Aged; Percutaneous Coronary Intervention; Prospective Studies; Pyridazines; Recovery of Function; Simendan; Treatment Outcome; Ventricular Function, Left | 2013 |
Liver function abnormalities, clinical profile, and outcome in acute decompensated heart failure.
Topics: Acute Disease; Aged; Alkaline Phosphatase; Cardiotonic Agents; Cholestasis; Dobutamine; Female; Heart Failure; Humans; Hydrazones; Liver Diseases; Liver Function Tests; Male; Prognosis; Prospective Studies; Pyridazines; Randomized Controlled Trials as Topic; Simendan; Transaminases | 2013 |
Economic evaluation of levosimendan versus dobutamine for the treatment of acute heart failure in Italy.
Topics: Cardiotonic Agents; Cost-Benefit Analysis; Dobutamine; Heart Failure; Hospitalization; Humans; Hydrazones; Pyridazines; Retrospective Studies; Rome; Simendan; Treatment Outcome | 2012 |
Positive inotropy for acute heart failure complicating myocardial infarction.
Topics: Acute Disease; Cardiotonic Agents; Clinical Trials as Topic; Drug Evaluation; Heart Failure; Humans; Hydrazones; Myocardial Infarction; Pyridazines; Simendan; Treatment Outcome; Ventricular Dysfunction, Left | 2002 |
15th Annual Congress of the European Society of Intensive Care Medicine, 29 September-2 October 2002, Barcelona, Spain: clinical research to improve outcome.
Topics: Acute Kidney Injury; Critical Care; Europe; Heart Failure; Humans; Hydrazones; Incidence; Intensive Care Units; Lung Volume Measurements; Outcome Assessment, Health Care; Phosphodiesterase Inhibitors; Positive-Pressure Respiration; Pyridazines; Renal Replacement Therapy; Sepsis; Simendan; Societies, Medical; Spain | 2003 |
Advances in positive inotropic therapy: levosimendan.
Topics: Animals; Cardiotonic Agents; Clinical Trials as Topic; Disease Models, Animal; Heart Failure; Hemodynamics; Humans; Hydrazones; Myocardial Contraction; Prognosis; Pyridazines; Simendan; Treatment Outcome | 2003 |
Preliminary clinical experience with the repetitive administration of levosimendan in patients with end-stage heart failure.
Topics: Adolescent; Adult; Aged; Biomarkers; Blood Pressure; Calcium Channels, L-Type; Cardiac Output, Low; Cardiotonic Agents; Diastole; Dobutamine; Dopamine; Drug Therapy, Combination; Echocardiography; Electrocardiography; Female; Follow-Up Studies; Greece; Heart Failure; Heart Ventricles; Hematocrit; Hemoglobins; Humans; Hydrazones; Infusions, Intravenous; Male; Middle Aged; Myocardial Contraction; Potassium; Pyridazines; Severity of Illness Index; Simendan; Stimulation, Chemical; Survival Analysis; Systole; Treatment Outcome; Ventricular Dysfunction, Left | 2003 |
The calcium sensitizer levosimendan and cardiac arrhythmias: an analysis of the safety database of heart failure treatment studies.
Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Electrocardiography; Female; Finland; Follow-Up Studies; Heart Failure; Humans; Hydrazones; Infusions, Intravenous; Male; Middle Aged; Myocardial Contraction; Probability; Pyridazines; Randomized Controlled Trials as Topic; Registries; Risk Assessment; Simendan; Treatment Outcome | 2004 |
Medical therapy in heart failure--is polypharmacy necessary?
Topics: Adrenergic beta-Antagonists; Algorithms; Angiotensin-Converting Enzyme Inhibitors; Cardiotonic Agents; Heart Failure; Hemodynamics; Humans; Hydrazones; Mineralocorticoid Receptor Antagonists; Polypharmacy; Pyridazines; Simendan; Ventricular Function, Left | 2004 |
Resumption of atrioventricular conduction by levosimendan after radiofrequency ablation of the AV node:.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Atrioventricular Node; Bundle-Branch Block; Cardiotonic Agents; Catheter Ablation; Heart Block; Heart Failure; Humans; Hydrazones; Male; Middle Aged; Pacemaker, Artificial; Pyridazines; Simendan | 2004 |
Effect of levosimendan on balance between ATP production and consumption in isolated perfused guinea-pig heart before ischemia or after reperfusion.
Topics: Adenosine Diphosphate; Adenosine Triphosphate; Animals; Carbon Isotopes; Cardiotonic Agents; Dose-Response Relationship, Drug; Female; Guinea Pigs; Heart Failure; Heart Rate; Hydrazones; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Male; Myocardial Reperfusion; Myocardial Stunning; Oxygen Consumption; Perfusion; Phosphorus; Pyridazines; Simendan; Ventricular Function, Left | 2004 |
Impact of levosimendan treatment on chronic heart failure.
Topics: Anti-Inflammatory Agents; Chronic Disease; Heart Failure; Humans; Hydrazones; Pyridazines; Simendan | 2004 |
Levosimendan improves LV systolic and diastolic performance at rest and during exercise after heart failure.
Topics: Animals; Cardiotonic Agents; Diastole; Dogs; Heart Failure; Hydrazones; Pacemaker, Artificial; Physical Exertion; Pyridazines; Rest; Simendan; Systole; Ventricular Function, Left | 2005 |
Efficacy and safety of intermittent, long-term, concomitant dobutamine and levosimendan infusions in severe heart failure refractory to dobutamine alone.
Topics: Adult; Aged; Cardiotonic Agents; Chronic Disease; Dobutamine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance; Drug Therapy, Combination; Exercise Test; Female; Heart Failure; Hemodynamics; Humans; Hydrazones; Infusions, Intravenous; Male; Middle Aged; Multivariate Analysis; Pyridazines; Radionuclide Ventriculography; Risk; Simendan; Survival Rate | 2005 |
Levosimendan reduces plasma B-type natriuretic peptide and interleukin 6, and improves central hemodynamics in severe heart failure patients.
Topics: Aged; Cardiotonic Agents; Enzyme-Linked Immunosorbent Assay; Female; Heart Failure; Hemodynamics; Humans; Hydrazones; Interleukin-6; Male; Middle Aged; Natriuretic Peptide, Brain; Nerve Tissue Proteins; Peptide Fragments; Pyridazines; Simendan | 2005 |
Anti-inflammatory effects of levosimendan in decompensated heart failure: impact on weight loss and anemia.
Topics: Anemia; Anti-Inflammatory Agents; Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Pyridazines; Simendan; Weight Loss | 2005 |
Levosimendan reduces plasma amino terminal proBNP in patients with decompensated heart failure.
Topics: Cardiotonic Agents; Heart Failure; Hemodynamics; Humans; Hydrazones; Interleukin-6; Natriuretic Peptide, Brain; Peptide Fragments; Pyridazines; Simendan | 2005 |
[Cost analysis of the treatment of acute decompensated heart failure. Levosimendan versus dobutamine].
Topics: Acute Disease; Adrenergic beta-Agonists; Cardiotonic Agents; Cost-Benefit Analysis; Dobutamine; Health Care Costs; Heart Failure; Hospital Costs; Humans; Hydrazones; Length of Stay; Pyridazines; Simendan | 2005 |
What is the in vivo mechanism of action of levosimendan?
Topics: Actins; Calcium; Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Myosins; Phosphodiesterase Inhibitors; Pyridazines; Simendan; Troponin C | 2005 |
Effects of levosimendan on restrictive left ventricular filling in severe heart failure: a combined hemodynamic and Doppler echocardiographic study.
Topics: Anti-Arrhythmia Agents; Blood Flow Velocity; Echocardiography, Doppler, Pulsed; Heart Failure; Hemodynamics; Humans; Hydrazones; Pyridazines; Regression Analysis; Simendan; Stroke Volume; Ventricular Function, Left | 2005 |
Duration of the beneficial effects of levosimendan in decompensated heart failure as measured by echocardiographic indices and B-type natriuretic peptide.
Topics: Adult; Aged; Blood Pressure; Cardiac Output; Cardiotonic Agents; Echocardiography; Female; Heart Failure; Heart Rate; Humans; Hydrazones; Male; Middle Aged; Natriuretic Peptide, Brain; Prospective Studies; Pyridazines; Simendan; Time Factors; Ventricular Function, Left | 2005 |
Resuscitation from adrenaline resistant electro-mechanical dissociation facilitated by levosimendan in a young man with idiopathic dilated cardiomyopathy.
Topics: Adult; Cardiomyopathy, Dilated; Cardiopulmonary Resuscitation; Cardiotonic Agents; Epinephrine; Heart Arrest; Heart Failure; Humans; Hydrazones; Male; Pyridazines; Simendan | 2006 |
Levosimendan therapy in decompensated chronic heart failure: favourable haemodynamic and neurohormonal effects but for how long?
Topics: C-Reactive Protein; Cardiotonic Agents; Heart Failure; Hemodynamics; Humans; Hydrazones; Interleukin-6; Natriuretic Peptide, Brain; Pyridazines; Simendan; Time Factors; Treatment Outcome | 2006 |
Pre-operative use of levosimendan in two patients with severe aortic stenosis and left ventricular dysfunction.
Topics: Aged; Aortic Valve Stenosis; Cardiotonic Agents; Coronary Artery Bypass; Coronary Artery Disease; Heart Failure; Humans; Hydrazones; Male; Middle Aged; Pyridazines; Simendan; Ventricular Dysfunction, Left | 2006 |
Levosimendan and plasma BNP levels: do inflammatory cytokines regulate BNP in chronic decompensated heart failure?
Topics: Alprostadil; Biomarkers; Cardiotonic Agents; Chronic Disease; Cytokines; Dose-Response Relationship, Drug; Heart Failure; Humans; Hydrazones; Natriuretic Peptide, Brain; Pyridazines; Simendan; Stroke Volume; Vasodilator Agents | 2006 |
The 2005 Scientific Sessions of the American Heart Association (AHA).
Topics: American Heart Association; Animals; Cardiotonic Agents; Heart Failure; Hematopoietic Stem Cell Transplantation; Home Care Services; Humans; Hydrazones; Monitoring, Physiologic; Myocardial Infarction; Pacemaker, Artificial; Pyridazines; Randomized Controlled Trials as Topic; Simendan; Treatment Outcome; United States | 2006 |
[Therapy of acute decompensated heart failure with levosimendan].
Topics: Adult; Aged; Calcium Channel Agonists; Cardiotonic Agents; Conscious Sedation; Critical Care; Dobutamine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Electrocardiography; Female; Heart Failure; Hemodynamics; Humans; Hydrazones; Male; Middle Aged; Norepinephrine; Pyridazines; Shock, Cardiogenic; Simendan | 2006 |
Management of acute decompensated heart failure: treatment, controversy, and future directions.
Topics: Acute Disease; Atrial Natriuretic Factor; Diuretics; Guideline Adherence; Heart Failure; Humans; Hydrazones; Natriuretic Peptide, Brain; Peptide Fragments; Practice Guidelines as Topic; Pyridazines; Randomized Controlled Trials as Topic; Simendan; Vasodilator Agents | 2006 |
Effects of levosimendan versus dobutamine on pressure load-induced right ventricular failure.
Topics: Animals; Cardiotonic Agents; Dobutamine; Dogs; Heart Failure; Hydrazones; Hypertension, Pulmonary; Prospective Studies; Pulmonary Artery; Pulmonary Circulation; Pyridazines; Random Allocation; Simendan; Ventricular Dysfunction, Right | 2006 |
Clinical significance of acute neurohormonal response after levosimendan treatment.
Topics: Aged; Cardiotonic Agents; Follow-Up Studies; Heart Failure; Humans; Hydrazones; Male; Natriuretic Peptide, Brain; Pyridazines; Simendan; Survival Rate; Treatment Outcome | 2006 |
Levosimendan in acute decompensation of anthracycline-induced cardiotoxicity.
Topics: Acute Disease; Adult; Anthracyclines; Breast Neoplasms; Chemotherapy, Adjuvant; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Heart Failure; Humans; Hydrazones; Infusions, Intravenous; Pyridazines; Simendan; Treatment Outcome | 2007 |
Intracoronary infusion of levosimendan to treat postpericardiotomy heart failure.
Topics: Aged; Cardiotonic Agents; Coronary Artery Bypass; Coronary Vessels; Heart Failure; Humans; Hydrazones; Infusions, Intra-Arterial; Male; Pericardiectomy; Pyridazines; Simendan | 2006 |
Use of levosimendan, a new inodilator, for postoperative myocardial stunning in a premature neonate.
Topics: Cardiac Output, Low; Cardiotonic Agents; Echocardiography; Follow-Up Studies; Gestational Age; Heart Failure; Humans; Hydrazones; Infant; Infant, Newborn; Infant, Premature, Diseases; Intensive Care Units, Pediatric; Male; Myocardial Stunning; Postoperative Complications; Pyridazines; Simendan; Time Factors; Transposition of Great Vessels; Treatment Outcome; Ventricular Dysfunction, Left; Ventricular Function, Left | 2007 |
Levosimendan for the treatment of acute heart failure syndromes: time to identify subpopulations of responding patients.
Topics: Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Patient Selection; Pyridazines; Randomized Controlled Trials as Topic; Simendan | 2007 |
Levosimendan: perpetuum mobile?
Topics: Cardiac Output; Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Myocardial Contraction; Pyridazines; Simendan | 2007 |
Peripartum cardiomyopathy: a new successful setting for levosimendan.
Topics: Adult; Cardiotonic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Heart Failure; Humans; Hydrazones; Infusions, Intravenous; Postpartum Period; Pregnancy; Pyridazines; Risk Assessment; Severity of Illness Index; Simendan; Treatment Outcome; Ventricular Dysfunction, Left | 2008 |
Could Ca2+ sensitizers rescue patients from chronic congestive heart failure?
Topics: Animals; Calcium; Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Phosphodiesterase Inhibitors; Pyridazines; Simendan | 2007 |
Levosimendan restores both systolic and diastolic cardiac performance in lipopolysaccharide-treated rabbits: comparison with dobutamine and milrinone.
Topics: Animals; Cardiotonic Agents; Diastole; Disease Models, Animal; Dobutamine; Heart Failure; Hydrazones; Lipopolysaccharides; Milrinone; Pyridazines; Rabbits; Sepsis; Simendan; Systole; Ventricular Function, Left | 2007 |
Levosimendan: a new option in acute septic cardiac failure?
Topics: Acute Disease; Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Pyridazines; Sepsis; Simendan | 2007 |
Patients with advanced heart failure and the effects of levosimendan.
Topics: Animals; Cardiotonic Agents; Echocardiography, Doppler; Heart Failure; Humans; Hydrazones; Infusions, Intravenous; Myocardial Contraction; Pyridazines; Simendan; Treatment Outcome; Ventricular Function, Right | 2007 |
A struggle to SURVIVE: to abandon or not to abandon levosimendan?
Topics: Acute Disease; Cardiotonic Agents; Dobutamine; Heart Failure; Humans; Hydrazones; Natriuretic Peptide, Brain; Pyridazines; Simendan; Survival Rate; Treatment Outcome | 2007 |
Is there a place for levosimendan in the intensive care unit?
Topics: Cardiotonic Agents; Critical Care; Evidence-Based Medicine; Heart Failure; Humans; Hydrazones; Intensive Care Units; Pyridazines; Randomized Controlled Trials as Topic; Simendan; Treatment Failure | 2007 |
Treatment of experimental verapamil poisoning with levosimendan utilizing a rodent model of drug toxicity.
Topics: Animals; Antidotes; Blood Pressure; Calcium Chloride; Cardiac Output; Disease Models, Animal; Heart Failure; Heart Rate; Hydrazones; KATP Channels; Male; Poisoning; Pyridazines; Rats; Rats, Wistar; Simendan; Survival Rate; Vasodilator Agents; Verapamil | 2008 |
Levosimendan improves renal function in acute decompensated heart failure: cause and clinical application. Editorial to: "Levosimendan improves renal function in patients with acute decompensated heart failure: comparison with dobutamine by Yilmaz et al."
Topics: Acute Disease; Cardiotonic Agents; Dobutamine; Glomerular Filtration Rate; Heart Failure; Humans; Hydrazones; Kidney; Pyridazines; Simendan | 2007 |
Is there a place for levosimendan in the intensive care unit?
Topics: Cardiotonic Agents; Critical Care; Heart Failure; Humans; Hydrazones; Intensive Care Units; Pyridazines; Simendan | 2007 |
Orally available levosimendan dose-related positive inotropic and lusitropic effect in conscious chronically instrumented normal and heart failure dogs.
Topics: Administration, Oral; Animals; Cardiotonic Agents; Diastole; Dogs; Dose-Response Relationship, Drug; Heart Failure; Hemodynamics; Hydrazones; Myocardial Contraction; Pyridazines; Simendan; Vasodilation; Ventricular Function, Left | 2008 |
Levosimendan and ventriculo-arterial coupling.
Topics: Cardiac Output; Cardiotonic Agents; Doppler Effect; Heart Failure; Humans; Hydrazones; Pyridazines; Simendan; Vascular Resistance; Ventricular Dysfunction, Left | 2008 |
Therapies for heart failure: a report from the Heart Failure Congress 2007.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Cardiotonic Agents; Diuretics; Genetic Therapy; Heart Failure; Heart Transplantation; Hormone Replacement Therapy; Humans; Hydrazones; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Pulmonary; Mineralocorticoid Receptor Antagonists; Pyridazines; Simendan | 2007 |
Can we believe in levosimendan?
Topics: Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Infusions, Intravenous; Pyridazines; Simendan | 2008 |
Levosimendan infusion improves haemodynamics in elderly heart failure patients undergoing urgent hip fracture repair.
Topics: Aged; Aged, 80 and over; Cardiac Output, Low; Cardiotonic Agents; Emergencies; Female; Heart Failure; Hemodynamics; Hip Fractures; Humans; Hydrazones; Infusions, Intravenous; Male; Natriuretic Peptides; Patient Selection; Preoperative Care; Pyridazines; Simendan; Survival Rate; Time Factors; Treatment Outcome; Troponin | 2008 |
Preoperative levosimendan in heart failure patients undergoing noncardiac surgery.
Topics: Aged; Aged, 80 and over; Cardiotonic Agents; Elective Surgical Procedures; Female; Heart Failure; Humans; Hydrazones; Male; Middle Aged; Postoperative Complications; Preoperative Care; Prospective Studies; Pyridazines; Risk Assessment; Simendan; Ultrasonography | 2008 |
[Is there a role for levosimendan in hospital emergency departments?].
Topics: Acute Disease; Cardiotonic Agents; Emergency Service, Hospital; Emergency Treatment; Heart Failure; Humans; Hydrazones; Pyridazines; Simendan | 2008 |
Natriuretic peptide-guided levosimendan therapy for heart failure: a promising new approach.
Topics: Adrenergic beta-Antagonists; Cardiotonic Agents; Dobutamine; Heart Failure; Humans; Hydrazones; Infusions, Intravenous; Natriuretic Peptide, Brain; Predictive Value of Tests; Prognosis; Pyridazines; Simendan; Time Factors | 2008 |
The prolonged lowering effect of levosimendan on brain natriuretic peptide levels in patients with decompansated heart failure: clinical implications.
Topics: Cardiotonic Agents; Dobutamine; Heart Failure; Humans; Hydrazones; Infusions, Intravenous; Natriuretic Peptide, Brain; Predictive Value of Tests; Prognosis; Pyridazines; Simendan; Time Factors | 2008 |
Cardiovascular effects of the calcium sensitizer, levosimendan, in heart failure induced by rapid pacing in the presence of aortic constriction.
Topics: Analysis of Variance; Animals; Aorta; Cardiac Pacing, Artificial; Cardiotonic Agents; Disease Models, Animal; Dogs; Electrodes, Implanted; Female; Heart Failure; Hemodynamics; Hydrazones; Male; Muscle Contraction; Muscle, Smooth, Vascular; Pyridazines; Simendan; Ventricular Function, Left | 1995 |
Safety of levosimendan and other calcium sensitizers.
Topics: Cardiotonic Agents; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Electrocardiography, Ambulatory; Heart Failure; Humans; Hydrazones; Male; Phosphodiesterase Inhibitors; Placebos; Pyridazines; Randomized Controlled Trials as Topic; Simendan | 1995 |
Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium.
Topics: Calcium; Cardiotonic Agents; Dose-Response Relationship, Drug; Female; Heart Failure; Humans; Hydrazones; Male; Middle Aged; Milrinone; Myocardial Contraction; Myocardium; Phosphodiesterase Inhibitors; Pyridazines; Simendan | 1998 |
[Acute hemodynamic and clinical effects of a new inotropic agent, levosimendan, in patients with severe heart failure].
Topics: Cardiotonic Agents; Heart Failure; Hemodynamics; Humans; Hydrazones; Pyridazines; Severity of Illness Index; Simendan | 2001 |
Beneficial effects of the Ca(2+) sensitizer levosimendan in human myocardium.
Topics: Calcium; Cardiotonic Agents; Cyclic AMP; Fluorescent Dyes; Fura-2; Heart; Heart Failure; Heart Transplantation; Humans; Hydrazones; In Vitro Techniques; Isoproterenol; Muscle Fibers, Skeletal; Muscle Relaxation; Myocardial Contraction; Pyridazines; Reference Values; Simendan; Systole; Ventricular Function, Left | 2002 |
[Calcium sensitizers--a new group of drugs that increase myocardium contractility].
Topics: Animals; Calcium; Cardiac Output, Low; Cardiotonic Agents; Clinical Trials as Topic; Heart; Heart Failure; Humans; Hydrazones; Myocardial Contraction; Pyridazines; Simendan; Ventricular Function, Left | 2000 |